Using alternate indicators to define need for public

health intervention for trachoma: Evidence from the Pacific Islands by Butcher, R
  
 
 
Using alternate indicators to define need for public 
health intervention for trachoma:  
Evidence from the Pacific Islands 
 
 
 
ROBERT M. R. BUTCHER 
 
 
 
Department of Clinical Research 
Faculty of Infectious and Tropical Diseases 
LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE 
 
 
 
Thesis submitted in accordance with the requirements for the degree of 
Doctor of Philosophy 
University of London 
 
 
 
Co-funded by the 
Fred Hollows Foundation and the Wellcome Trust 
 
 
 
September 2017 
  Trachoma in the Pacific Islands 
 
I. ABSTRACT 
 
Introduction: Trachoma is the most common infectious cause of blindness worldwide. The 
presentation of trachoma in the Pacific small island states varies. This study focuses on Fiji, 
where the trichiasis prevalence recorded prior to this study was very high, and the Solomon 
Islands, where the prevalence of trachomatous inflammation – follicular (TF) is high enough to 
warrant intervention with mass antibiotic treatment, but there is apparently little or no 
trachomatous trichiasis (TT). This study aims to supplement clinical data with photographic and 
molecular tools to better characterise presentation and microbiological correlates of disease.   
 
Methods: Pre-intervention population-based prevalence surveys for trachoma were carried out 
independently and in conjunction with the Global Trachoma Mapping Project (GTMP). 
Additionally, one focused post-intervention survey was performed. Standardised clinical data 
collection was supplemented with ocular swab, dried blood spot and photograph collection. 
Quantitative and sequence-based nucleic acid techniques were used for targeted and non-
targeted pathogen detection and characterisation. Enzyme immunoassays were used for 
serological analysis. Clinical data was supplemented with photographs.  
 
Results: Within the mosaic pattern of clinical trachoma in the Pacific, the prevalence of TT was 
found to be very low in Fiji and the Solomon Islands. Prevalence of ocular Chlamydia 
trachomatis (Ct) infection in these countries was also very low. Further investigations in the 
Solomon Islands demonstrated Ct isolates found to be most closely related to ocular reference 
strains. Several pathogens that are known to cause follicular conjunctivitis were found, but 
neither frequency nor load of infection was associated with TF. Amplification of 16S ribosomal 
RNA amplicons showed diverse ocular microbial communities but no dominant metagenomic 
communities associated with TF. There is evidence of accumulation of mild scarring as age 
increases, but little evidence of severe scarring, or association between any trachoma 
phenotype and exposure to Ct.  
 
Conclusion: In Solomon Island communities studied, no evidence was found of significant 
burden of Ct infection, Ct transmission, trachomatous inflammation – intense, accumulation of 
severe scarring in older people or TT. We therefore suspect TF in the Solomon Islands to be of 
an as-yet unidentified aetiology. The WHO simplified grading system also appeared to lack 
diagnostic accuracy in Fiji. There are direct implications for implementation of control measures 
in the Pacific. There are additional connotations worldwide; as the global elimination effort 
continues and phenotypically similar conditions are unmasked, we suspect the positive 
predictive value of simplified clinical grading to drop. Use of molecular tools could differentiate 
communities with a high burden of infection, a key correlate of blinding disease, from those 
where resources may be better allocated elsewhere.  
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III. THESIS OUTLINE 
 
In accordance with London School of Hygiene & Tropical Medicine (LSHTM) thesis style 
guidance, this thesis is presented as a publication-style thesis framed around four key 
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1. INTRODUCTION  
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1.1 Study context  
 
Visual impairment and blindness constitute a major socioeconomic burden to those affected, the 
families and carers of those affected, and society at large (1). Trachoma is a chronic 
keratoconjunctivitis caused by the intracellular bacterium Chlamydia trachomatis (Ct) and is 
thought to be responsible for approximately 1.4% of blindness cases worldwide, making it the 
leading infectious cause of blindness (2). The burden of trachoma was estimated at over 38 
million disability-adjusted life years in 2000, with an estimated economic impact of over US$2 
billion (3). The magnitude of the trachoma problem galvanised the World Health Organization 
(WHO) into convening the Alliance for the Global Elimination of Trachoma by 2020 (GET2020) 
with the specific goal of eliminating trachoma as a public health problem by 2020. This target 
was subsequently endorsed by World Health Assembly resolution 51.11 in 1998, and has been 
highlighted as a priority of the VISION 2020 “Right to Sight” initiative (www.iapb.org/vision-2020) 
(4,5). The persistent will and investment of international partners has yielded significant 
improvements in our understanding of the epidemiology, pathogenesis and treatment of 
trachoma over recent decades. However, several challenges remain for the elimination 
programme. Active (inflammatory) trachoma is thought to be widespread throughout the Pacific 
Island region, but the prevalence of blinding disease is suspected to be low (6). Local decision 
makers have questioned whether the aetiology of the observed conjunctivitis differs from 
trachoma in areas where the blinding sequelae of trachoma are prevalent (R Le Mesurier, 
personal communication). No insight into aetiology or pathogenesis is offered by the currently 
available clinical data. This highlights one key issue; namely whether the diagnostic tools 
available are sufficiently specific to differentiate trachoma from phenotypically similar disease 
and whether they are appropriate to guide intervention decisions. 
 
1.1.1 Literature search methods 
 
A literature search was conducted with the objective of summarising available data on trachoma 
and identify key publications that provide the context for the work in this thesis. The primary 
resource for identifying publications was PubMed, but Embase, Scopus and other databases 
were utilised when necessary. This literature search used the following search terms individually 
and in combination: “trachoma”, “population-based”, “chlamydia trachomatis”, (“bacteria*” OR 
“viral”) AND “conjunctivitis”, “ocular” AND “trachomatis”, “prevalence”, “infection”, “diagnosis”, 
“Pgp3”, “antibodies”, “Haemophilus influenzae”, “Streptococcus pneumoniae”, “immunology”, 
“pacific”, “pacific islands” OR “Fiji” OR “Solomon Islands” OR “Kiribati” OR “Vanuatu”, 
“blindness”. Reference lists of identified papers were also screened for relevant articles. The 
literature search was conducted between 2013 and 2016. In some cases (for example, in 
sections 1.3 and 1.6), multiple references that together support a general concept have been 
amalgamated and visualised. References where no English language version was available 
were excluded.  
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1.2 Natural history of trachoma 
 
Trachoma begins in early childhood and, if not interrupted, can persist over a lifetime (figure 
1.2.1). In an untreated community, Ct circulates among young children causing conjunctivitis 
characterised by follicular and papillary inflammation. There can be a period of latency following 
inoculation where the infection is detectable but no clinical signs are visible. Infection can 
spontaneously resolve and clinical signs may persist for a period following clearance of 
infection, as illustrated in figure 1.2.2 (7).  
 
Figure 1.2.1. Cartoon illustrating the natural progression of untreated trachoma. Modified from Francis and Turner 
(8). 
 
Scar tissue begins to accumulate in white bands on the tarsal conjunctiva after many repeated 
cycles of re-exposure to and resolution of infection (9,10). Continued inflammatory stimuli (11) 
cause conjunctival fibrosis to continue throughout a lifetime, eventually becoming so severe that 
the eyelid is distorted. The distortion of the eyelid can draw the eyelashes out of their normal 
plane and cause them to abrade the globe of the eye. Severity of disease can range between 
mild (one or two misdirected lashes) and severe (five or more misdirected lashes) and cases 
can be progressive (12). Lashes contacting the cornea present the most serious threat to 
eyesight as the ongoing abrasion can cause damage and subsequent scarring eventually 
leading to opacity. Corneal opacity (CO) is the blinding stage of trachoma and is effectively 
untreatable for the majority of people living in at-risk communities. 
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Figure 1.2.2. Modelled relationship between clinical signs of disease and infection. Taken from Grassly and 
colleagues (7). 
 
1.3 Epidemiology of clinical disease 
 
Trachoma is thought to have been endemic in human populations for many thousands of years; 
medical records from ancient Egypt, China and Greece describe in-turned eyelashes which are 
presumed to refer to trachomatous trichiasis (TT) (5,13). In modern times, trachoma has mostly 
disappeared from developed countries where living conditions, household water facilities and 
access to health care are improved but remains endemic to many impoverished communities. 
Over 200 million people are suspected to be living in trachoma-endemic areas, and 1.9 million 
people irreversibly blind or visually impaired from the condition (14). Estimating the absolute 
number of people with trachoma is difficult as communities affected are often isolated and 
poorly served by health care providers. Previous estimates of disease magnitude have been 
based on a diverse range of studies that used differing methodologies for training trachoma 
graders and assessing population prevalence. More recently, the Global Trachoma Mapping 
Project (GTMP) used standardised grader training and survey methodology to reduce the 
inherent subjectivity of grading and sampling (15); estimates of disease prevalence generated 
through that project are considered to be more comparable than other estimates.  
 
Transmission of the causative agent of trachoma is thought to be mechanical via flies 
(particularly eye-seeking species such as Musca sorbens) (16,17) and fomites (inanimate 
mechanical vectors such as cloths or bed linen). Visible secretions around the nose and eyes 
and flies on the face at time of examination are associated with trachoma (18). Clustering of 
both disease (19–21) and infection (22,23) are seen at the household and village level. An 
individual’s living environment can influence whether those secretions or vectors to carry them 
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are prevalent within the community. Uncovered faeces can be a risk factor for trachoma (24), 
because they provide breeding sites for flies (25). Limited access to water for face washing is 
another risk factor for trachoma, as it may discourage regular cleaning of ocular and nasal 
secretions from the face, therefore increasing their chance of facilitating transmission (26).  
 
Figure 1.3.1. Age-specific prevalence of trachomatous inflammation–follicular (TF) in children. TF is most 
common in children aged <5 years old, and peak TF is commonly found in those aged 3-4 years of age. References 
identified during literature search in December 2015 (27–32). 
 
The highest prevalence of clinical signs of inflammatory disease is found in those under the age 
of 5 years in many trachoma-endemic areas (30). The age-specific prevalence of TF peaks 
around the age of 3–4 years (figure 1.3.1). Clinical signs of trachoma were found to have a 
mean duration of approximately 13 weeks (33), although longitudinal cohort studies have shown 
this to be highly variable within and between individuals (10). Clinical disease signs, infection 
intensity and infection duration decrease with age (33). This is presumed to be due to 
accumulation of partial immunity to Ct, although it is not yet clear what constitutes ‘immunity’ to 
Ct. Trachomatous scarring (TS) typically begins to occur after several years of continuous 
cycles of re-infection, by late childhood in endemic areas. TS is characterised by visible bands 
of scarring. In severe cases, this might include Arlt’s line, a thick band of scar tissue near the lid 
margin stretching across the conjunctiva, often seen with other bands of scarring in a weaved 
pattern in trachoma. The prevalence of scars can reach almost 25% in children aged 1–10 
years living in the most severely affected communities (34), although is lower than this in most 
areas. Cohorts of children in Tanzania have been shown to reach 15-20% scarring incidence 
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over 5-year study periods (9,10,35,36). Frequency and severity of scarring increases with age 
(9). Scarring can be highly prevalent in trachoma-endemic communities, for example, in 
northern Tanzania, where 40.1% of the adult (>18 years) population had evidence of some 
degree of scarring attributed to trachoma (11), or central Tanzania where 38% of those over the 
age of 40 years had some evidence of scarring, almost 50% of which worsened over a 5-year 
study period (9). The most severe conjunctival scars in the population were also found in those 
over the age of 40 years (9). In an aboriginal Australian community, 45.5% of people over the 
age of 45 years showed evidence of clearly visible scarring on conjunctival photographs (37).  
 
Most children in endemic communities will experience ocular infection with Ct yet not all will 
develop scarring, and still fewer will progress to TT. Deposition of scarring on the tarsal 
conjunctiva is driven by a variety of factors over several years, the evidence for which has been 
recently reviewed (36,38). The reasons for incidence and progression of disease, and especially 
for differences in susceptibility to these processes, are not clear. Female gender, increasing 
age, prolonged or regular infection with Ct and prolonged, severe trachoma (defined as having 
trachomatous inflammation – intense [TI] at the majority of study visits) are risk factors for 
progression from active to scarring trachoma (10,35). Although infection with Ct is a risk factor 
for the incidence of scarring, cases of infection with Ct are rarely detected in older people where 
progression of scarring continues. Progression from mild to severe scarring is associated with 
severe inflammation. Inflammation in those with progressive scarring was associated with up-
regulation of expression of pro-inflammatory genes such as psoriasin (S100A7) and chemokine 
ligand CXCL5 (39). Other nonchlamydial bacteria are associated with inflammation in adults 
living in trachoma-endemic areas (11). 
 
Trachomatous trichiasis is typically found in older people, and is more frequently observed in 
women (40,41). TT disproportionately affects those from underprivileged backgrounds (42), and 
can have a significant impact on quality of life (43). Development of sight-threatening TT is a 
complex lifetime process and the childhood prevalence of TF is not necessarily reflective of the 
population burden of TT in a given area. This is evident when examining cross-sectional survey 
data, where considerable heterogeneity is observed in the relationship between TF in children 
compared to TT in adults (Spearman’s rho: 0.61, p<0.0001; figure 1.3.2).  
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Figure 1.3.2. Prevalence of trachomatous inflammation – follicular (TF) in those aged 1–9 years compared to 
prevalence of trachomatous trichiasis (TT) in those over aged 15 years. References were identified from PubMed 
in October 2015 using the terms “population-based” and “trachoma”, studies were selected where TT and TF have been 
assessed in the same population before MDA (24,26,44–65). District-level data were extracted where more than a 
single district was reported on in a single publication. Not all studies included on the plot presented aged-standardised 
prevalence estimates, therefore unadjusted estimates were extracted for the purposes of this illustration. 
 
1.4 Classification of trachoma  
 
Trachoma is characterised by clinical assessment of conjunctival disease signs. In the early 
twentieth century, the ophthalmologist Arthur MacCallan produced the first of several systems to 
classify trachoma (66). The WHO simplified grading system, a distillation of the complex, 
multistage process of trachoma into five key signs, has subsequently become the tool of choice 
for field assessment of trachoma (figure 1.4.1, table 1.4.1). It has been particularly useful as a 
public health tool because it can be deployed by nonspecialist personnel (67). The simplified 
trachoma grading system focusses on clinical signs which can be graded reproducibly. While 
inter-grader agreement for TF and TT are good, TI and TS have been shown to require more 
training to achieve consensus (67,68). As with many diagnostic systems, cases at the periphery 
of the diagnostic criteria are often the most difficult to characterise (69). The simplified system 
lacks detail, and therefore other systems such as Dawson’s 1981 system (referred to as the 
FPC system from here; figure 1.4.1, table 1.4.2), which involves assessment of follicles (F), 
papillae (P) and cicatricae (C) on the conjunctivae (70) can be necessary for some research 
applications. When even further detail is required, systems are occasionally modified to suit 
specific research needs, for example for finer differentiation of severity of follicles and 
inflammation (71), scarring (9,11) or trichiasis (12).  
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Figure 1.4.1. Zones for grading trachoma using (A) simplified and (B) FPC systems. The clinical signs to be 
assessed in each of these zones are described in tables 1.4.1 and 1.4.2. Simplified system developed by Thylefors and 
colleagues (67). FPC system developed by Dawson and colleagues (70). Images created by the WHO and reproduced 
with permission. 
 
Although the definitions for each trachoma grade are clear, differing interpretation of features of 
the conjunctiva by examiners make clinical grading subjective. Retrospective re-grading of 
clinical photographs has been suggested as a quality control mechanism that could reduce the 
subjectivity of clinical grading. In practice, the agreement between two photograph grades, 
between photograph grade and clinical grade, and between two clinical grades of the same eye 
are similar (72,73). Photograding has not been proven to offer additional benefits over clinical 
grading using the WHO simplified system, and is much less practical. Photography requires 
sophisticated camera equipment and operator experience, and photograding is time consuming. 
It is therefore not used at the national programme level. For research purposes or in 
circumstances where the fidelity of clinical grading may be questioned, a retrospectively 
gradable record of phenotype is valuable for discussion, and can provide a source for 
consensus for those grades (particularly those related to severity of inflammation or scarring) 
that are less reproducible in the field (37).  
 
Not all conjunctival features are included in the simplified grading system. Concretions (benign 
lipid deposits) and cobblestone papillae (fluid-filled sacs) are two common features that may be 
mistaken for follicles (figure 1.4.2). Other clinical signs of inflammation have historically been 
associated with trachoma, such as corneal pannus, where continued inflammation causes blood 
vessels to encroach the upper corneal limbal margin, or limbal follicles, which give rise to 
Herbert’s Pits after repeated formation. Pannus does not appear to be any more specific for Ct 
infection than follicles (74) (figure 1.4.3).  
A B 
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Figure 1.4.2. Trachoma graders should be aware of superficially similar conjunctival features. (A) Giant papillae 
(B) Concretions.  
 
 
Figure 1.4.3. Clinical signs of trachoma not included in the WHO simplified classification system. (A) Pannus (B) 
Herbert’s Pits. 
 
Population-based prevalence survey (PBPS) is recommended by the WHO to estimate 
trachoma prevalence (75). Trachoma is known to cluster at the household and village level, so 
random sampling at both levels is necessary to achieve the most accurate prevalence 
estimates. Focussed survey protocols have been developed to determine whether PBPS is 
warranted. The Trachoma Rapid Assessment (TRA) protocol utilises historical and 
contemporary records of trachoma to identify suspected high-risk areas for sampling. Schools 
or community gatherings can be used to recruit individuals for survey to maximise the number 
of people who can be examined in a short space of time. This protocol should give the assessor 
the best chance of finding trachoma if it is there, but also does not give all villages, houses or 
people equal chance of inclusion; these biases preclude accurate estimates of disease burden 
from this technique (76). 
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Table 1.4.1. World Health Organization simplified grading system. To meet the criteria for any of these grades, the features must be visible in the central part of the tarsal conjunctiva (figure 1.4.1 A). 
Reproduced from Thylefors and colleagues (67).  
Grade Definition 
Trachomatous inflammation – follicular (TF)* ≥5 follicles of ≥0.5mm in diameter in the central upper tarsal conjunctivae. 
Trachomatous inflammation – intense (TI)* Pronounced inflammatory thickening of the upper tarsal conjunctiva obscuring over 50% of the deep tarsal vessels 
Trachomatous Scarring (TS) Visible scarring in the conjunctiva  
Trachomatous Trichiasis (TT) At least one eyelash rubbing the globe of the eye, or evidence of recent epilation of in-turned lashes 
Corneal opacity (CO) Easily visible corneal opacity over the pupil 
*The presence of TF and/or TI is referred to as ‘active trachoma’ 
 
Table 1.4.2. World Health Organization ‘FPC’ trachoma grading system. Zones for grading purposes are depicted in figure 1.4.1 B. Reproduced from Dawson and colleagues (70). 
Feature 
Severity 
0 (None/absent) 1 (Mild) 2 (Moderate) 3 (Severe) 
Follicles (F) None present <5 follicles in zones 2 and 3 combined 
≥5 follicles in zones 2 and 3 combined 
but <5 in zone 3 
≥5 follicles in each of three zones 
Papillae (P) Normal appearance 
Individual vascular tufts prominent, but deep 
vessels not obscured 
More prominent papillae, and normal 
vessels appear hazy even by naked 
eye 
Conjunctiva thickened and opaque, 
normal tarsal vessels are hidden >50% 
of the surface 
Cicatricae (C) None 
Fine scattered scars on the upper tarsal 
conjunctiva, or scars on other parts of the 
conjunctiva 
More severe scarring but without 
shortening or distortion of the upper 
tarsus 
Scarring with distortion of the upper 
tarsus 
Trichiasis or Entropion (T/E) None 
Lashes deviated towards the eye but not 
touching globe 
Lashes touching the globe but not 
rubbing in the cornea 
Lashes constantly rubbing cornea 
Corneal scarring (CS) Absent 
Scarring or opacity but not involving the 
visual axis, clear central cornea 
Scaring or opacity involving the visual 
axis with the pupillary margin visible 
through the opacity 
Central scarring or opacity with the 
pupillary margin not visible through the 
opacity 
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1.5 Management of trachoma 
 
Globally, the prevalence of trachoma is declining. A proportion of this decline may be secular 
(due to socioeconomic development leading to improvement of living conditions (77,78)) but can 
mostly be attributed to successful treatment. Treatment for trachoma involves a package of 
interventions termed the ‘SAFE’ strategy, incorporating Surgery, Antibiotics, promotion of Facial 
cleanliness and Environmental improvement (14). SAFE is effective at reducing trachoma 
prevalence (79–82). Treatment targets Ct infection and sight-threatening entropion at the 
community level. Population-based prevalence of the clinical signs of active trachoma are used 
as a proxy for the community burden of infection with ocular Ct (83), and is the basis of 
management decisions and elimination targets.  
 
WHO considers trachoma to be a public health problem in districts where ≥0.1% of the entire 
population, or ≥0.2% of those 15 years-old or above, have TT but have not already been 
identified and offered management. Patients with TT who refuse surgery, patients who suffer 
recurrence after surgery and patients awaiting surgery with a date set are excluded from the 
prevalence estimate with this definition (14). Cases of TT are managed surgically by re-directing 
misdirected lashes away from the globe. Surgery is effective but does not always offer 
prolonged benefit, as post-operative recurrent trichiasis is common. Of the two most commonly 
practised techniques, posterior lamellar is preferred to bilamellar tarsal rotation surgery as 
recurrence is less common with that procedure (84). Inflammation from bacterial stimuli can 
associate with recurrent trichiasis in some settings (85,86). Post-surgical treatment with 
antibiotics has been investigated to help reduce inflammation and recurrence of trichiasis; 
success of this approach has been mixed (87,88). Alternative nonsurgical options may have 
similar outcomes for minor cases if used appropriately (89). There is a significant backlog of 
trichiasis patients (over 3 million cases (14)), the management of which is complicated by 
barriers to surgery such as lack of trained surgical staff, geographical isolation and fears 
surrounding the procedure (90).  
 
Districts (administrative regions of 100,000 to 250,000 people (83)) where ≥5% of those aged 
1–9 years have TF are also considered to have a public health problem, and intervention is 
considered to be a priority where the prevalence of TF in the 1–9-year age group is ≥10% (91). 
At least three rounds of MDA are recommended if the prevalence of TF in children aged 1–9 
years is higher than 10%, or five rounds of MDA if prevalence exceeds 30% (91), followed by an 
impact survey to determine whether further treatment is needed. Macrolide and tetracycline 
antibiotics are first-line treatments for chlamydial infection. Both are bacteriostatic by directly 
inhibiting bacterial protein synthesis machinery and have additional positive immunomodulatory 
effects on host cells. Following oral administration, the tissue concentration of azithromycin is 
high, so the immunomodulatory effects of this treatment may persist well after clearance from 
the blood (92). Trachoma can be treated by topical application of 1% tetracycline eye ointment 
twice daily for 6 weeks. However, treatment adherence is poor and a single, oral dose of 
azithromycin is equally safe (93), efficacious (94,95) and therefore, in practice, more 
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appropriate for mass distribution. Mass distribution of azithromycin once annually to at least 
80% of a community has been demonstrated to be effective in reducing the prevalence of active 
trachoma and infection (96–99), and is also thought to reduce incidence of TS, suggesting 
reduced progression of disease (34,100). The relative expense of the drug is mitigated by a 
huge (>500 million doses donated, 56 million treatments administered (14)), sustained donation 
programme of azithromycin (under brand name Zithromax®) from Pfizer, Inc. Azithromycin is a 
broad-spectrum antibiotic with clinical effects on many common pathogens, including those of 
Plasmodium, Mycoplasma, Legionella, Neisseria, Haemophilus, Moraxella, Streptococcus, 
Chlamydia, Treponema and Staphylococcus genera. Perhaps unsurprisingly therefore, MDA 
seems to have substantial collateral benefits outside of trachoma control, such as treatment of 
sexually transmitted infections (101), endemic treponematoses (102) and malaria (103). Short-
term reduction in episodes of diarrhoeal disease and respiratory tract infections has also been 
reported (104,105). All-cause mortality has been shown to reduce following MDA programmes 
(106). No evidence has yet been found that MDA induces antibiotic resistance in Ct (107). 
Conversely, there is some evidence for negative effects of community-wide antibiotic exposure. 
An increase in macrolide resistance mutations in faecal Escherichia coli has been observed up 
to 6 months post-MDA (108). Carriage of azithromycin-resistant Streptococcus pneumoniae 
(Sp) has been shown to be more common in some MDA-treated communities (109,110), but not 
in others (111). Macrolide-resistant nasopharyngeal Sp strains circulating within a treatment-
naïve community appear to clonally expand following MDA (112). Where resistant strains were 
found, they appeared to decline following cessation of treatment (113). It has also been 
hypothesised that increased detection and treatment of chlamydial infections in the urogenital 
setting can lead to greater susceptibility to infection by interrupting the natural accumulation of 
acquired immunity and therefore cause infection incidence to increase (114), although 
prospective data on this phenomenon is lacking.  
 
Antibiotic treatment is the mainstay of treating Ct infection, but following treatment cessation, 
recrudescence of Ct infection and trachoma has been observed (115), thought to be mainly due 
to incomplete suppression of circulating Ct burden or re-introduction by immigrants to the 
community (116). To maintain suppression of Ct, reduction in transmission is targeted by 
promoting removal of ocular and nasal secretions through facial cleanliness. Promotion of face 
washing alongside an antibiotic distribution programme compared to antibiotic alone has been 
associated with a higher proportion of children with clean faces, and clean faces were 
associated with lower active trachoma (117,118). Trachoma can cause ocular discharge so 
disentangling correlation and causation is difficult. Environmental improvement is a flexible 
component of the SAFE strategy, and should specifically target the water, sanitation and 
hygiene (WASH) needs of a given community. Identifying risk factors such as latrine availability 
and appropriateness and availability of facilities for face washing can direct environmental 
improvement programmes to the areas of greatest importance to trachoma. Therefore, the E 
component of SAFE is highly heterogeneous and location-specific (119). One example of the 
heterogeneity in interventions and efficacy is latrine provision, which in some circumstances has 
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been shown to be associated with lower prevalence of trachoma (120) whereas in others it has 
not (121).  
 
1.6 Ocular infection with Chlamydia trachomatis 
 
Intracellular inclusions and follicular conjunctivitis were observed following inoculation of 
primates (Halberstaedter and von Prowazek, 1907) and later humans (122) with conjunctival 
scrapings from trachoma patients. Ct was cultured in egg yolk sacs directly from conjunctival 
scrapings from trachoma patients, firstly in Ecuador (although the study was hampered by 
contamination issues) and subsequently in China (123,124). Originally thought to be a virus, Ct 
is now known to be an obligate intracellular bacterium, and a major ocular and urogenital 
pathogen of humans. It is closely related to other pathogens of mammals within the 
Chlamydiaceae family. The two-stage life cycle of Ct begins when infectious elementary bodies 
(EBs) bind to the outer membrane of host epithelial cells and enter inside a vesicle, 
sequestering themselves from the cytoplasm. The vesicles fuse together to form an inclusion, in 
which the EBs develop into replicative reticulate bodies (RBs) and begin to replicate by binary 
fission. Within about 48 hours, the RBs return to EBs, and the inclusion is exocytosed into the 
extracellular space (125).  
 
The epidemiology of ocular Ct infection and its relationship to active trachoma has recently 
been reviewed (126). In most treatment-naïve settings where trachoma is moderately prevalent, 
ocular infection with Ct correlates well with TF at the population level (Spearman’s rho 0.86, 
p<0.0001; figure 1.6.1). The association is weaker in low-prevalence (127–129) and post-
treatment scenarios (130). Infection is typically more prevalent and present at higher loads in 
those under 5 years of age than the rest of the population; the majority of active trachoma in a 
population is also commonly found in that age group. Estimates of the duration of infection in 
young children suggest it may persist for an average of approximately 4 weeks (33), although, 
similar to clinical signs, this is highly variable in cohort studies (10). During an infection with 
ocular Ct, ocular and nasal secretions carry infectious bodies (131,132). Ocular Ct is thought to 
be transmitted between people by carriage of these secretions on fingers, flies and fomites. 
Transmission dynamics of ocular Ct can vary seasonally where rainfall is periodic, thought to be 
due to reduced water availability for face washing in the dry season and reduced fly activity at 
cooler temperatures in the wet season (133). 
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Figure 1.6.1. Population prevalence of ocular Chlamydia trachomatis (Ct) infection compared to prevalence of 
trachomatous inflammation – follicular (TF). References identified through literature search using the terms 
‘trachoma’ and ‘infection’ in December 2015. Studies reporting population prevalence of both TF and Ct measured by 
nucleic acid amplification test in a trachoma treatment-naïve population sample selected for survey for reasons not 
related to eye health were eligible for inclusion (22,30,31,71,79,97,113,115,129,130,134–151).   
 
Serological profiling of antibodies to the primary chlamydial antigen Major Outer Membrane 
Protein (MOMP) is used to categorise Ct into the ocular serovars A–C, urogenital serovars D–K 
and lymphogranuloma venereum serovars L1–3 (152,153). Genotyping of the ompA gene, 
which encodes MOMP, yields further variation within the serovars based on evolutionary 
accumulation of single nucleotide polymorphisms (SNPs), although due to differential rates of 
evolution to other chlamydial genes, this is not thought to be illustrative of evolutionary 
relationships (154). Panels of slowly evolving housekeeping genes have been used to further 
distinguish Ct variants (155,156). Multilocus sequence typing (MLST) panels detect numerous 
genovars within defined serovars, diversity often not reflected by ompA sequencing alone (157). 
The precise mechanism of tissue tropism in chlamydial serovars has yet to be fully elucidated. 
Ocular strains are unable to make tryptophan, whereas urogenital strains can, synthesising 
tryptophan to evade interferon (IFN)γ-mediated host tryptophan sequestration (158,159). 
Recently, Ct strains have been isolated from the conjunctiva where the majority of the genome 
resembles urogenital strains, but ompA and some polymorphic membrane proteins (pmps) are 
more closely related to those from typical ocular strains. The authors suggest this indicates the 
capacity of Ct to recombine with urogenital strains could be a source of re-emergence of ocular 
infection after clearance (160). However, the children from whom these strains were isolated 
were very young and were born to mothers recruited into a study of urogenital Ct infection, 
suggesting a distinct possibility that these isolates originated from the mother’s genital tract. 
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Their clinical status, graded using the FPC system, was not consistent with either TF or TI, 
therefore further work is required to determine the relevance of these findings.   
 
The Ct genome consists of a single, circular double-stranded DNA chromosome of just over 1 
million base pairs (bp), and a 7.5-kilobase (kb) plasmid (161). The plasmid copy number is 
variable in cultured strains and in naturally occurring infections. A median 5.3 plasmids per 
chromosome (range 1-18) was found in West African clinical samples, but no relationship  was 
observed between plasmid copy number and virulence (162). Polymorphism in the Ct genome 
is most common in three major variable regions; the ompA gene, the pmps and a plasticity zone 
(PZ) (163). Recombination is also known to occur throughout the genome (164,165), and 
whole-genome sequence (WGS) analysis illustrates that it is common (166). To sufficiently 
enrich DNA from a clinical specimen for successful sequencing, organisms can be cultured. 
However, multiple passage of organisms through cell lines in the absence of immune pressure 
could lead to in vitro evolution; to mitigate this, culture-independent enrichment techniques have 
been developed (167,168).  
 
Enhancements in sequencing technology have enabled genetic differences between strains to 
be defined with very fine resolution. However, it is not known whether pathogen genotype has 
an influence on trachomatous disease severity. In trachoma-endemic areas, most people are 
exposed to Ct, but not all go on to develop TS and even fewer to TT. Pathogen genetics may 
play a role (the host factors that may contribute to this are discussed below). Several putative 
virulence factors have been identified. As a key chlamydial immunogen, MOMP is thought to be 
involved in virulence (169). It appears to be susceptible to selective pressure, however, no 
association has been found between genotype and disease severity. The pmps, suspected to 
be involved in protein trafficking across intra- and extra-cellular membranes, also exhibit 
increased diversity compared to the rest of the genome and certain subtypes associate with 
urogenital serovars E and F, which are the most prevalent worldwide, perhaps indicating an 
advantageous genotype (170). Type III secretion machinery proteins are often associated with 
virulence in other bacteria; the incA component of the Ct type III secretion system appears to 
play a key role in inclusion formation and its absence is associated with attenuated urogenital 
disease signs (171). Within the PZ, the chlamydial cytotoxin gene is highly variable, and tissue 
tropism-specific deletions have been characterised (172). The plasmid has been indicated as a 
major virulence factor in animal models. Plasmid-free urogenital Ct inoculation of mice resulted 
in fewer successful infections than inoculation of plasmid-containing strains (173). Isolates can 
survive in natura with major deletions (174) or complete absence (175) of the plasmid. This 
indicates the plasmid is not an essential factor for growth and survival, but plasmid-free clinical 
isolates are rare, suggesting some selective pressure for its retention (176). A plasmid-free Ct 
strain was investigated as a live-attenuated vaccine in macaques, and showed a significant 
attenuation of clinical disease when compared to inoculation with plasmid-competent strains 
(177). Cultured ocular Ct strains with variations in several genes performed differently in various 
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in vitro growth measures. Targeted re-sequencing of these genes in Tanzanian clinical isolates 
replicated the increased variability found, suggesting a role in trachoma pathogenesis (178). 
 
1.7 Non-Chlamydia trachomatis microbes and trachoma 
 
A range of bacteria can be isolated from the conjunctiva in trachoma-endemic settings. Bacteria 
that commonly grow from eye swabs come from genera such as Corynebacterium, 
Propionibacterium, Staphylococcus and Streptococcus. Other genera, such as Micrococcus, 
Bacillus, Moraxella, Pseudomonas, and Haemophilus, are also well represented, although their 
frequency is more variable (11,129). Culture-independent techniques such as 16S ribosomal 
RNA gene amplicon sequencing have indicated the microbial community structures at the 
conjunctiva are similar to those of the skin (179). Bacterial genera such as Corynebacterium, 
Propionibacterium, Staphylococcus and Streptococcus also dominate in people not living in 
trachoma-endemic areas (180). Many less common genera are sporadically detected at the 
conjunctiva (180–183). Host–microbe interactions at mucosal surfaces are of growing interest. 
External stimuli, such as contact lens wear, are known to affect the conjunctival flora (184), but 
significant shifts in microbiome structure in relation to disease have yet to be observed 
(185,186).  
 
The correlation between TF and Ct is reasonably good at the population level prior to 
interventions against trachoma (acknowledging the methodological limitations described 
previously), but at the individual level Ct cannot be identified from all cases of TF, especially 
after MDA or where TF is at low prevalence. There are a number of differential diagnoses for 
follicular conjunctivitis (70). Causes of follicular conjunctivitis can be broadly summarised into: 
bacterial infection (follicles thought to be more frequent in conjunctivitis caused by species of 
Staphylococcus, Haemophilus, Streptococcus and Moraxella), viral infection (adenoviruses, 
molluscum contagiosum, Herpes Simplex Virus, table 1.7.1), atopic and toxic (cosmetic or 
topical medications). Some similar conditions are differentiated by additional pathognomic 
signs, such as giant papillae in atopic conjunctivitis. Others exhibit markedly different 
demographic distribution, such as folliculitis caused by chemical irritants (make-up or topical 
medications; affecting people using those products) or ophthalmia neonatorum (vertical 
transmission of Ct and other infections specifically affecting neonates). Zoonotic causes of 
follicular conjunctivitis include non-trachomatis chlamydial infection (from keeping birds, cats 
and pigs), Newcastle Disease Virus (from poultry) and Parinaud's oculoglandular syndrome 
(from cat scratches) (70,187,188).  
 
Studies describing non-Ct bacteria isolated from the conjunctiva in trachoma endemic settings 
are discussed in table 1.7.2. Sp and Haemophilus influenzae (Hi) are commonly isolated, 
however, few studies have been able to show a significant association between non-Ct bacteria 
and clinical signs of disease. In a treatment-naïve, low-prevalence Tanzanian community, Sp, 
Hi type B and Hi non-type B correlated more strongly with clinical signs of active trachoma than 
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Ct (129). In a post-treatment setting, Sp and Hi type B infection correlated with signs of active 
trachoma, whereas Moraxella catarrhalis (Mc; a common cause of ocular inflammation) and 
Staphylococcus aureus (Sa) did not (189). Other Chlamydiaceae, such as C. psittaci and 
C. pneumoniae have also been detected by PCR on the conjunctivae of patients with follicular 
inflammation in the absence of detectable Ct-specific MOMP peptides; these cases were 
presumed to have arisen from keeping animals (187). Bacteria, such as coagulase-negative 
Staphylococcus (CoNS), Corynebacterium (considered commensal during the study), Sp and Hi 
type B (pathogenic), were more frequently cultured from adults with TS than those without in a 
case–control study conducted in Tanzania (11).  
 
It is not clear whether nonchlamydial infections cause prevalent follicular inflammation in their 
own right, or whether their prevalence in trachoma-endemic environments is related to 
underlying Ct endemicity. In primate models, inoculation of Hi (type B or non B) or Sp alone did 
not induce follicles, and did not increase the intensity of follicular inflammation when co-
administered with Ct (190), so it is possible that inflammation from non-Ct infection is influenced 
by prior Ct infection. Several different bacteria are cultivable from conjunctivitis patients in areas 
where trachoma is not endemic (191). Variation in the relative dominance of Sp, Hi and Mc at 
mucosal surfaces can cause inflammation, for example in children with otitis media (192). It is, 
therefore, theoretically possible for these pathogens to contribute to conjunctival inflammation, 
but no empirical data from trachoma-endemic settings suggest that disruption of the relative 
abundance of these pathogens contributes to trachomatous disease prevalence.    
Trachoma in the Pacific Islands 
 
 
Table 1.7.1. Viral causes of follicular conjunctivitis. Distinguishing features not typically seen in trachomatous 
conjunctivitis are described. 
 
Virus Virus type Differentiating features Ref. 
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can be epidemic or associated with acute 
haemorrhagic conjunctivitis 
(196–200) 
Herpes simplex virus dsDNA 
herpesvirus 
Redness, irritation, watering, lid inflammation, 
follicles more common on lower lid 
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presentation  
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Rare complication of mumps, marked parotid 
lymphadenopathy  
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Coxsackievirus ssRNA 
enterovirus 
Acute haemorrhagic conjunctivitis and associated 
pathologies 
(211) 
Ds: double stranded; ss: single stranded.  
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illa
ge
 
14
6 
in
di
vi
du
al
s 
of
 a
ll 
ag
es
, 2
8%
 h
ad
 T
F,
 
36
%
 h
ad
 T
I, 
37
%
 
ha
d 
TS
, 2
0 
ha
d 
TT
. 
12
7 
sw
ab
s 
w
er
e 
co
lle
ct
ed
 
U
pp
er
 ta
rs
al
 
co
nj
un
ct
iv
a 
sw
ab
be
d 
Sw
ab
s 
st
or
ed
 in
 
SP
G
 (D
N
A 
ex
tra
ct
io
n 
an
d 
PC
R
) 
or
 M
4 
tra
ns
po
rt 
m
ed
ia
 (A
m
pl
ic
or
) 
39
%
 o
ve
ra
ll 
Am
pl
ic
or
 p
os
iti
ve
, 
31
%
 o
f T
S/
TT
 
pa
tie
nt
s 
Am
pl
ic
or
 
po
si
tiv
e.
 N
on
-
tra
ch
om
at
is
 in
fe
ct
io
n 
ac
co
un
ts
 fo
r 5
0%
 o
f 
in
fe
ct
io
n 
ca
se
s 
in
 
th
is
 g
ro
up
 
C
t, 
C
. p
ne
um
on
ia
e,
 
C
. p
si
tta
ci
  
C
t, 
C
. p
ne
um
on
ia
e,
 
C
. p
si
tta
ci
 
C
t 
Tr
ac
ho
m
a 
in
 th
e 
Pa
ci
fic
 Is
la
nd
s 
 
 
G
am
bi
a 
(2
15
) 
Tw
o 
ca
se
-c
on
tro
l 
st
ud
ie
s:
 T
T 
ca
se
s 
an
d 
m
at
ch
ed
 
co
nt
ro
ls
; T
S 
ca
se
s 
an
d 
m
at
ch
ed
 
co
nt
ro
ls
. I
s 
ba
ct
er
ia
l 
in
fe
ct
io
n 
as
so
ci
at
ed
 
w
ith
 T
T 
or
 T
S?
 
12
1 
TT
 c
as
es
 a
nd
 
no
rm
al
 c
on
tro
ls
, 1
17
 
TS
 c
as
es
 a
nd
 
no
rm
al
 c
on
tro
ls
 
An
ae
st
he
tiz
ed
 u
pp
er
 
ta
rs
al
 c
on
ju
nc
tiv
a 
sw
ab
be
d 
fo
r C
t, 
an
ae
st
he
tiz
ed
 lo
w
er
 
fo
rn
ix
 s
w
ab
be
d 
fo
r 
ba
ct
er
ia
l c
ul
tu
re
   
Am
pl
ic
or
 fo
r C
t. 
ST
G
G
 m
ed
iu
m
 fo
r 
tra
ns
po
rt,
 s
tre
ak
ed
 
on
to
 b
lo
od
 a
ga
r, 
M
cC
on
ke
y 
ag
ar
 
(a
er
ob
ic
), 
ge
nt
am
ic
in
 b
lo
od
 
ag
ar
, a
nd
 b
ac
itr
ac
in
 
ch
oc
ol
at
e 
ag
ar
 
37
.2
%
 o
f T
T 
ca
se
s 
co
m
pa
re
d 
to
 7
.4
%
 o
f 
TT
 c
on
tro
ls
 h
ad
 a
t 
le
as
t o
ne
 in
fe
ct
io
n.
 
In
fe
ct
io
n 
m
or
e 
co
m
m
on
 in
 th
os
e 
w
ith
 m
or
e 
se
ve
re
 
TT
. 1
1.
1%
 o
f T
S 
ca
se
s 
ha
d 
in
fe
ct
io
n 
co
m
pa
re
d 
to
 6
%
 o
f 
TS
 c
on
tro
ls
. M
an
y 
di
ffe
re
nt
 s
pe
ci
es
 
de
te
ct
ed
, S
p 
by
 fa
r 
m
os
t p
re
va
le
nt
. 
1/
24
2 
TT
 
ca
se
s/
co
nt
ro
ls
 h
ad
 
C
t i
nf
ec
tio
n.
 4
4 
te
st
ed
 T
S 
ca
se
-
co
nt
ro
l p
ai
rs
 
ne
ga
tiv
e 
S
p,
 S
. v
iri
da
ns
, 
S
tre
pt
oc
oc
cu
s 
gr
ou
p 
A/
C
/D
/n
on
sp
ec
ifi
c,
 
S
a,
 P
. a
er
ug
in
os
a,
 
M
or
ax
el
la
, H
i, 
K
le
bs
ie
lla
, 
N
ei
ss
er
ia
, C
ol
ifo
rm
, 
S
al
m
on
el
la
, 
E
nt
er
ob
ac
te
r 
sa
ka
za
ki
i 
S
p 
(1
6.
5%
), 
N
on
-
au
re
us
 
S
ta
ph
yl
oc
oc
cu
s 
(6
.6
%
) 
In
fe
ct
io
n 
w
ith
 a
ny
 
ba
ct
er
ia
 a
ss
oc
ia
te
d 
w
ith
 T
T,
 s
ev
er
ity
 o
f 
TT
 a
nd
 in
fla
m
m
at
io
n 
G
am
bi
a 
(8
8)
 
Tr
ic
hi
as
is
 p
at
ie
nt
s 
ra
nd
om
ly
 a
ss
ig
ne
d 
to
 tr
ic
hi
as
is
 s
ur
ge
ry
 
pl
us
 a
zi
th
ro
m
yc
in
 o
r 
tri
ch
ia
si
s 
su
rg
er
y 
al
on
e 
to
 s
ee
 
w
he
th
er
 
az
ith
ro
m
yc
in
 h
ad
 a
n 
ef
fe
ct
 o
n 
re
cu
rre
nc
e 
of
 tr
ic
hi
as
is
 
20
4 
TT
 c
as
es
 
re
ce
iv
in
g 
su
rg
er
y 
pl
us
 a
zi
th
ro
m
yc
in
, 
22
2 
TT
 c
as
es
 
re
ce
iv
in
g 
su
rg
er
y 
 
O
ne
 a
na
es
th
et
iz
ed
 
co
nj
un
ct
iv
al
 s
w
ab
 
fo
r C
t, 
on
e 
co
nj
un
ct
iv
al
 s
w
ab
 
fo
r b
ac
te
rio
lo
gy
 
Am
pl
ic
or
 fo
r C
t. 
ST
G
G
 m
ed
iu
m
 fo
r 
tra
ns
po
rt,
 s
tre
ak
ed
 
on
to
 b
lo
od
 a
ga
r, 
M
cC
on
ke
y 
ag
ar
 
(a
er
ob
ic
), 
ge
nt
am
ic
in
 b
lo
od
 
ag
ar
, a
nd
 b
ac
itr
ac
in
 
ch
oc
ol
at
e 
ag
ar
 
5%
 o
f s
tu
dy
 g
ro
up
 
ha
d 
C
t i
nf
ec
tio
n.
 
Ba
ct
er
ia
l p
at
ho
ge
ns
 
w
er
e 
is
ol
at
ed
 fr
om
 
29
.8
%
 b
ef
or
e 
su
rg
er
y 
an
d 
14
.9
%
 
at
 1
2 
m
on
th
s.
 
In
fe
ct
io
n 
w
ith
 C
t a
nd
 
an
y 
ot
he
r b
ac
te
ria
 
no
t a
ss
oc
ia
te
d 
w
ith
 
az
ith
ro
m
yc
in
 
ad
m
in
is
tra
tio
n.
 
K
le
bs
ie
lla
 a
ttr
ib
ut
ed
 
to
 th
e 
w
et
 s
ea
so
n 
S
tre
pt
oc
oc
cu
s 
gr
ou
p 
A/
D
/n
on
sp
ec
ifi
ed
, 
P
. a
er
ug
in
os
a,
 
N
ei
ss
er
ia
, C
ol
ifo
rm
, 
Pr
ot
eu
s,
 E
. c
ol
i, 
S
al
m
on
el
la
, 
S
er
ra
tia
, 
E
nt
er
ob
ac
te
r 
sa
ka
za
ki
i, 
Fu
ng
us
 
Ba
se
lin
e:
 S
p 
(4
2.
4%
), 
S
. v
iri
da
ns
 
(8
.3
%
), 
S
tre
pt
oc
oc
cu
s 
gr
ou
p 
C
 (8
.3
%
), 
St
re
pt
oc
oc
cu
s.
 
(8
.3
%
), 
S
a 
(1
1.
1)
. 
6 
m
on
th
s 
po
st
-
su
rg
er
y:
 K
le
bs
ie
lla
 
(1
6.
3%
), 
M
or
ax
el
la
 
(5
.4
%
), 
S
a 
(2
8.
3%
), 
S
tre
pt
oc
oc
cu
s 
(5
.4
%
), 
S
. v
iri
da
ns
 
(8
.7
%
), 
S
p 
(2
0.
7%
). 
12
 m
on
th
s 
af
te
r 
su
rg
er
y:
 S
p 
(2
6.
0%
), 
S
tre
pt
oc
oc
cu
s 
(7
.8
%
), 
S
tre
pt
oc
oc
cu
s 
gr
ou
p 
C
 (1
0.
4%
), 
S
a 
(2
0.
8%
), 
M
or
ax
el
la
 
(1
2%
), 
H
i (
12
%
) 
In
fe
ct
io
n 
w
as
 m
or
e 
co
m
m
on
 a
s 
tri
ch
ia
si
s 
se
ve
rit
y 
in
cr
ea
se
d 
Tr
ac
ho
m
a 
in
 th
e 
Pa
ci
fic
 Is
la
nd
s 
 
 
N
ep
al
 
(2
16
) 
As
se
ss
in
g 
ch
an
ge
s 
in
 o
cu
la
r f
lo
ra
 a
fte
r 
az
ith
ro
m
yc
in
 
tre
at
m
en
t 
12
2 
ch
ild
re
n 
ag
ed
 1
-
10
 a
ss
es
se
d 
be
fo
re
 
an
d 
2 
w
ee
ks
 a
fte
r 
tre
at
m
en
t w
ith
 o
ra
l 
az
ith
ro
m
yc
in
. 3
8%
 
ha
d 
TF
 
R
ig
ht
 u
pp
er
 ta
rs
al
 
co
nj
un
ct
iv
a 
sw
ab
 
St
an
da
rd
 c
ul
tu
re
 
te
ch
ni
qu
es
 a
nd
 
an
tib
io
tic
 
su
sc
ep
tib
ilit
y 
te
st
in
g 
 
Tr
ea
tm
en
t g
ro
up
 
ha
s 
40
%
 p
at
ho
ge
ns
 
is
ol
at
ed
 b
ef
or
e 
tre
at
m
en
t, 
15
%
 a
fte
r 
tre
at
m
en
t. 
C
on
tro
l 
gr
ou
p 
ha
s 
15
%
 
be
fo
re
 tr
ea
tm
en
t, 
16
%
 a
fte
r t
re
at
m
en
t. 
R
ed
uc
ed
 p
re
va
le
nc
e 
of
 S
tre
pt
oc
oc
cu
s,
 
H
ae
m
op
hi
lu
s 
an
d 
M
or
ax
el
la
 2
 w
ee
ks
 
af
te
r a
zi
th
ro
m
yc
in
 
M
or
ax
el
la
, E
. c
ol
i, 
N
ei
ss
er
ia
 
Pr
e-
tre
at
m
en
t: 
S
p 
(2
2%
) a
nd
 
H
ae
m
op
hi
lu
s 
(7
.4
%
); 
po
st
-
tre
at
m
en
t 
(d
en
om
in
at
or
 fo
r 
tre
at
ed
/n
ot
 tr
ea
te
d 
gr
ou
ps
 n
ot
 
av
ai
la
bl
e)
: S
p 
(9
.2
%
), 
H
ae
m
op
hi
lu
s 
(5
.5
%
) 
N
ot
 te
st
ed
 
N
ep
al
 
(1
87
) 
41
2 
co
nj
un
ct
iv
iti
s 
pa
tie
nt
s 
sc
re
en
ed
 
fo
r C
t H
sp
60
. 
Se
ro
ne
ga
tiv
e 
LP
S-
po
si
tiv
e 
pa
rti
ci
pa
nt
s 
ch
os
en
 a
s 
ca
se
s,
 
se
ro
po
si
tiv
e 
pa
rti
ci
pa
nt
s 
ch
os
en
 
as
 c
on
tro
ls
 
15
 c
as
es
, 2
4 
co
nt
ro
ls
 
U
pp
er
 ta
rs
al
 
co
nj
un
ct
iv
al
 s
w
ab
s 
G
ra
m
 s
ta
in
in
g,
 
ba
ct
er
ia
l c
ul
tu
re
 o
n 
bl
oo
d,
 c
ho
co
la
te
 a
nd
 
m
an
ni
to
l a
ga
r, 
vi
ra
l 
cu
ltu
re
 fo
r H
SV
 a
nd
 
Ad
V,
 D
FA
 s
lid
es
 
pr
ep
ar
ed
 fo
r M
O
M
P 
N
o 
C
t D
N
A 
in
 c
as
e 
or
 c
on
tro
l g
ro
up
. C
, 
ps
itt
ac
i o
r C
. 
pn
eu
m
on
ia
e 
fo
un
d 
in
 4
/1
5 
ca
se
s,
 b
ut
 
no
t i
n 
co
nt
ro
ls
 
C
. p
si
tta
ci
, C
t, 
C
. 
pn
eu
m
on
ia
e 
 
N
ot
 re
po
rte
d 
N
ot
 te
st
ed
 
Tu
ni
si
a 
(2
17
) 
Te
st
 u
se
 o
f c
yt
ol
og
y 
as
 to
ol
 fo
r d
ia
gn
os
is
 
15
1 
ch
ild
re
n 
w
ith
 
tra
ch
om
a 
at
 fi
rs
t 
ex
am
in
at
io
n,
 tr
ea
te
d 
an
d 
fo
llo
w
ed
 u
p 
sp
or
ad
ic
al
ly
. 9
3/
92
7 
sp
ec
im
en
s 
ha
d 
in
cl
us
io
ns
 
Ki
m
ur
a 
sp
at
ul
a 
fro
m
 
ea
ch
 e
ye
 
Sp
re
ad
 o
nt
o 
m
ic
ro
sc
op
e 
sl
id
e 
an
d 
st
ai
ne
d 
C
yt
ol
og
y 
su
ita
bl
e 
di
ag
no
st
ic
 in
 th
e 
ab
se
nc
e 
of
 fa
ci
lit
ie
s 
fo
r f
lu
or
es
ce
nt
 
an
tib
od
y 
st
ai
ni
ng
 o
r 
cu
ltu
re
 
R
el
at
iv
el
y 
fre
qu
en
t 
Ko
ch
-W
ee
ks
 
ba
ci
llu
s 
(m
od
er
n 
na
m
e 
H
i b
io
gr
ou
p 
ae
gy
pt
us
)-l
ik
e 
sl
en
de
r r
od
s 
44
4/
92
7 
sm
ea
rs
 h
ad
 
at
 le
as
t o
ne
 v
is
ib
le
 
ba
ct
er
ia
, o
f w
hi
ch
 
53
%
 w
er
e 
po
or
ly
-
st
ai
ni
ng
 s
le
nd
er
 ro
ds
 
or
 c
oc
co
ba
ci
lli 
(p
ro
ba
bl
y 
H
ae
m
op
hi
lu
s)
, 4
9%
 
de
ns
el
y 
st
ai
ni
ng
 
co
cc
i, 
35
%
 
M
or
ax
el
la
-li
ke
 
di
pl
oc
oc
cu
s 
N
ot
 te
st
ed
 
Su
da
n 
(2
18
) 
C
ro
ss
 s
ec
tio
na
l 
m
ic
ro
bi
ol
og
ic
al
 
di
ag
no
si
s 
of
 
tra
ch
om
a 
in
 th
e 
Su
da
n 
46
 c
hi
ld
re
n 
w
ith
 
ac
ut
e 
tra
ch
om
a 
Bl
un
te
d 
pt
er
yg
iu
m
 
kn
ife
 s
cr
ap
ed
 tw
ic
e 
ac
ro
ss
 th
e 
pa
lp
er
be
ra
l 
co
nj
un
ct
iv
a 
Fi
rs
t s
cr
ap
e 
st
or
ed
 
in
 2
-S
P 
an
d 
cu
ltu
re
d 
in
 h
en
s 
eg
gs
. 
Se
co
nd
 s
cr
ap
e 
sp
re
ad
 o
nt
o 
m
ic
ro
sc
op
e 
sl
id
e 
fo
r 
st
ai
ni
ng
 a
nd
 
m
or
ph
ol
og
y 
ex
am
in
at
io
n 
O
ve
r h
al
f o
f 
tra
ch
om
a 
ca
se
s 
S
a 
54
%
 h
ad
 C
t c
ul
tu
re
d 
in
 e
gg
s.
 2
1.
7%
 h
ad
 
D
ip
th
er
oi
d,
 6
.5
%
 S
. 
al
bu
s,
 6
.5
%
 E
. c
ol
i 
N
o 
tra
ch
om
a-
ne
ga
tiv
e 
pe
op
le
 
ex
am
in
ed
 
Tr
ac
ho
m
a 
in
 th
e 
Pa
ci
fic
 Is
la
nd
s 
 
 
Tu
ni
si
a 
(2
19
) 
Ef
fe
ct
 o
f t
ra
ch
om
a 
tre
at
m
en
t o
n 
pu
ru
le
nt
 
co
nj
un
ct
iv
iti
s 
27
7 
ch
ild
re
n 
in
 tw
o 
Tu
ni
si
an
 v
illa
ge
s,
 
17
%
 h
ad
 tr
ac
ho
m
a 
in
cl
us
io
ns
 o
n 
m
ic
ro
sc
op
y,
 >
18
%
 
ha
d 
ba
ct
er
ia
l 
no
nt
ra
ch
om
ao
tu
s 
co
nj
un
ct
iv
iti
s 
Bo
th
 lo
w
er
 
co
nj
un
ct
iv
al
 s
ac
s 
sw
ab
be
d 
w
ith
 b
ro
th
-
so
ak
ed
 s
w
ab
 
C
ul
tu
re
, G
ra
m
 s
ta
in
, 
an
tib
io
tic
 
su
sc
ep
tib
ilit
y 
as
sa
y,
 
sm
ea
re
d 
on
to
 s
lid
e 
Ba
ct
er
ia
l 
co
nj
un
ct
iv
iti
s 
re
du
ce
d 
by
 
tra
ch
om
a 
tre
at
m
en
t 
N
ot
 re
po
rte
d 
H
ae
m
op
hi
lu
s 
(4
0%
), 
M
or
ax
el
la
 (1
6%
), 
S
. 
vi
rid
an
s 
(6
5%
), 
C
oN
S 
(1
3%
), 
D
ip
th
er
oi
ds
 
[C
or
yn
eb
ac
te
riu
m
] 
(5
2%
), 
N
ei
ss
er
ia
 
(5
.5
%
) 
N
ot
 te
st
ed
 
M
or
oc
co
 
(2
20
) 
Sa
m
pl
es
 
co
nt
in
uo
us
ly
 
co
lle
ct
ed
 d
ur
in
g 
on
e 
ye
ar
 tr
ea
tm
en
t 
su
rv
ei
lla
nc
e 
C
hi
ld
re
n 
ag
ed
 0
-8
 
se
le
ct
ed
 a
t r
an
do
m
 
in
 tr
ea
tm
en
t u
ni
ts
 
Bl
un
t s
pa
tu
la
 
sc
ra
pi
ng
s 
of
 u
pp
er
 
ta
rs
al
 c
on
ju
nc
tiv
a,
 
in
ne
r a
ng
le
 o
f t
he
 
lid
s 
an
d 
fro
m
 th
e 
ou
te
r c
an
th
us
. 
Sc
ra
pi
ng
s 
sm
ea
re
d 
on
to
 s
lid
e,
 G
ra
m
 
st
ai
n 
an
d 
m
or
ph
ol
og
ic
al
 
ex
am
in
at
io
n 
us
ed
 
fo
r i
de
nt
ifi
ca
tio
n 
68
%
 o
f t
ho
se
 <
2 
ye
ar
s 
ha
d 
co
nj
un
ct
iv
iti
s,
 3
2%
 
of
 th
os
e 
2–
8 
ye
ar
s 
ha
d 
co
nj
un
ct
iv
iti
s.
 
Su
bs
et
 o
f 2
12
7 
ex
am
in
ed
 fo
r 
tra
ch
om
a 
72
%
 h
ad
 
Tr
-II
 a
nd
 2
3%
 h
ad
 
Tr
-II
I 
N
ei
ss
er
ia
, 
S
ta
ph
yl
oc
oc
ci
 
H
ae
m
op
hi
lu
s 
(8
1%
), 
M
or
ax
el
la
 (2
0.
1%
), 
S
p 
(1
9%
), 
C
. x
er
os
is
 
(9
.0
%
) 
N
ot
 te
st
ed
 
U
SA
 (2
21
) 
C
lin
ic
al
 tr
ia
l o
f 
tra
ch
om
a 
tre
at
m
en
t 
14
0 
sc
ho
ol
 c
hi
ld
re
n 
 
Fo
rn
ix
 s
w
ab
 
C
ho
co
la
te
 a
nd
 b
lo
od
 
ag
ar
 
41
%
 o
f 
no
rm
al
/s
ca
rre
d 
(T
r-
IV
) p
eo
pl
e 
ha
d 
at
 
le
as
t o
ne
 b
ac
te
ria
 
cu
ltu
re
d,
 4
3%
 o
f 
pe
op
le
 w
ith
 'a
cu
te
' 
tra
ch
om
a 
(T
r-I
/II
/II
I) 
N
ot
 re
po
rte
d 
N
ot
 re
po
rte
d 
N
ot
 te
st
ed
 
In
di
a 
(2
22
) 
C
hi
ld
re
n 
re
cr
ui
te
d 
ov
er
 1
 y
ea
r -
 m
et
ho
d 
un
cl
ea
r 
37
9 
ch
ild
re
n 
ag
ed
 6
 
m
on
th
s 
to
 1
4 
ye
ar
s 
w
ith
 tr
ac
ho
m
a.
 O
f 
th
os
e,
 1
02
 c
hi
ld
re
n 
ha
d 
Tr
-IV
 
Lo
w
er
 fo
rn
ix
 
sa
m
pl
ed
 (m
et
ho
d 
no
t c
le
ar
) 
G
ro
w
n 
on
 v
ar
io
us
 
ty
pe
s 
of
 a
ga
r 
M
an
y 
di
ffe
re
nt
 
ba
ct
er
ia
l g
en
er
a 
id
en
tif
ie
d 
S
. h
ae
m
ol
yt
ic
us
, 
G
ra
m
 n
eg
at
iv
e 
ba
ci
lli,
 M
. l
ac
un
at
a,
 
H
ae
m
op
hi
lu
s 
M
c,
 S
. a
lb
us
, 
D
ip
th
er
oi
ds
, S
. 
vi
rid
an
s,
 S
. 
py
og
en
es
, 
D
ip
lo
co
cc
us
 
pn
eu
m
on
ia
e 
N
ot
 te
st
ed
 
Tr
ac
ho
m
a 
in
 th
e 
Pa
ci
fic
 Is
la
nd
s 
 
 
Ta
iw
an
 
(2
23
) 
C
ro
ss
-s
ec
tio
na
l 
su
rv
ey
 o
f p
re
-s
ch
oo
l 
an
d 
fir
st
 g
ra
de
 
ch
ild
re
n 
an
d 
th
ei
r 
fa
m
ilie
s 
in
 th
re
e 
sc
ho
ol
s 
to
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1.8 Diagnosis of Chlamydia trachomatis infection 
 
Basing treatment decisions on clinical signs of disease is helpful for national programmes, as 
measurement of active disease prevalence requires little specialist equipment or infrastructure. 
However, MDA is expensive, and resources must be prioritized. Clinical signs of trachoma can 
be driven by nonchlamydial pathogens and, after several rounds of MDA, can persist in the 
absence of detectable Ct infection at the population level (224). Nucleic-acid amplification tests 
(NAATs) are much more specific for infection than clinical signs of inflammation, and may 
provide a cost-effective alternative to clinical signs where unnecessary additional rounds of 
MDA are avoided (135). There is, therefore, a potential role for molecular diagnostics in making 
treatment decisions. 
 
Diagnosis of Ct infection was originally based on culture and microscopy, which later gave way 
to the fluorescence-based detection of chlamydial antigens (225) and probe hybridisation of Ct 
DNA (226). Use of NAATs has now been accepted as the gold standard due to their superior 
sensitivity and specificity (139,227,228). Commercial Ct diagnostics are developed for highly 
sensitive and specific detection of infection at the individual level, and are most commonly used 
in the urogenital setting. Some commercial tests have been validated for detection of ocular Ct 
infection, for example Aptima Combo 2 (GenProbe) (229) or the Gene Xpert (Cepheid) (230). 
Both are exquisitely sensitive and offer a diagnostic result that has been globally validated. 
However, they are closed systems which exclusively use proprietary technology, and are often 
prohibitively expensive at the programme level. They also offer very limited additional 
information outside of a binary infection result, meaning the platform cannot be shared between 
programmes to conserve resources. Using noncommercial open-platform NAATs provides 
comparable specificity at a fraction of the financial cost. There can be a performance cost to 
sensitivity, but discrepant results are often the lowest load infections (231), which are thought to 
be of limited importance in transmission (232). RNA-based tests, such as Aptima Combo 2, are 
thought to be highly specific and more sensitive than DNA-based tests due to greater 
abundance of targets (a single organism may have multiple mRNA transcripts per gene copy 
(233)). Diagnostics targeting the Ct plasmid are more sensitive because there are multiple 
plasmids per Ct cell (162). Testing for a fixed copy number target offers comparable specificity 
and allows, in some formats, the accurate quantitation of genome copies (231).  
 
Long-lived markers of infection, such as antibodies, can also be used to investigate past 
exposure to a pathogen. Infection with Ct elicits a substantial humoral response (234,235), 
although the functional importance of this response is unclear. Antibodies to Ct heat-shock 
protein 60 (hsp60) have been shown to associate with worse outcomes in pelvic inflammatory 
disease (236), and with more severe TS (237). Pgp3 has been identified as an 
immunodominant protein, and a specific marker of prior Ct infection in both animal models (238) 
and human patients (239–241). Enzyme-linked immunosorbent assay (ELISA) for anti-Pgp3 
immunoglobulin G (IgG) has shown good comparative performance to anti-MOMP commercial 
tests in patients with urogenital infections (242). Serological responses to chlamydial proteins 
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CT694 and Pgp3 from presumed ocular infection has been shown in a trachoma-endemic 
region of Tanzania (243). At a given cross-sectional time point, a proportion of people living in 
trachoma-endemic communities will be infected but many more will have been exposed in the 
preceding months due to ongoing transmission. Therefore, in a Ct-endemic community, a high 
proportion of children are anticipated to be seropositive. For example, in 160 Tanzanian children 
living in villages to which azithromycin had been distributed, 15% of children had signs of TF, 
and 49% were positive for Pgp3 antibodies. The proportion of seropositive children can also 
differentiate between communities of differing trachoma endemicity (244). Longitudinal analysis 
of seroepidemiology indicates a decrease in anti-Pgp3 and anti-CT694 antibodies 6 months 
following treatment, indicating some degradation of IgG with time, however, no instances of 
seroreversion were identified (245). The Pgp3 amino acid sequence is well conserved between 
Ct serovars therefore serological profiling of Pgp3 cannot distinguish prior ocular from urogenital 
infection; in adult populations seropositivity may sometimes be induced by urogenital infection. 
Some decrease in Pgp3 seroreactivity was observed up to 6 months after most recent 
urogenital Ct infection, but appeared to stabilise for the longer term (246). By modelling the rate 
of change in seroprevalence between age groups, rates of seroconversion can be inferred. If a 
treatment programme successfully reduces infection burden and an F and E programme 
successfully reduces transmission, the rate of seroconversion should also reduce following 
implementation of interventions (224). Where these tools have been used in the post-treatment 
setting alongside NAATs and clinical grading, all three are correspondingly low (247,248). 
 
1.9 Immunology of trachomatous disease 
 
Ocular and urogenital Ct infection trigger acute and chronic inflammatory responses, the current 
understanding of which has been reviewed (249). In vitro studies show that initial infection with 
Ct triggers production of pro-inflammatory factors from epithelial cells, such as IL6 and 
granulocyte macrophage colony stimulating factor (250). Analysis of the conjunctival 
transcriptome of Gambian children with and without TF highlighted pathways involved in antigen 
presentation, cytokine and chemokine production and responses, and both NK- and 
lymphocyte-mediated cytotoxicity. A dominant innate signature was also seen in those with TF 
(251). Immuno-histochemical analysis of biopsies from Omani children with active disease 
illustrated mixed inflammatory infiltrate dominated by CD4+ and CD8+ T-lymphocytes at the 
conjunctiva (252,253). IFNγ is considered the primary mechanism of infection clearance, the 
source of which is suspected to be Th1 and NK cells (254). Those with TF and Ct infection 
exhibit a slightly altered gene expression pattern with higher levels of inflammatory gene 
expression. IL1β, TNFα, MMP9 and IL10 are upregulated in TF, whereas infection triggers 
additional transcription of IFNγ and IL12 p40 subunit (255). Tanzanian children with active 
trachoma had increased transcription of S100A7, IL17A, CXCL5 and CCL18, regardless of 
whether there was a current Ct infection (256). Repeated exposure to Ct appears to result in 
accumulation of partial immunity, as frequency (30) and duration (33) of infection reduces with 
increasing age in trachoma-endemic communities.  
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A key driver of TS is inflammation. Transcriptome analysis of conjunctival swabs from TS cases 
and controls showed no association between TS and the T-helper (Th)1 cell-mediated IFNγ-
producing phenotype seen in children with active disease. Instead, TS was associated with 
increased expression of pro-inflammatory mediators such as S100A7 and interleukin (IL)1β, and 
matrix metalloproteinase (MMP)7, -9 and -12 (257). In addition, inflammation is a key 
determinant of post-surgical relapse to TT, with which S1007A, among other genes, appears to 
associate strongly (86). Dysregulation of the MMP1 to tissue inhibitor of matrix 
metalloproteinase 1 ratio and increased expression of S100A7 is also associated with disease 
recurrence after TT surgery (86,213). Epigenetic factors such as microRNAs have also been 
shown to be differentially regulated in inflammatory TS cases (258). The processes of 
inflammation, scarring and trichiasis can progress even after the cessation of episodes of 
detectable infection (39,85,86,259). Other nonchlamydial infections are associated with 
trachomatous inflammation, and are thought to drive immunopathology. Some of the suspected 
pathogens are described in section 1.6 (11,215). The importance of innate defences in the 
development of scarring was highlighted when the transcription of several MMP genes (MMP7, 
MMP9, MMP10 and MMP12) was found to be up-regulated in patients from whom 
nonchlamydial pathogens were isolated. The innate immune response may therefore contribute 
to accumulation of conjunctival scarring in the absence of detectable Ct infection (259).  
 
A number of host genetic factors have been identified which influence the outcome of 
trachomatous disease. Polymorphisms in IFNγ (260), TNFα (261) and MMP9 (262) have been 
shown to be associated with increased risk of severe scarring. Specific Human Leukocyte 
Antigen (HLA) and Killer Immunoglobulin-like Receptor (KIR) genotype constellations also 
associated with scarring in trachoma (263). SNPs in genes associated with chlamydial cell entry 
and host cellular metabolism appear to be differentially present in cases of scarring (264).  
 
1.10 Trachoma in the Pacific Islands 
 
To meet global elimination targets, previously under-represented populations must be sought 
out and included in worldwide initiatives. Much of our understanding of the biology of trachoma 
comes from research from a small number of countries, such as Nepal, Tanzania and The 
Gambia. Very little has been published on trachoma from small Pacific Island countries. 
Countries in the WHO Western Pacific Region, such as China (212),  Cambodia (265) and 
Australia (266), have incorporated research into their control strategies which shows a clinical 
picture appropriately diverse given the large economic, cultural and ethnic disparities throughout 
the region. When the availability and quality of trachoma mapping was summarised in 2005, the 
Pacific Islands were noted to have particularly sparse data (267). Many of the independent 
Pacific Island small states, including Solomon Islands, Vanuatu and Fiji, often face significant 
challenges in provision of basic services and infrastructure to geographically isolated regions, 
and therefore perform poorly in development indices (268). Indigenous Pacific Islands 
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populations are dominated by three genetically distinct ethnicities: Melanesian, Polynesian and 
Micronesian (269). A map of the Pacific Islands is shown in figure 1.10.1. 
 
Trachoma is rarely mentioned in reports of causes of blindness throughout the Pacific. Trauma, 
cataract and diabetic retinopathy (figure 1.10.2) were among the most common causes of visual 
impairment in Fiji and Solomon Islands in one literature review from 2002. The same report 
suggested trachoma to be a major cause of visual impairment in Papua New Guinea, although 
no evidence was presented to substantiate the claim (270). Pterygium is also common (figure 
1.10.2). A small number of cases of trachoma were also identified in Vanuatu and Tonga during 
surveys of general blindness, although the method for assessing trachoma was not clear 
(271,272). Trachoma was also uncommon or completely absent in surveys of blindness in the 
Cook Islands, Samoa, Fiji and Tonga (273–275). Anecdotally, trichiasis patients rarely present 
to ophthalmic services and surgical outreach programmes (R Le Mesurier, personal 
communication), although cases have been operated on recently (figure 1.10.3). TT was rarely 
seen during recent outreach clinics to the Pacific (276). 
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Figure 1.10.2. Common threats to vision in the Pacific Islands. (A) Pterygium, (B) cataract and (C) diabetic 
retinopathy. 
 
Figure 1.10.3. Right eye of a Solomon Islander from Malaita province who presented for trichiasis surgery in 
2016. >10 eyelashes are deviated and contact with the globe of the eye, including over the cornea (Photo credit: O 
Sokana). 
 
Historical reports have indicated the presence of trachoma in the Pacific region. In 1934, 
MacCallan amalgamated existing data on trachoma across the British Empire, and noted 
prevalent conjunctivitis in Fiji, of which he had “little doubt that it is trachoma”. He also noted 
eight cases of trachoma in the British Solomon Island Protectorate (renamed as the Solomon 
Islands following their independence from British rule in 1976), and concluded that it “looks as if 
trachoma were definitely prevalent” (278). Qualitative, observational studies indicated presence 
of trachoma in Fiji and Papua New Guinea (279–281). Trachoma in Papua New Guinea was 
noted to be endemic but “of mild intensity and rarely caused visual deficit” (282). Mann recorded 
a high proportion of examined individuals with trachoma (MacCallan stage Tr I-IV, not separated 
in discussion) throughout modern-day Papua New Guinea, Fiji, Samoa and Niue during her 
global expeditions in the 1950s; the method of selection of participants was not clear so no 
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estimate of prevalence can be made (283). Trachoma has also been mentioned in more recent 
summaries of neglected tropical disease (NTD) prevalence in the region (284) although 
accurate prevalence estimates are missing. In response to the requirement for more data, a 
Trachoma Rapid Assessment (TRA) was undertaken in Nauru, Kiribati, the Solomon Islands, 
Vanuatu and Fiji in 2007 (6). The findings strongly indicated presence of active trachoma, 
scarring and trichiasis in the region, and warranted further investigation (6). The average 
reported rate of trichiasis surgeries at the National Referral Hospital (NRH) in the Solomon 
Island capital Honiara was four per year over a four-year period (6). Very few studies have 
investigated ocular Ct infection in the Pacific. Bodian observed Giemsa-stained “Prowasek–
Halberstaeder inclusions” consistent with Ct infection in conjunctival specimens from 42 out of 
100 adult Fijians in the 1940s. The clinical status of study subjects was carefully described, with 
most classified as having active trachoma because of scarring, corneal pannus and 
inflammation, whereas very few had follicles (285). Ocular Ct infections have also been 
detected in the Pacific region by yolk sac culture in Taiwan in the 1950s (286)  and by PCR in 
Australia (71).  
 
The International Agency for the Prevention of Blindness commissioned PBPSs for trachoma in 
the Solomon Islands, Fiji and Kiribati between 2011 and 2012 (287). The clinical picture of 
trachoma in the region was highly variable. Kiribati appeared to have a moderate burden of TT 
(1.5% in those aged ≥15 years), Fiji had a very high burden of TT (7.4% in those aged ≥15 
years), but the Solomon Islands had only three cases, despite over 2000 adults taking part in 
screening. All three countries were reported to have TF prevalence in those aged 1–9 years 
between 10% and 25% in study districts. The report also highlighted low levels of improved 
latrine availability. Interestingly, water availability was found to be good, perhaps due to regular 
rainfall from the tropical climate. The prevalence of trichiasis in Fiji in particular was surprising 
given contemporary studies of major causes of blindness specifically reported that trachoma did 
not appear to be prevalent (275). The GTMP has subsequently supported several surveys in 10 
districts across Melanesia (288–290). The data are summarised in table 1.10.1. Of the GTMP 
survey districts, 6/9 had more than 10% TF in the 1–9 year-olds, whereas 1/9 districts had 
greater than 0.2% TT in those over 15 years of age (the WHO classification of a public health 
problem). The GTMP also carried out a survey in Kiritimati, in the east of Kiribati and showed 
there to be sufficient TF and TT to present a threat to public health, replicating the data from 
Tarawa in the west of Kiribati.   
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Table 1.10.1. Current population-based prevalence estimates of trachoma endemicity in the Pacific.  
 
Country 
(population*) 
EU 
Examined  
(1–9 years) 
% TF1-9 
Examined  
(15+ years) 
% TT15+ 
Study year 
(reference) 
Papua New 
Guinea 
(7,300,000) 
South Fly/Daru** 790 11.2 821 0 
2016 
(288) 
Madang** 1033 9.4 2062 0 
Southern Highlands (east)** 1391 12.2 773 0 
National Capital District** 888 6.0 1987 0 
Southern Highlands (west)** 859 11.7 1579 0 
West New Britain** 1000 11.4 837 0.5 
Solomon 
Islands 
(560,000) 
Western** 996 20.4 1679 0.16 2013 
(290) Choiseul** 881 6.1 1446 0 
Isabel 1064 24.3 590 0.3 
2011 
(287) 
Central 772 19.2 1013 0.1 
Guadalcanal 1000 15.3 - - 
Honiara 1026 12.0 - - 
Malaita 1066 19.2 - - 
Makira 1071 22.3 753 0 
Vanuatu 
(253,000) 
Full country excluding Tafea** 928 12 2511 0.04 
2013 
(289) 
Fiji 
(881,000) 
Northern 1000 20.9 1016 6.2 
2012 
(291) 
Central and Eastern 1000 10.6 - - 
Suva 1000 10.4 - - 
Western 1000 19.6 954 8.7 
Kiribati 
(102,000) 
South Tarawa and Betio 999 21.3 959 1.5 
2012 
(287) 
Kiritimati** 406 28.0 416 0.2 
2016 
(292) 
EU: Evaluation unit; TF1-9: Trachomatous inflammation–follicular in those aged 1–9 years; TT15+: Trachomatous 
trichiasis in those aged 15 years and over. 
* 2016 population estimates 
** GTMP estimates of prevalence are adjusted for age and gender. 
 
The first part of this thesis includes data on trachoma prevalence in four states of the western 
Pacific including Kiribati, Vanuatu, the Solomon Islands and Fiji. The remainder will focus on the 
Solomon Islands and Fiji (figure 1.10.4).  
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A 
B 
 
Figure 1.10.4. Provincial maps of (A) Fiji and (B) Solomon Islands. Prepared using Miller Projection with QGIS 
2.16.3 [256]. Shapefiles taken from Natural Earth and www.gadm.org. 
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Both Solomon Islands and Fiji are made up of hundreds of widely dispersed coral atolls and 
steep-sided volcanic islands. The climate is tropical with warm temperatures and high humidity. 
In comparison to other trachoma-endemic areas, the Solomon Islands do not experience wide 
seasonal variation in rainfall (illustrated in figure 1.10.5). Most healthcare services in both 
countries are provided through the Ministry of Health and Medical Services (MHMS) and 
healthcare facilities in urban centres, but a substantial proportion of the population live 
traditional lifestyles with very limited resources in remote, dispersed islands. The Solomon 
Islands had an estimated population of 515,810 in 2011 (293), and the population is rising due 
to the high birth rate (estimated at 4.1 births per woman). The population is predominantly of 
Melanesian (94.5%) or Polynesian (3.0%) ethnicity. Fiji is situated to the south east of the 
Solomon Islands, has an estimated population of 837,271 in 2012 (294), of which 56.8% are 
iTaukei (native Fijian) and 37.5% are Indian Fijian. Neither the Solomon Islands nor Fiji had 
implemented any trachoma-targeted interventions prior to the beginning of the study, however, 
during the study time period a single round of azithromycin MDA was distributed in the Solomon 
Islands in the final quarter of 2014, along with a public awareness campaign consisting of 
newspaper articles (295), radio adverts and public posters (figure 1.10.6). The first round of 
azithromycin MDA in Fiji is planned for February 2017. 
 
 
Figure 1.10.5. Temperature and rainfall in Addis Ababa, Ethiopia, and Lata, Solomon Islands. Seasonality in 
rainfall in is observed in Ethiopia (pink bars) but not in Solomon Islands (grey bars). In both Ethiopia (red line) and 
Solomon Islands (black line) the mean temperature is consistent all year round. Data are monthly averages from the 
past 12 years, collected by the Ethiopian National Meteorology Agency and the Solomon Islands Meteorological 
Services, respectively.   
 
Current data therefore suggest the Pacific Islands present a mosaic pattern of trachoma, with 
Solomon Islands and Vanuatu having very little trichiasis, Kiribati having moderate trichiasis 
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warranting intervention, and with Fiji having inconsistent levels of trichiasis between studies. 
The prevalence of TF is mostly between 10 and 30%, with only one evaluation unit (EU) below 
the 10% threshold for priority intervention. In Vanuatu and Solomon Islands in particular, the 
prevalence of TF is sufficient to warrant MDA to most of the population, yet the prevalence of 
TT is insufficient to be classed as a public health problem. There is uncertainty about the true 
pattern in areas where data is inconsistent (e.g. Fiji) or unusual (e.g., Solomon Islands) 
therefore a number of questions must be addressed. These are the source of the hypotheses in 
chapter two. Firstly, it is important to ascertain whether these findings are reproducible. If so, 
the burden of ocular Ct infection in both Fiji and the Solomon Islands should be ascertained to 
determine whether light can be shed on the respectively high and low prevalence’s of trichiasis.  
 
 
Figure 1.10.6. Trachoma public awareness campaign poster outside Henderson International Airport, Honiara.  
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2. STUDY HYPOTHESES AND RATIONALE   
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2.1 Hypotheses 
 
Figure 2.1.1 is a schematic describing the current conceptualisation of trachoma disease 
pathogenesis and progression, and highlights the points targeted for assessment in this thesis. 
 
2.1.1 Hypothesis 1 
 
In Melanesia, TF prevalence is above the threshold for intervention whereas TT prevalence is 
too low to be classified as a public health problem; the previous findings are reproducible and 
not an artefact of individual surveys. 
 
2.1.2 Hypothesis 2 
 
Clinical signs of TF and ocular infection with Ct are not associated in areas where high TF is 
concurrent with low TT. 
 
2.1.3 Hypothesis 3 
 
One or more alternative pathogens associate more closely with TF than Ct does in areas where 
there is a discordance between TF and TT. 
  
2.2 Rationale 
 
Active trachoma appears to be sufficiently prevalent in Melanesia to warrant intervention with 
MDA. However, trichiasis appears to be rare, and, in most areas, present at a prevalence lower 
than WHO’s threshold for what constitutes a public health problem. Local policy makers are 
thereby presented with a dilemma over whether to invest in costly community-wide drug and 
WASH interventions when trachoma does not appear to constitute a significant threat to vision 
in this region. Research is urgently required to determine whether there is any evidence of 
intense transmission of Ct, thought to be the principal driver of inflammation that predisposes 
people to scarring and eventually trichiasis. A better understanding of this problem is critical to 
local policy, but the decline in the global burden of trachoma will cause the positive predictive 
value (PPV) of TF as a marker to drop, and therefore this work is also likely to be highly 
valuable in wider, global-level decisions about which tools are appropriate to characterise 
disease patterns and guide treatment decisions. 
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3. TRACHOMA IN THE PACIFIC: A CONTEMPORARY 
OVERVIEW 
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3.1 Introduction 
 
Reproducible, transparent and consistent survey methodologies are critical to ensuring within- 
and between-region comparability. There are several Pacific Island countries where trachoma 
data have, until recently, been very sparse. Historical observational reports are not useful for 
determining the current burden of disease, and TRA methodology cannot provide accurate 
population-based prevalence estimates. This chapter sets out to determine whether the clinical 
picture in the Pacific is reproducibly detected. Clinical data are collected in a series of field 
surveys. The methodology used is defined, demonstrating that it meets international 
expectations for generation of high-quality trachoma prevalence data. 
 
3.1.1 Objective 
 
In the Pacific, the trachoma phenotype is suspected to be unusual but given the temporal and 
spatial variability of disease and the inherent subjectivity of clinical grading, the first objective of 
this study was to determine whether the phenotype could be reproduced. This data will 
contribute to the map of trachoma throughout the region. In the Solomon Islands and Fiji, this 
was done in conjunction with ongoing GTMP activities.  
 
3.2 Methods 
 
3.2.1 Study ethics and consent 
 
The study adhered to the tenets of the Declaration of Helsinki. 
 
Solomon Islands and Fiji surveys dovetailed with GTMP activities, which was covered under 
LSHTM ethics approval 6319. All surveys, including those where specimens were collected, 
were additionally approved by the LSHTM Observational Ethics Committee (Solomon Islands 
and Fiji: 6360, amendment 10145; Vanuatu and Kiribati: 11158). Respective national ethics 
review boards from the Solomon Islands (HRC13/18), Vanuatu (MOH/DG 01/21 GKT-lr), Fiji (no 
reference provided) and Kiribati (email dated 25th May 2016) each individually approved the 
protocol for use in-country.  
 
The study was described verbally to all study participants in local language prior to enrolling. All 
study participants were required to provide written consent to take part in the study. For those 
under the age of 18 years, a parent or guardian provided written consent on their behalf. 
 
3.2.2 Study design 
 
Surveys were designed to meet the standards set by the GTMP, or to utilize protocols 
compatible with the GTMP data collection (15). Two-stage random cluster PBPS were planned. 
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A number of factors were taken into account when choosing the EU, including provincial and 
national population, logistic implications of EU geographic distribution, existing programmatic 
opportunities for collaboration and local knowledge of NTD context. Based on these, the island 
of Tarawa was selected in Kiribati, rural areas of the whole country of Vanuatu (the larger 
towns, Luganville and Port Vila, were excluded), the rural areas of Viti Levu (Ra, Ba and 
Nadroga-Navosa provinces) in Western Division of Fiji and the Temotu and Rennell and Bellona 
provinces of the Solomon Islands.  
 
International Agency for the Prevention of Blindness surveys in 2012 demonstrated prevalence 
of TF in children in Kiribati, Fiji and Solomon Islands to be around 20% (287). In an area with 
endemic Ct infection and that prevalence of TF, the prevalence of ocular Ct might be expected 
to be approximately 10% across the region. To ensure homogeneity between studies and with 
the GTMP, all studies were designed to estimate a prevalence of Ct infection of 10% in children 
aged 1–9 years with a precision of ±3% at the 95% confidence level. The design effect used 
was 2.65. To account for estimated nonresponse rate, the target sample size was inflated by 
10%. Based on those assumptions, 1120 children per EU were needed to meet the sample 
size. Based on the census data in Solomon Islands, Vanuatu and Fiji, there were 1.2 children 
aged 1–9 years expected per household and therefore 934 households were needed to meet 
the sample size (293,294,296). In Kiribati, 1.8 children were expected per household, so at least 
623 households were required (297). For the purposes of baseline surveys, one team was 
considered to be able to examine 30 households per day in Solomon Islands, Vanuatu and Fiji 
and 25 households per day in Kiribati. A total of 32 clusters were therefore randomly selected in 
each of the Melanesian EUs and 25 clusters in the Kiribati EU from a list of all clusters in an EU. 
In Fiji, Vanuatu and Kiribati, probability-proportionate-to-size sampling was used to ensure 
appropriate chance of inclusion for all clusters based on size.  In Solomon Islands, simple 
random selection was used to select villages as reliable village size data were not available. In 
each cluster, a list of occupied households was compiled with the help of village leaders and an 
appropriate number of households were randomly drawn from a hat.  
 
3.2.3 Clinical grading and data collection 
 
In each country, ophthalmic or general nurses were recruited to conduct clinical grading. An 
internationally standardised grader training scheme, developed as part of the GTMP (15), was 
used to validate graders. Participating graders attended trachoma theory classes, achieved a 
kappa agreement score (a measurement of inter-rater agreement between -1 and +1, where -1 
is perfect disagreement, 0 is agreement no better than random chance and +1 is perfect 
agreement (298)) in excess of 0.8 with grades assigned by an experienced trachoma grader 
when grading photographs, and achieved a kappa score of 0.7 when grading eyelids of school 
children also graded by a certified grader trainer, who had been validated against a very 
experienced trachoma grader. Graders were not formally certified for TT grading; kappa scores 
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were based on TF grade due to the lack of TT cases in school-aged children for validation, 
however, the definition of TT was thought to be sufficiently clear to allow graders to identify it.  
 
Each participant over the age of 1 year in all selected survey households had both eyes graded 
for TT in primary gaze and then had both eyelids everted for grading of TF and TI. TS, CO and 
other ocular morbidities were not systematically assessed in these surveys due to a lack of 
internationally standardised training schema for them. 
 
Data were collected by dedicated data recording staff using Open Data Kit (ODK) electronic 
data capture system on Android operating system smartphones. For the pre-MDA Solomon 
Island and Fiji surveys, the data collection tool was developed externally for the GTMP; for the 
Vanuatu and Kiribati surveys, a bespoke data collection tool was designed.   
 
In all surveys, conjunctival, photographic and blood specimens were collected as part of other 
studies, some of which are presented below, and others are part of ongoing operational 
surveillance programmes.  
 
3.2.4 Data cleaning and analysis 
 
Raw survey data were imported from ODK servers in .csv file format. Data were used 
anonymously, with a unique study identifier used to link demographic and disease data. 
Duplicated participant entries and those who either declined examination or could not be 
examined were removed from the final dataset used to estimate prevalence. 
 
Raw prevalence estimates were adjusted for age using 1-year age bands for the 1–9-year age 
group, and adjusted for age and gender using 5-year age bands for the ≥15-years age group 
taken from the most recent available census data.  
 
3.2.5 Role of the candidate  
 
The data presented below result from field studies and analyses that this author led (Vanuatu, 
Kiribati) or was involved in via collaboration with GTMP activities (Solomon Islands, Fiji). Data 
generated concurrently that I did not play a role in (for example, Solomon Island GTMP data 
from Choiseul and Western Province) are summarised in the thesis introduction. 
 
The clinical data collected in the Temotu, Rennell and Bellona in the Solomon Islands and 
Western Division of Fiji were collected as part of the GTMP. As such, the study design, the 
planning for the survey, the staff training and the implementation of the survey was primarily a 
result of collaboration between the respective MHMS in each of the countries and the GTMP 
Working Group. Data were collected using a version of the bespoke GTMP app that was 
modified to facilitate collection of specimens. Data for the primary GTMP analysis were curated 
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and cleaned at the Task Force for Global Health in Atlanta, and owned by each respective 
MHMS (15). 
 
The infection surveys described in chapters four to seven were embedded within the GTMP 
studies; I was directly involved in the planning of the infection component of both surveys and 
therefore indirectly in the execution of the clinical component. I accompanied the team in 
Temotu, Rennell and Bellona to assist with specimen collection. I performed the age-
adjustments presented here independently of the GTMP age-standardisation process with the 
permission of the Solomon Islands MHMS (the end result was the same). The age-adjusted 
prevalence estimates from Fiji were generated by GTMP investigators.  
 
The studies in Vanuatu and Kiribati were carried out independently of the GTMP. The projects 
were conceived by the Pacific Trachoma Initiative meeting in March 2015. The surveys were 
designed, planned and executed by Chrissy Roberts, David Mabey and the candidate. 
 
3.3 Results 
 
3.3.1 Study demographics 
 
The study enrolled over 12,000 people of all ages prior to MDA from a total resident population 
of almost half a million people. The sample size required to estimate a TF prevalence with 
sufficient precision to determine whether MDA is required (10% ± 3%) was achieved in all EUs. 
In the 1–9-year-old age group, both genders were evenly represented in all four surveys. Men 
were typically under-represented in the ≥15-years age group. The proportion of the respective 
national populations covered by these EUs ranged from 5% (Solomon Islands) to 76% 
(Vanuatu). 
 
Table 3.3.1.1. Descriptive summary of populations surveyed in this study.  
Evaluation Unit 
Total 
population* Examined 
Children 
(1–9 years) 
Adults 
(≥15 years) 
n % male n % male 
Solomon Islands (Temotu, Rennell and Bellona) 24,403 3674 1135 53.6 2061 42.5 
Vanuatu (excl. Luganville, Port Vila) 176,816 3472 1112 52.5 1941 41.2 
Kiribati (Tarawa) 56,284 2922 1036 49.5 1602 31.9 
Fiji (rural Viti Levu, Western Division) 184,039 2306 1038 51.7 933 34.5 
Total 441,545 12,374 4322 - 6537 - 
n: denominator. 
* Population estimates from most recent census data (293,294,296,297) 
 
3.3.2 Active trachoma 
 
Trachoma was endemic in study EUs in Solomon Islands, Vanuatu and Kiribati. In each of these 
EUs, the prevalence was (according to WHO guidelines for trachoma control) high enough to 
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warrant intervention with at least three rounds of MDA prior to re-assessment. In Kiribati, the 
prevalence of TF indicated five rounds of MDA should be conducted prior to re-assessment. In 
Fiji, the adjusted trachoma prevalence was below the WHO target for treatment. In all EUs, very 
few cases of TI were graded clinically, despite some (such as Kiribati) having substantial 
burdens of TF.  
 
Table 3.3.2.1. Cases of trachomatous inflammation – follicular (TF) and trachomatous inflammation – intense 
(TI), and age-adjusted prevalence of TF in children aged 1–9 years. 
Evaluation Unit n TF (%) TI ± TF (%)  
Age-adjusted 
TF prevalence 
95% confidence 
interval 
Solomon Islands 1135 296 (26.1) 2 (0.2) 22.0 18.5-26.0 
Vanuatu  1112 184 (16.5) 0 (0.0) 16.5 14.3-18.7 
Kiribati  1036 436 (42.1) 7 (0.7) 38.2 35.7-41.5 
Fiji 1038 34 (3.3) 2 (0.2) 2.8 1.4-4.3 
n: denominator; TF: Trachomatous inflammation – follicular; TI: Trachomatous inflammation – intense. 
 
3.3.3 Trichiasis 
 
None of the Melanesian EUs studied had trichiasis above the threshold classed as a public 
health problem by the WHO. In Kiribati, the prevalence of trichiasis was well in excess of the 
WHO threshold for intervention, which suggests that there is a requirement for surgical 
intervention as part of the SAFE strategy. 
 
Table 3.3.3.1. Cases of trichiasis and age- and sex-adjusted prevalence of trichiasis in adults aged 15 years and 
over. 
Evaluation Unit n TT (%) 
Age- and sex-adjusted 
TT prevalence 
95% confidence 
interval 
Solomon Islands 2061 2 (0.1) 0.1 0.0-0.1 
Vanuatu  1941 0 (0.0) 0.0 0.0-0.3 
Kiribati  1602 18 (1.1) 0.9 0.5-1.2 
Fiji 933 0 (0.0) 0.0 0.0-0.2 
n: denominator; TT: Trachomatous trichiasis. 
 
3.4 Discussion 
 
The evidence from this study supports the anecdotal and PBPS evidence from the Pacific, 
suggesting active trachoma is prevalent throughout the region, but prevalence of clinical signs 
of TT are rare in Melanesia. The clinical scenario in Kiribati seems more severe, with a much 
higher prevalence of TF, and more cases of TI and TT. Based on this and the previous 
evidence, SAFE implementation is urgently required in Kiribati. Under current WHO guidelines, 
Vanuatu, Fiji and Solomon Islands are eligible for intervention with A, F and E components of 
SAFE. These are costly interventions, and particularly the F and E components require long-
term sustained investment in WASH infrastructure. Moreover, entire nations are exposed to 
broad-spectrum antibiotics, and although evidence does not consistently show a threat of 
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resistance emergence after MDA, decisions must be well-justified prior to commencement of 
treatment. In that context, the prevalence of TT in these countries becomes an important factor 
for consideration. Previous data (6,281) show that cases of trichiasis are found in Melanesia, 
however, the prevalence seems to be at or below the WHO’s definition of a public health 
problem in all recent PBPS from the region. This raises an important question for how trachoma 
must be managed here: is trachoma a threat to public health? If not, should programmes invest 
in costly interventions and community-wide antibiotic exposure to meet guidelines that have not 
been extensively evaluated in the Pacific Island context? While the simplified system appears to 
be an excellent tool throughout sub-Saharan Africa to estimate the endemicity status of a 
district, in Melanesia the evidence generated using clinical grading by this system is 
inconsistent. Tools are under development for programmatic use to combat the lack of 
association between clinical signs of trachoma and infection following MDA; these tools may be 
useful in the Pacific to further characterise disease and define need for intervention. The 
exception to this pattern is Fiji where the prevalence of TT was previously recorded at almost 
8% across the country (291), one of the highest in the world. This estimate is not independently 
reproducible when using highly standardised techniques, thereby justifying the caution with 
which this figure was treated by the authors of the original manuscript (291).  
 
The subsequent chapters present data on ocular infections with a view to investigating the 
potential reasons for the scarcity of TT. The specimens analysed were collected during the 
surveys in Fiji and Solomon Islands. In chapter four, conjunctival swabs from Fijian children are 
analyzed to further support the low prevalence of TT by determining whether it is concurrent 
with prevalent ocular Ct infection.  
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4. OCULAR CHLAMYDIA TRACHOMATIS INFECTION IN 
FIJI  
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4.1 Manuscript 
 
Previous surveys of trachoma in Fiji had indicated that trichiasis was common, and comparable 
in prevalence to some of the most heavily endemic districts of sub-Saharan Africa. The 
following publication considers the burden of Ct infection in Fijian children, and indicate that the 
low estimate of TT prevalence was concurrent with a low prevalence of ocular Ct infection 
(299).  
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Abstract
Background
Trachoma is the leading infectious cause of blindness and is caused by ocular infection with
the bacterium Chlamydia trachomatis (Ct). While the majority of the global disease burden
is found in sub-Saharan Africa, the Western Pacific Region has been identified as trachoma
endemic. Population surveys carried out throughout Fiji have shown an abundance of both
clinically active trachoma and trachomatous trichiasis in all divisions. This finding is at odds
with the clinical experience of local healthcare workers who do not consider trachoma to be
highly prevalent. We aimed to determine whether conjunctival infection with Ct could be
detected in one administrative division of Fiji.
Methods
A population-based survey of 2306 individuals was conducted using the Global Trachoma
Mapping Project methodology. Population prevalence of active trachoma in children and tri-
chiasis in adults was estimated using the World Health Organization simplified grading sys-
tem. Conjunctival swabs were collected from 1009 children aged 1–9 years. DNA from
swabs was tested for the presence of the Ct plasmid and human endogenous control.
Results
The prevalence of active trachoma in 1–9 year olds was 3.4%. The age-adjusted preva-
lence was 2.8% (95% CI: 1.4–4.3%). The unadjusted prevalence of ocular Ct infection in
1–9 year-olds was 1.9% (19/1009), and the age-adjusted infection prevalence was 2.3%
(95% CI: 0.4–2.5%). The median DNA load was 41 Ct plasmid copies per swab (min 20,
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Discussion
TheWestern Division of Fiji has a low prevalence of clinical trachoma. Ocular Ct infections
were observed, but they were predominantly low load infections and were not correlated
with clinical signs. Our study data suggest that trachoma does not meet the WHO definition
of a public health problem in this Division of Fiji, but the inconsistency with previous studies
warrants further investigation.
Author Summary
Trachoma, caused by ocular strains of Chlamydia trachomatis, represents a major global
public health issue, and is the subject of an international elimination campaign. Until
recently, data on trachoma in the Pacific Island states have been sparse. The most recent
studies have conflicted in their estimates of trachomatous disease burden in Fiji, therefore,
surveys using alternative markers (infection testing plus grading) to those already used
(grading alone) are warranted to try to shed further light on trachoma epidemiology in
this setting. We used an externally validated clinical assessment protocol to show that evi-
dence of active trachoma is present at a low prevalence, and we did not find any cases of
trichiasis, the sight-threatening stage of trachoma. From testing of conjunctival swabs with
a validated, next-generation PCR, we also found that C. trachomatis was present at a low
prevalence. Our clinical data suggest that trachoma does not meet the WHO definition of
a public health problem in this Division of Fiji, but the inconsistency with previous studies
warrants further investigation.
Introduction
Trachoma is the leading infectious cause of blindness, and is caused by ocular infection with
the bacterium Chlamydia trachomatis (Ct). Trachoma is thought to be a public health problem
in 51 countries, with 232 million people at risk of blinding disease [1]. Infection may present as
an acute and self-limiting keratoconjunctivitis, but numerous re-infections can lead to poten-
tially blinding sequelae.
Globally, the highest prevalence of active trachoma is found in sub-Saharan Africa [1].
Transmission of infection is thought to be through direct contact with hands or cloths which
transfer ocular or nasal discharge between individuals [2], although the bacteria can also be
spread by passive contact with eye-seekingMusca sorbens flies [3].
Trachoma is diagnosed by clinical examination of the eye. Active trachoma is characterised
by the presence of 5 or more>0.5mm lymphoid follicles in the central part of the upper tarsal
conjunctiva (trachomatous inflammation–follicular, TF) and/or pronounced inflammatory
thickening of the upper tarsal conjunctiva obscuring more than half the normal deep tarsal ves-
sels (trachomatous inflammation-intense, TI) [4]. Scar tissue deposited during resolution of
inflammatory disease episodes leads, in some individuals to the misdirection of eyelashes so
that they touch the eyeball; this state is known as trachomatous trichiasis (TT) [4,5].
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TheWorld Health Organization (WHO) advocates the use of the SAFE strategy–Surgery for
trichiasis, Antibiotics, Facial cleanliness, and Environmental improvement, for elimination. Annual
mass drug administration (MDA) of the antibiotic azithromycin is recommended for at least 3
years in any district where the prevalence of TF in 1–9 year olds is estimated to be 10% or greater.
The decision to undertake MDA is informed by data from a population-based prevalence survey
(PBPS) [6] in any district that has been identified as being of concern. The Global TrachomaMap-
ping Project (GTMP) [7] is currently undertaking PBPSs in all secure probably-endemic districts
worldwide, in an effort to complete the baseline trachoma map by the end of 2015.
Cases of trachoma have historically been reported in Fiji [8–11]. A 2007 rapid assessment
found a high prevalence of active trachoma in targeted Fijian villages, but no cases of TT [12].
In 2012, a PBPS was undertaken in each of Fiji’s four divisions, which estimated division-level
prevalences of TF in 1–9 year olds ranging from 10.4–20.9% (19.6% inWestern Division). Indi-
viduals aged over 15 years were examined only in Western and Northern Divisions, with preva-
lences of TT in that age group estimated at 8.7% and 6.2%, respectively [13]. The 2012 PBPS
results suggested that trachoma was highly endemic in Fiji, and that the prevalence of TT was
among the highest in the world. This was in stark contrast to the experience of Fijian ophthal-
mologists who see cases of TT quite infrequently [12–14].
We conducted a PBPS for TF and TT in the Western Division of Fiji (total rural population
184,039; Fig 1) [15]. In addition we collected conjunctival swabs from children, which were
Fig 1. The four administrative divisions of Fiji, with the selected clusters in theWestern divisionmarked as points. Prepared
using ArcGIS 10.2 (ESRI).
doi:10.1371/journal.pntd.0004798.g001
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then processed and subjected to PCR with the aim of estimating the prevalence of ocular Ct
infection.
Methods
Ethics statement
The study was conducted in accordance with the Declaration of Helsinki. Consent was
obtained from the leader of each community prior to entry into the community. Where possi-
ble, village chiefs, local headmen or local leaders were contacted in advance of the survey to
gain consent to enter the respective villages. In indigenous Fijian villages, sevu-sevu, a tradi-
tional welcome ceremony involving sharing a Kava root-infused water with village leaders, was
performed in accordance with the local custom. The study was designed to be paper-free which
enabled real-time data upload and review, and streamlined field logistics. In this rural Fijian
context, it was considered culturally appropriate for those over the age of 15 to consent for
themselves. Verbal informed consent to be examined was obtained from each participant over
the age of 15 years. For participants under the age of 15 years, consent for examination and to
have specimens collected was given on their behalf by a legally responsible parent or guardian.
The Fiji National Research Ethics Review Committee and the London School of Hygiene &
Tropical Medicine ethics committee approved this consent protocol. All consent was recorded
electronically via the Android phone-based data-capture system [7].
Study design
A cross-sectional, cluster random sample survey methodology was conducted in November
and December 2013. Villages identified from local census lists were considered as potential
clusters in the sampling. A total 31 villages were selected for inclusion, with 30 households
sampled per cluster. The total number of villages was calculated based on the anticipated num-
ber of children per household from the latest available census data [15]. In the first stage, after
the exclusion of urban centres, villages were sampled with probability proportional to size. At
the second stage of sampling, 30 households within a village were selected. Households were
selected at random on the day of survey from a list of village households compiled by the village
health worker or the village leader. Any person aged one year or more living in a sampled
households was invited to participate. Effort was made to ensure participation by absent house-
hold members by returning later in the day where possible.
Sample size
The study was powered to estimate a 10% prevalence of ocular Ct infection in 1–9 year olds
with absolute precision of ±3% and 95% confidence. A design effect correction of 2.65 was
used, based on previous trachoma surveys [7]. We included 10% oversampling in order to
account for non-response, the required sample size was 1120 children in this age group. Based
on 2007 census data, we expected to find 1.2 children aged 1–9 years per household, therefore
we estimated 30 households from each of 31 clusters would be sufficient to recruit 1120 chil-
dren. The overall sampling methodology was in accordance with that used in the GTMP [7].
Data collection
Data were collected on an Android smartphone using a slightly modified version of the GTMP
LINKS app, which is an implementation of the Open Data Kit toolbox for mobile data collec-
tion efforts (https://opendatakit.org/) and has been described elsewhere [7]. GPS coordinates
were recorded for each participating household. The age and sex of each household member
Ocular Chlamydia trachomatis in Fiji
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was then recorded, along with a record of consent to examination, refusal or absence at the
time of the survey.
Clinical assessment
A single GTMP-certified [7] trachoma grader examined both eyes of each participant using a
2.5× binocular loupe and sunlight. Each eye was assessed for the presence or absence of TT, TF
and TI, according to the WHO simplified grading system [4,7]. An individual trained in the
use of the Android phone application recorded results. Disposable gloves were used during
swab collection, and alcohol hand gel was used between individuals to prevent carry-over con-
tamination from one subject to the next. Participants found to have active trachoma were pro-
vided with a course of 1% tetracycline ointment and directions in its method of application.
Participants found to have any significant ocular pathology were referred to the nearest eye
care centre for management.
Conjunctival sampling
For each participating child aged 1–9 years, a specimen was taken from the right upper tarsal
conjunctiva with a polyester swab (Puritan Medical Products, ME, USA) and using a standard-
ised collection procedure [16]. The specimen was taken immediately after clinical grading and
the swab was immediately returned to its packet, secured and labelled with an anonymised
five-digit numeric code. Swabs were kept in the field in a cool, dry container and were then air-
dried overnight, before being transferred to 5°C storage the following morning; they were then
maintained at this temperature until processing, between 1 and 5 months later.
Control swabs
Fifteen negative field control swabs were collected by passing a swab within 15 cm of the eyes
of a seated subject, chosen by random selection from the list of all specimen labels prior to
commencement of the survey; specimen labels were used sequentially. Positive control swabs
were prepared by briefly submerging swab heads in an homogenized solution of Ct strain
A2497[17] elementary bodies and cultured hep2C cells at a dilution factor of 1 in 500, sus-
pended in a phosphate-buffered saline. 15 such positive control swabs were prepared in Lon-
don and stored in 2 mL Eppendorf tubes, then frozen and retained at LSHTM, UK. 15 further
positive controls were prepared in the field, and were stored at 5°C until analysis. Field control
swabs and swabs from study subjects were indistinguishable, and laboratory staff were masked
to swab status.
DNA extraction
Genomic DNA was extracted in to 50 μL nuclease free water using the Norgen Genomic DNA
Purification kit (Norgen Biotek, Canada) according to manufacturer's protocol. For quality
control, a sample with DNA extracted from a clean swab was included in each extraction
batch.
C. trachomatis infection testing
A Ct-specific droplet digital PCR (ddPCR) assay was used according to a published protocol
[18], and with the minor modification that an 8 μL aliquot of DNA was used in each reaction.
Briefly, each well contained 1X ddPCR supermix, 0.2 μM fluorescent probes and 0.9 μM for-
ward and reverse primers for Homo sapiens RPP30 and Ct plasmid ORF 2. Thermal cycling
conditions were 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for
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1 minute; then a final hold for 10 minutes at 98°C. A modified omcB probe was used to
improve quenching efficiency and limit background fluorescence (Table 1).
Specimens from persons with TF and/or TI were tested for the presence of Ct omcB, a well-
conserved genomic target, to ensure that cases of infection were not missed due to insertion/
deletion or recombination events disrupting the site of the diagnostic primers for plasmid
DNA [20].The number of plasmids per chromosome was also assessed using the method
described by Last et al [19]. A single well was run for each sample.
Statistical analysis
Data analysis was carried out using R [21]. Observed cluster-level frequencies of TF were
adjusted for age in one-year age-bands using data from the 2007 Fiji census [7,15]. Confidence
intervals were calculated by bootstrapping adjusted cluster-level proportions [22]. A binomial
confidence interval was used for the upper bound of the TT prevalence estimate [23]. ddPCR
data were analysed using QuantaSoft software (BioRad, Hemel Hempstead, UK). A positive
ddPCR result was defined as one having a greater than 95% confidence in a non-zero load
under a Poisson approximation, as described elsewhere [18].
Results
Descriptive epidemiology
A total of 413 households were visited over 31 clusters. No data were collected on non-partici-
pation of households. We enumerated 2306 individuals for inclusion in the study, of whom
Table 1. Primer and probe sequences forC.trachomatis targets and control using ddPCR. [19]
Molecular target and primer or
probe
Nucleotide sequence and modiﬁcations
Homo sapiens RNase P/MRP 30-kDa
subunit (RPP30) (endogenous control)
RPP30-F 50 AGA TTT GGA CCT GCG AGC G 30
RPP30-R 50 GAG CGG CTG TCT CCA CAA GT 30
RPP30_HEX_BHQ1 50 HEX-TTC TGA CCT GAA GGC TCT GCG CG-BHQ1 30
C. trachomatis cryptic plasmid
pLGV440 (circular; genomic DNA;
7,500 bp)
Ct-plasmid-F 50 CAG CTT GTA GTC CTG CTT GAG AGA 3’
Ct-plasmid-R 50 CAA GAG TAC ATC GGT CAA CGA AGA 3’
Ct-plasmid_FAM_BHQ1b 50 6FAM-CCC CAC CAT TTT TCC GGA GCG A-BHQ1 30
Ct-plasmid_HEX_BHQ1c 50 HEX-CCC CAC CAT TTT TCC GGA GCG A-BHQ1 30
C. trachomatis (serovar A) omcB gene
Ct-omcB-F 50 GAC ACC AAA GCG AAA GAC AAC AC 30
Ct-omcB-R 50 ACT CAT GAA CCGGAG CAA CCT 30
Ct-omcB-FAM-BHQ1 50 6FAM-CCA CAG CAA AGA GAC TCC CGT AGA CCG-BHQ1
30
aMRP, mitochondrial RNA processing endoribonuclease; 6FAM, 6-carboxyﬂuorescein reporter; BHQ1,
black hole quencher 1; HEX, hexachloroﬂuorescein reporter.
b C. trachomatis plasmid probe used in screening (ﬁrst) assay.
c C. trachomatis probe used in quantitative (second) assay.
doi:10.1371/journal.pntd.0004798.t001
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1038 were aged 1–9 years, 335 were aged 10–14 years and 933 were aged 15 years and over.
Ten (0.4%) individuals declined consent to participate; 2296 were examined. The median age
of those examined was 11 years (mean: 20; min: 1; 1st quartile: 5; 3rd quartile: 32; max: 91),
and 1289 (56.1%) were female. Following data cleaning, 1009 children were included in the
study, which is very close to the targeted sample size of 1018.
Clinical assessment
Data records without paired clinical and swab data (n = 29/1038) were discarded from the anal-
ysis. TF was observed in 34/1009 (3.4%) 1–9 year-olds. The age-adjusted prevalence of TF was
2.8% (95% CI 1.4–4.3%;). TI was observed in 2/1009 (0.2%) 1–9 year-olds. The age-adjusted
prevalence of TI was 0.1% (95% CI: 0.0–0.3). No cases of TT were observed in 928 examined
participants aged 15 and over. The age-adjusted prevalence of TT in those aged 15 years and
above was 0% (95% CI 0–0.2%).
In addition to the 34 cases of TF found in those aged 1–9 years, 6.4% (21/330) of those aged
10–14 years and 1.1% (10/928) of those aged 15 years and over were found to have clinical
signs of TF and/or TI. The median age of those with TF was 8 years (mean: 11; min: 1; first
quartile: 5; third quartile: 11; max: 83).
Ocular C. trachomatis infection
A total of 1038 children aged 1–9 years had ocular swabs taken and analysed. 16 (1.5%) swabs
were unusable due to labelling errors. Of the 1022 remaining, 13 (1.3%) failed quality control
because there was no detectable endogenous human target. 1009 (97.1%) specimens passed
quality control (>95% confidence in non-zero human RPP30 load). The mean droplet number
per well was 14062 (first quartile 12634, median 13837, third quartile: 15247). The median
endogenous control load was 9576 RPP30 copies/swab. 19/1009 (1.9%) tested positive for the
presence of Ct plasmid DNA. 1/34 (3.1%) children with active disease tested positive for Ct
DNA and 18/977 (1.8%) children without active disease tested positive (Table 2). There was no
association between cases of TF and cases of infection (p = 0.644 Mantel-Haenszel Chi-square).
No new cases of infection were detected when active disease cases were retested with a multi-
plex plasmid/omcB ddPCR assay.
The median load of infection in positive specimens was 41 Ct plasmid copies/swab (min 20,
first quartile 32, mean 6665, third quartile 161, max 86354). Among the 19 swabs that tested
positive for the plasmid, seven additionally tested positive for presence of omcB in the multi-
plexed plasmid/omcB test. The mean plasmid:chromosome ratio was 4.4 plasmids per chromo-
some (range 1–12), consistent with the findings of Last et al [19]. The age-adjusted prevalence
of ocular Ct infection in 1–9 year-olds was 2.3% (95% CI: 0.4–2.5%).
Control swabs
All 30 positive control swabs (15 field and 15 lab) tested positive for Ct. The field control swabs
had a 58.7% reduction in mean Ct plasmid load as compared to those stored frozen. Mean Ct
Table 2. Qualitative test for infection in persons with and without clinically active trachoma.
TF/TI absent TF/TI present Total
(n, %) (n, %)
ddPCR–ve 957 (98.2) 33 (97.1) 989
ddPCR +ve 18 (1.8) 1 (2.9) 19
Total 975 (100) 34(100) 1009
doi:10.1371/journal.pntd.0004798.t002
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omcB load for the field storage group was also reduced by 58.7%. The reductions in mean load
of both plasmid and omcB were statistically significant (Pearson’s Chi-squared test p = 0.0002
and 0.000016 for difference in plasmid and omcB, respectively)). The mean load of human
DNA from hep2C cells was 45% lower in the frozen swabs than in the swabs that were stored
in the field, but this difference was not statistically significant (80 vs 148 copies/swab; p = 0.18)
(Fig 2). Of the 15 negative control swabs collected in the field, 1 swab was lost in transit. The
other 14 negative control swabs tested negative for both human and Ct DNA.
Discussion
We estimate there to be a low prevalence of active trachoma and a correspondingly low preva-
lence of ocular Ct infection in the Western Division of Fiji. These data represent the first data
on ocular Ct infection in the Pacific Island small states and represent a significant step towards
improving knowledge of trachoma in the region.
We found no association between infection and active trachoma. This result is unsurprising,
given the generally low correlation between signs of disease and ocular Ct infection in low prev-
alence settings [24–27]. It has been suggested that this may be because where Ct prevalence is
low, other pathogens may be associated with the active trachoma phenotype [27,28]. It is possi-
ble that nucleic acid amplification testing may miss some low-load Ct positive samples due to
the relatively high sampling variation when an analyte is at very low concentrations. Some
commentators have suggested the sensitivity of this ddPCR assay may be too low for trachoma
programs [29] due to the sensitivity observed in a ‘face value’ diagnostic evaluation by Roberts
and colleagues. However, it was demonstrated that the discrepant results occurred in a mathe-
matically predictable manner related to the analyte concentration and that most PCR-based
technology will share an absolute limit to the number of analyte copies per test that will be
reproducibly detected. It was highlighted that in a traditional discrepant analysis the sensitivity
of this ddPCR assay could have been as high as 98% [30] and we therefore believe the test was
appropriate in this setting.
Fig 2. Comparative Ct omcB and plasmid load recovered from swabs stored at -20°C (n = 15) and +5°C
(n = 15) for the duration of the study (November 2013 –July 2014).
doi:10.1371/journal.pntd.0004798.g002
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For logistical reasons, swabs that were collected during this survey were not frozen during
storage. A number of studies have illustrated that host [31] and chlamydial DNA [32,33] are
stable in the short term when stored dry. Evidence from our positive control swabs indicates
that a substantial proportion of chlamydial and human DNA is lost during storage over a few
months at 5°C. However, this will only result in loss of qualitative diagnostic accuracy at very
low loads of infection, consistent with the findings of Dize and colleagues [34]. In our positive
control swabs, the ratio of plasmid to chromosome targets was the same regardless of storage
conditions, indicating a similar rate of degradation between both genome components. We
described above the difficulties caused by sampling error when diagnosing very low load infec-
tions, and degradation during storage may have caused previously detectable samples to
become not reproducibly detectable. Improving specimen transport and storage conditions
may have resulted in a closer association between clinical signs of disease and Ct infection.
However, as low-load infections may be poorly associated with TF [16] and of limited impor-
tance in driving transmission at community level [35], we consider their detection not to be
critical. The loss of sensitivity is however a limitation when considering the findings of this
cross-sectional prevalence study.
We did not find any cases of TT in this population. This is in contrast to the previous
(2012) PBPS, which found a high prevalence of TF (19.6% in 1–9 year-olds) and TT (8.7% in
!15 year-olds) in this Division [13,36]. A 2009 rapid assessment found communities in which
a high proportion of examined children had TF, but–like the present work—no cases of TT
[12]. The source of these discrepancies is the subject of on-going research but we have observed
social practices of eyelash epilation in Fiji that may have been misdiagnosed as trachomatous
trichiasis.
The number of children per household was higher in this survey than in the 2007 national
census, and we therefore reached our sample size in a lower number of households than
expected. Data were not collected on households not enrolled in the study, nor on household
demographics that may have explained why our sample size was reached with fewer houses
than originally thought. However, the target sample size was very nearly achieved, and our
individual participation rate was over 99%, therefore the risk of attrition bias is considered to
be low. The difference in TF prevalence between the present data and the 2012 PBPS could be
due to poor consensus between graders, seasonal variation in trachoma prevalence or an arte-
fact of the cross-sectional study designs. The 2012 survey followed a PBPS protocol with ran-
dom selection at village and household level with a comparable number of children sampled
overall. The survey presented here sampled lower numbers of villages and households, but this
is unlikely to sufficiently explain the large difference between the resultant TF prevalences
found. Specific information on which villages were surveyed in the earlier study was not avail-
able, therefore it is not clear whether there was overlap between clusters visited; our randomisa-
tion process may have missed trachoma hotspots in Western Division by chance. The low
estimate of Ct infection prevalence in this study does not support the estimated prevalence of
TF observed in the previous survey, and could be a result of the relative non-specificity of phe-
notypic markers in trachoma.
The reported prevalence of TF and TT in Fiji varies significantly between studies. Tests for
infection confirm that ocular Ct infections do still occur in Fiji, albeit infrequently and at rela-
tively low load. Our clinical data suggest that trachoma does not meet the WHO definition of a
public health problem in this Division of Fiji, but the inconsistency with previous studies war-
rants further investigation. It is also not clear whether the results from this division will be gen-
eralizable to the rest of the country. Recommendations on how best to incorporate this
information into trachoma management plans are sparse. Estimating the age-specific preva-
lence of serological markers for exposure to chlamydial infection [37,38], photographic
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evidence of phenotype, and exploration of other associations of TF in Fiji could be beneficial in
developing those recommendations.
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CHAPTER 4: NOTES AND ADDITIONAL INFORMATION 
 
4.2 Note A: Influence of storage temperature on longevity of Ct DNA 
 
Typically, frozen storage is considered to be optimal for Ct specimen transport. Transport media 
is favored by commercial diagnostic manufacturers, but refrigerated storage of dry swabs does 
not affect diagnostic performance in the medium term (40 days) (300). Short-term dry storage at 
room temperature also does not affect diagnostic performance (301). In section 4.2, analysis of 
DNA recovery from synthetically prepared swabs suggests that storing swabs dry and 
refrigerated but unfrozen, fewer Ct targets were detected by ddPCR than from comparator 
swabs which were frozen. In the discussion, it is acknowledged that this may impact the 
detection of very low load specimens, and may result in an underestimate of infection 
prevalence. Synthetic swabs were prepared in the laboratory and stored under different 
conditions for up to 6 months to replicate this finding in vitro. 
 
4.2.1 Methods 
 
4.2.1.1 Suspension preparation 
 
A suspension of cultured human epithelial type 2 (HEp-2) cells and serovar A Ct EBs in 
phosphate-buffered saline (PBS) was prepared to inoculate onto swabs. Stock HEp-2 cells were 
kindly provided by Dr Tamsyn Derrick (LSHTM). These were seeded into a 75 cm2 culture flask 
containing Dulbecco’s Modified Eagle Medium and grown until near-confluence. Cells were 
scraped from the flask and counted using a haemocytometer to determine the necessary 
dilution factor for spiking onto swabs. HEp-2 cells were spiked into PBS at approximately 
400,000 per 1mL of PBS. Purified Ct A2497 EBs, kindly donated by Professor Martin Holland 
(LSHTM), were spiked into the same suspension at a dilution of 2µL of EBs per 1mL of PBS to 
achieve a high concentration of Ct and moderate concentration of Homo sapiens targets per 
PCR reaction.  
 
4.2.1.2 Swab preparation 
 
The suspension was sonicated and homogenized, and 50µL was aliquoted onto the head of 
polyester-coated swabs (Puritan Medical Products, Guilford, USA). Swabs were allocated to 
storage under one of three conditions: dry storage in polystyrene tubes at room temperature 
(uncontrolled, typically 22-25°C), dry storage in paper envelopes at room temperature inside a 
vacuum-sealed container with silica desiccant (in the field the purpose of this would be to 
ensure rapid and efficient desiccation of swab material and deter unwanted growth of microbial 
contaminants), or dry storage in polystyrene tubes at -20°C. Four swabs were prepared and 
processed per time point per storage condition. A single negative swab was prepared per time 
point per storage condition to control for contamination. 
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4.2.1.3 Swab processing 
 
Swabs were removed from storage at 7, 30, 90 and 180 days and DNA was extracted using the 
swab protocol of the QIAamp DNA mini kit (Qiagen, Manchester, UK) according to 
manufacturer’s instructions. Proprietary lysis buffer supplemented with 20 units of proteinase K 
was added directly to the swabs and incubated for 1 hour at 56°C. Lysate was bound to a silica 
spin column, washed and eluted into 100µL of 10mM Tris-Cl 1mM ethylenediaminetetraacetic 
acid (EDTA) buffer (TE). Swabs were tested using quantitative PCR. The primers and probes 
used are outlined in table 1 of the manuscript in section 4.2. Each 10-µL PCR reaction 
contained primers and probes at 300nM, 1x TaqMan Universal II Master Mix (Thermo Fisher 
Scientific, Waltham, USA) and 2µL of extracted DNA. Four technical replicates were tested per 
reaction.  
 
4.2.1.4 Data analysis 
 
Quantitation threshold and baseline parameters were set in SDS (version 2.4; Thermo Fisher 
Scientific, Waltham, USA). Exported quantitation cycle (Cq) data were analysed in R (302). 
Linear regression was used to determine whether the Cq decreased significantly with time in 
each individual treatment. The gradients of linear models were examined to determine whether 
there was a significant downward trend in load.  
 
4.2.2 Results 
 
Ct and human DNA was readily detectable in all samples at all time points, suggesting no 
diagnostic impediment caused by 6 months storing high-load DNA at room temperature. All 
three treatments showed a significant increase in Cq required to detect Ct over 6 months 
according to linear regression models, indicating a decrease in target abundance. The gradient 
for each regression model had very subtle variations, but were broadly very similar. Based on 
these models the estimated rate of reduction in detectable load was 0.01–0.02% of the 7-day 
specimen Cq per day. After 6 months, the mean Cq for detection of plasmid had increased by 
18% for the frozen swabs, and by 21% and 14%, respectively, for the desktop and vacuum 
contained room temperature swabs. The Cq for omcB target detection had increased by 9% for 
the frozen swabs, and by 17% and 14%, respectively, for the desktop and vacuum contained 
room temperature swabs. As Cq is an inverse exponential scale, these increases in 
approximately 1–3 cycles represent a decrease of between 70 and 90% of the material in real 
terms. 
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Table 4.2.2.1. Coefficients from linear regression models examining the relationship between cycle threshold 
and time in days. 
Treatment Ct pORF2 Ct omcB 
Gradient p-value Gradient p-value 
Dry, frozen 0.019 < 0.0001 0.011 < 0.0001 
Dry, desktop, room temperature 0.018 < 0.0001 0.018 < 0.0001 
Dry, vacuum box, room temperature 0.015 < 0.0001 0.016 < 0.0001 
Ct: Chlamydia trachomatis; pORF: Plasmid open reading frame; omcB: outer membrane protein complex B. 
 
A 
B 
 
Figure 4.2.2.1. Change in recovered load of (A) Chlamydia trachomatis plasmid and (B) genomic targets 
following long-term storage frozen and at room temperature. Points represent mean of four swabs per time point 
per condition. Dashed lines represent linear regression model between load and time.  
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4.2.3 Discussion 
 
These data demonstrate that there was a degradation of material with time for swabs stored 
dry, both when frozen and when stored at room temperature. Over prolonged periods, this loss 
may render the majority of the DNA undetectable. Intuitively, this might attributable to 
degradation of specimen DNA. However, due to the exquisite sensitivity of nucleic acid 
amplification techniques, this is only likely to lead to diagnostic failure in a minority of very low 
load specimens. The linear regression analysis suggests that the rate of degradation is 
consistent, regardless of storage temperature. This supports previous data showing that Ct 
DNA persisted for up to 2 years in a number of transport media, regardless of storage 
temperature (303). This finding is important for this study because it suggests that the reduced 
detection of targets in the field stored swabs described in the manuscript (299) may not have 
been due to more rapid degradation, but due to unequal spiking in the first instance. There was 
no pre-storage comparator group so it is not possible to further examine this possibility. 
However, the manuscript acknowledges that the Ct infection prevalence estimate may be an 
under-estimate because of the storage technique used, but in vitro data suggest that freezing 
the swabs would have led to a similar prevalence estimate. The data also suggest that long-
term storage may lead to an under-estimate of prevalence if no transport media is used. 
 
4.3 Trachoma in Fiji 
 
From the findings presented in this chapter and subsequent studies, it seems most likely that 
the previous estimates of TT prevalence had somehow been inflated. Further research in to the 
trichiasis problem in Fiji was conducted by Macleod, Yalen and colleagues who undertook 
behavioral surveys to investigate the reasons for the inflated estimate during Kama and 
colleagues’ survey. During a PBPS of epilating behaviors (304) (Appendix 3), approximately 7% 
of people in the Western Division of Fiji were found to epilate their eyelashes for cultural and 
social reasons not related to trachoma. Of 125 epilators, 124 did not have evidence of TS. This 
prevalence was remarkably similar to the rate of TT in the Western Division and authors 
identified that in the WHO simplified grading definition of trachoma, “evidence of recent epilation 
of in-turned lashes” could be applied to all epilated lashes, as it may not be clear to an examiner 
whether the epilated lash has been in-turned (304). Those cases were correctly identified as TT 
under the WHO simplified grading system, and the work has supported a revision of protocol for 
grading TT, whereby the eyelid must be everted where possible and TS observed before TT 
can be called. 
 
Subsequent to the work that constitutes this paper, a serosurveillance study was undertaken in 
Fiji (305) (Appendix 2), which found that whilst 20.9% of children aged 1–14 years had 
antibodies to Pgp3, seropositivity did not significantly increase between the ages of 1 and 14 
years, indicating little or no transmission of ocular Ct during childhood years. The 
seroprevalence to Pgp3 was significantly higher in iTaukei Fijians than in Indian Fijians. This 
could be attributable to the documented higher urogenital Ct prevalence in that group, 
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suggesting the Pgp3 exposure in children in Fiji may in part be due to urogenital exposure 
during parturition (305).  
 
While data on epilation may provide a plausible explanation for the unusually high TT estimate, 
unanswered questions remain in Fiji. The prevalence of TF also varied markedly between this 
and previous studies. One limitation of the study in section 4.1, and a potential reason for the 
discrepancy between this and previous prevalence estimates, is the difference in sampling 
frame of the two studies. Kama et al. visited all divisions, and also may have included both 
Yasawa and Mamanuca Island groups in their sampling frame for the Western Division. Those 
living in the western part of Vitu Levu are likely to experience a different way of life to those in 
the outer island groups, and are likely to have better infrastructure and access to healthcare 
facilities. The outer islands may, therefore, be expected to have higher trachoma prevalence, 
although data to support this hypothesis are only anecdotal (A Cama, personal communication), 
and excluding them from the sampling frame may lead to an underestimate of Division-wide 
disease prevalence. The cluster distribution in Kama’s study is not explicitly depicted in the 
manuscript, therefore we cannot estimate the effect of this beyond speculation. Additionally, 
during the study in section 4.1, a total of 1038 children were recruited into the study from 413 
households, suggesting more 1–9 year olds per household than the national average (0.9 
children aged 0–9 years per household listed in the 2007 National Census, compared to 2.5 
children aged 1–9 years identified per household in this survey). There may be several 
explanations for this, for example, social practices in Viti Levu may involve communal living and 
may not be amenable to the definition of a household used in this survey, or larger households 
may have been selected by chance. Detailed data on household or family membership were not 
collected during the survey in section 4.1, therefore the effect of this difference on the study 
outcome cannot be quantified. In some settings, larger household size has been associated 
with increased risk of active trachoma (306) so selection of larger households may lead to 
overestimation of disease prevalence. Given the very low TF prevalence observed in our 
survey, this seems unlikely. However, the aim of the study was to measure the association 
between Ct infection and TF in Fiji and not to repeat the findings of the previous survey; these 
differences in study design between different studies did not significantly inhibit the capacity of 
the study to address that aim.  
 
Our understanding of trachoma in Fiji has undoubtedly been advanced by these studies. 
However, the Fijian context has highlighted a much more important issue; namely that as the 
simplified trachoma grading system is rolled out around the world, confounding features may be 
identified which reduce the specificity of the system for identifying trachoma.  
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5. OCULAR CHLAMYDIA TRACHOMATIS INFECTION IN 
THE SOLOMON ISLANDS  
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5.1 Introduction 
 
From the clinical data presented in chapter three, three patterns of disease were observed. In 
Kiribati, trachoma presents a significant public health problem. In Fiji, TF estimates differ 
between surveys, but recent data from the Western Division suggest trachoma not to be 
prevalent there. Vanuatu and the Solomon Islands both appeared to have prevalent TF, but no 
TT. The absence of TT led us to question the involvement of ocular Ct infection in this context. 
Temotu province in the Solomon Islands was suggested to have the highest TF prevalence by 
local collaborators, and was therefore selected as the most appropriate site to investigate the 
relationship between ocular Ct and TF. Due to the small size of Rennell & Bellona province, it 
was included in the EU.  
 
The findings presented in this chapter generate subsequent lines of enquiry that eventually 
suggested that, although trachoma was present in the Solomon Islands, a substantial proportion 
of the clinical signs could not be attributed to ocular Ct infection.  
 
5.2 Manuscript 
 
In this manuscript, a combination of PBPS, test for infection and WGS are used to demonstrate 
that cases of TF, TI, TS, TT and Ct infection with ocular strains were found in the Solomon 
Islands, but that the level of Ct infection was lower than found in other populations with similar 
TF burden. Interestingly, the peak age-specific burden of trachoma was not in children under 5 
years, as has been observed elsewhere (30), but apparently in 6 year-olds.  
 
These data suggest that the use of clinical signs as a tool for guiding trachoma intervention 
might not be universally appropriate and that TF levels in Solomon Islands did not accurately 
reflect the population burden of ocular Ct. This topic will be revisited in more detail in chapters 
six and seven.  
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Abstract
Background
Trachoma is endemic in several Pacific Island states. Recent surveys across the Solomon
Islands indicated that whilst trachomatous inflammation—follicular (TF) was present at lev-
els warranting intervention, the prevalence of trachomatous trichiasis (TT) was low. We set
out to determine the relationship between chlamydial infection and trachoma in this
population.
Methods
We conducted a population-based trachoma prevalence survey of 3674 individuals from
two Solomon Islands provinces. Participants were examined for clinical signs of trachoma.
Conjunctival swabs were collected from all children aged 1–9 years. We tested swabs for
Chlamydia trachomatis (Ct) DNA using droplet digital PCR. Chlamydial DNA from positive
swabs was enriched and sequenced for use in phylogenetic analysis.
Results
We observed a moderate prevalence of TF in children aged 1–9 years (n = 296/1135,
26.1%) but low prevalence of trachomatous inflammation—intense (TI) (n = 2/1135, 0.2%)
and current Ct infection (n = 13/1002, 1.3%) in children aged 1–9 years, and TT in those
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aged 15+ years (n = 2/2061, 0.1%). Ten of 13 (76.9%) cases of infection were in persons
with TF or TI (p = 0.0005). Sequence analysis of the Ct-positive samples yielded 5/13 (38%)
complete (>95% coverage of reference) genome sequences, and 8/13 complete plasmid
sequences. Complete sequences all aligned most closely to ocular serovar reference
strains.
Discussion
The low prevalence of TT, TI and Ct infection that we observed are incongruent with the
high proportion of children exhibiting signs of TF. TF is present at levels that apparently war-
rant intervention, but the scarcity of other signs of trachoma indicates the phenotype is mild
and may not pose a significant public health threat. Our data suggest that, whilst conjuncti-
val Ct infection appears to be present in the region, it is present at levels that are unlikely to
be the dominant driving force for TF in the population. This could be one reason for the low
prevalence of TT observed during the study.
Author Summary
Trachoma is the most common infectious cause blindness worldwide, and the target of a
global elimination initiative. A package of community-wide interventions is recommended
to treat trachoma, which aim to reduce transmission of the causative agent Chlamydia tra-
chomatis. These interventions require significant, prolonged investment. Clinical observa-
tion of follicles on the underside of the eyelid is used to assess requirement for and success
of intervention. However, we now know that there are nonchlamydial causes of these folli-
cles, so the observation of this clinical sign may not be specific for chlamydial infection. A
recent study showed that infection testing can be cost-effective in low infection prevalence
settings, as the money spent on infection testing is more than offset by the savings from
avoiding additional rounds of community-wide interventions. We show here that, despite
a high prevalence of clinical signs of disease, the estimated prevalence of chlamydial infec-
tion is low. The prevalence of the sight-threatening end stage of disease is also low, so we
must consider whether the costly community-wide interventions are appropriate in this
setting. The use of molecular tools at the population level to guide trachoma policy is still
under investigation; this study will contribute to the pool of data required to assess the util-
ity of these tools.
Introduction
Trachoma, caused by ocular strains of Chlamydia trachomatis (Ct), is the leading infectious
cause of blindness worldwide [1]. Ocular infection with Ct is associated with a characteristic
follicular conjunctivitis, known as “trachomatous inflammation—follicular” (TF) [2], which
can persist for some time after the initiating infection has been cleared. In some individuals,
infection can also cause the sign “trachomatous inflammation—intense” (TI). Repeated and
prolonged bouts of severe inflammatory disease can lead to trachomatous scarring [3] (TS)
which, in some individuals, can eventually cause the eyelashes to turn inwards, producing tra-
chomatous trichiasis (TT), a condition in which the lashes painfully abrade the cornea. In com-
bination with other trachoma-induced changes to the ocular surface, this may lead to corneal
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opacity (CO) and blindness [2,4]. In 2014, the World Health Organization (WHO) estimated
trachoma to be a public health problem in 51 countries, and responsible for approximately 2.2
million cases of visual impairment. Efforts to globally eliminate the disease as a public health
problem are promising, with several countries having reported reaching elimination goals [1].
The island states of the Western Pacific Region are made up of several thousand widely dis-
persed volcanic islands and coral atolls. It has long been suspected that trachoma is endemic in
these islands, with reports from the early twentieth century indicating that trachoma was pres-
ent [5–9]. More recently, trachoma rapid assessments (TRA) conducted in the Pacific indicated
the presence of trachoma in Fiji, Vanuatu, Solomon Islands, Nauru and Kiribati. Although
TRAs do not give accurate estimates of disease prevalence, the TRA data suggested that, whilst
TF levels appeared high, both TI and TT were surprisingly scarce [10].
A population-based prevalence survey (PBPS) is the gold standard for estimating district-
wide trachoma burden [11] and trachoma PBPSs took place between 2011 and 2014 in some
districts of the Solomon Islands, Kiribati and Fiji [12]. They reported that TF prevalence was
above the WHO-recommended threshold (!10% TF in children aged 1–9 years) for public
health interventions in the Melanesian-dominated districts studied (Solomon Islands and Fiji).
Those surveys also reported surprisingly low levels of TT [12,13] (at or below the WHO elimi-
nation threshold of 0.1% in the all-ages population[14]) compared to those observed in other
populations with highly prevalent TF [15,16].
The seemingly discrepant (with respect to out-of-region comparators) finding of high prev-
alence of TF in populations with negligible levels of TI or TT led us to question whether ocular
Ct infections are present in Melanesia. We augmented GTMP mapping of Temotu and Rennell
and Bellona provinces in the Solomon Islands, with tests for infection and next-generation
sequencing, to determine the prevalence of Ct, and whether Ct and active trachoma were asso-
ciated. If Ct was detected in conjunctival specimens, we considered whether those strains were
of an ocular or genital genotype. We considered how our results compare to other published
datasets.
Methods
Ethics statement
The study adhered to the tenets of the Declaration of Helsinki. The London School of Hygiene
& Tropical Medicine Ethics Committee (6319 and 6360) and the Solomon Islands National
Health Research and Ethics Committee (HRC13/18) granted ethical approval for this study.
Village and household heads were consulted prior to enrolment. Individuals were informed
of the nature and requirements of the study prior to enrolment, by a staff member fluent in
local dialects, and were asked to provide written evidence of consent. For those aged 18 years
and under, written consent of a parent or guardian was required.
Study design
Our study was conducted alongside GTMP survey teams as they undertook mapping of one
evaluation unit (EU) in the Solomon Islands in October and November, 2013. In the GTMP
study, an EU was defined as a single administrative province, however, Temotu and Rennell
and Bellona were grouped together into a single EU due to their small populations. Local
healthcare workers identified Temotu and Rennell and Bellona as the provinces with the high-
est suspected trachoma burden in the country. The study was a cross-sectional cluster-rando-
mised PBPS of trachoma. We determined a priori that 1019 children aged 1–9 years should be
sampled to estimate infection prevalence of 10% with a precision of ±3% at the 95% confidence
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level, assuming a design effect of 2.65 [17]. Our sample size was framed around the population
of children in this age range, as they are the group most likely to harbour infection [15,18].
The Land Registry listed 533 villages across the two provinces in 2013. Local healthcare
workers identified villages that were not currently inhabited, and remaining villages were eligi-
ble for simple random selection. In each cluster a targeted number of households were ran-
domly selected from a full list of village households to recruit the required number of children.
All household residents over the age of 1 year in each selected household were eligible for inclu-
sion [17].
Clinical examination and photography
Clinical examination was conducted by graders who had been certified according to GTMP
protocols [17]. Clinical grading was carried out using the WHO simplified system, in which tri-
chiasis is defined as at least one eyelash in contact with the eyeball (or evidence of recent
removal of in-turned eyelashes), TF is defined as 5 or more follicles of>0.5mm diameter on
the central part of the upper tarsal conjunctiva, and TI is defined as pronounced inflammatory
thickening of the upper tarsal conjunctiva obscuring>50% of the deep tarsal vessels [2].
Conjunctival photographs were taken using a Nikon D3000 SLR camera and graded by an
independent photograder who had previously had a kappa agreement score in excess of 0.9
when grading photographs also graded by a master grader. The photograder was masked to the
corresponding field grade for each photograph.
Clinical sample collection, handling and processing
Conjunctival swabs were collected from all children aged 1–9 years. Polyester-coated cotton
swabs (Puritan Medical Products, Guilford, ME, USA) were passed three times over the right
tarsal conjunctiva with a 120° turn in between each pass [19–21]. The examiner changed their
gloves between participants to avoid cross contamination in the field. 1 in 30 swabs did not
touch the conjunctiva but were passed within 15 cm of a seated participant then stored and
processed in identical fashion to other study specimens, to act as field contamination controls.
Swabs were stored immediately in RNAlater (Life Technologies, Paisley, UK), kept on ice
packs in the field before short-term storage at 4°C, and frozen within 48 hours of collection
[22]. Specimens were transported to the UK on dry ice where they were stored at -80°C until
they were extracted with Qiagen AllPrep DNA/RNAmini kits (Qiagen, Manchester, UK)
according to manufacturer’s recommendations.
Droplet digital PCR
DNA specimens were tested for the Ct plasmid using a droplet digital PCR assay targeting a
single Ct plasmid target in duplex with a human ribonuclease gene, which acted as endogenous
control. The published assay methodology was used [23] with minor protocol adjustments to
the tested sample volume (4.95μL increased to 8μL) and oligonucleotide concentrations
(primer concentration increased from 300nM to 900nM; probe concentration decreased from
300nM to 200nM). Samples were considered valid if there was>95% confidence in non-zero
endogenous control concentration, and positive according to published criteria (>95% confi-
dence in non-zero chlamydial plasmid load [23]). Samples from children with TF were retested
with an alternative, quantitative assay targeting both chlamydial chromosomal and plasmid
targets [24]. The oligonucleotides used are shown in Table 1.
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Chlamydial genome and plasmid sequencing
Chlamydial DNA was preferentially enriched in clinical samples using custom Ct-specific RNA
baits in a SureSelect system, as developed by the PATHSEEK consortium. Due to the low bio-
mass of conjunctival swabs, human carrier DNA was added to achieve the required DNA input
concentration for sequencing. Samples were sequenced on the Illumina MiSeq platform [25].
Literature search
Articles were identified through two specific literature searches to illustrate how our data com-
pared to existing published studies. PubMed hits, references contained within those articles
and relevant articles from the authors’ own archives were considered eligible for inclusion.
Using the terms “population-based” and “trachoma”, we identified population-level studies
where TF had been reported in children aged 1–9 years and TT had been reported in adults
over the age of 15 years in the same population. District-level data were extracted where more
than a single district was reported on in a single publication. Using the search terms “tra-
choma” and “infection”, we identified studies reporting population-level nucleic acid-based
infection data alongside clinical data on TF (with or without TI). Data from communities who
had received one or more rounds of MDA were excluded. During both literature searches,
studies where age-specific trachoma prevalence in 1- or 2-year age bands was presented were
also reviewed.
Data recording and analysis
Field data were recorded using a purpose-built Open Data Kit (https://opendatakit.org/) app
[17]. Age adjustments were carried out using 5-year census age bands [26]. All analyses were
carried out using R version 3.2.2 [27]. The overall agreement between field exam and photo-
graphic grade was determined using kappa agreement scores. The relationship between TF and
Ct infection was tested using logistic regression. Ct loads in children with and without TF were
compared using the MannWhitney U test.
Following preliminary assessment of mapping quality to various Ct strains, 251-bp paired
end reads were trimmed and mapped to Ct reference strain AHAR-13 genome sequence (Gen-
Bank accession CP000051.1) and B/Jali20 plasmid genome sequence (FM865436.1) using
Table 1. Oligonucleotides used in this study. Chlamydial targets adapted for ddPCR [23,24] based on sequences from Pickett and colleagues [87].
Endogenous control target adapted from Luo and colleagues [88].
Target Oligo Sequence (5ʹ to 3ʹ)
Chlamydia trachomatis omcB Primer (F) GACACCAAAGCGAAAGACAACAC
Primer (R) ACTCATGAACCGGAGCAACCT
Probe FAM**-CCACAGCAAAGAGACTCCCGTAGACCG-BHQ1
Chlamydia trachomatis plasmid ORF2 Primer (F) CAGCTTGTAGTCCTGCTTGAGAGA
Primer (R) CAAGAGTACATCGGTCAACGAAGA
Probe FAM*/HEX**-CCCCACCATTTTTCCGGAGCGA-BHQ1
Homo sapiens RPP30 Primer (F) AGATTTGGACCTGCGAGCG
Primer (R) GAGCGGCTGTCTCCACAAGT
Probe HEX*-TTCTGACCTGAAGGCTCTGCGCG-BHQ1
F: forward; R: reverse; BHQ: Black Hole Quencher; omcB: outer membrane protein complex B; ORF: open reading frame; RPP30: ribonuclease P/MRP
30kDa subunit
*Diagnostic assay [23]
**Quantitative assay [24]
doi:10.1371/journal.pntd.0004863.t001
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Bowtie 2 [28]. SAMtools and BCFtools were used to index and assemble reads, and bases were
called by collapsing reads vertically [29]. Trimmed reads were also mapped to E/Bour (genome
HE601870.1, plasmid HE603212.1) to determine whether the choice of reference influenced
branching points in the phylogram.
Consensus sequences were submitted for megablast search on National Centre for Biotech-
nology Information (NCBI) GenBank to determine nearest relatives based on genetic sequence.
Whole genomes were aligned with progressiveMauve [30]. A core alignment was generated by
extraction and amalgamation of locally collinear blocks using stripSubsetLCBs [31]. Distance
matrices and bootstrapped phylogeny was inferred using phangorn, ape and SeqinR packages
in R [32–34]. Regions orthologous to ompA, trpA and the plasticity zone (PZ; a ~20 kb region
of the Ct chromosome between dsbB and ycfV [35]) were analysed in isolation due to their dis-
proportionately high variability and influence on pathogenicity compared to the rest of the Ct
chromosome. These were extracted from consensus sequences using BLASTn in the NCBI
BLAST+ suite, and aligned using MUSCLE alignment software [36].
Results
Enrolment and disease prevalence
The combined population of Temotu (21,362), and Rennell and Bellona (3041) comprises
4.7% (24,403/515,870) of the total population of the Solomon Islands, according to the 2009
national census [26]. We surveyed 959 households in 32 clusters throughout this EU. 4049 peo-
ple were enumerated, and 3674 (91%) consented to participate (a total of 17% of the provincial
population, average 4.2 people per household). Data was not collected on the reasons people
did not take part. The examined population included 1135 children aged 1–9 years (53% male),
and 2061 adults aged 15 years and over (42% male). The median age was 18 years (min 1, max
100, inter-quartile range [IQR]: 8–38 years). In this population there were 397 (10.9%) cases of
TF, 5 (0.1%) cases of TI, and 2 (0.1%) cases of trichiasis in either eye of subjects of all ages iden-
tified by field grading. 84% of cases of TF were bilateral.
In children aged 1–9 years, the prevalence of active trachoma (defined as presence of TF
and/or TI in either eye) was 26.3% (TF: 26.1% [296/1135]; TI: 0.2% [2/1135]). The proportion
of males in this age group with active trachoma was significantly higher than that of females in
the same age group (28.9% [176/608] versus 23.1% [122/527], p = 0.027). When adjusted for
age and sex, the prevalence of active trachoma was 22% (95% confidence interval [CI]: 18.5–
26.0%). In adults aged 15 years and over, the prevalence of active trachoma was 1.2% (TF: 1%
[21/2061]; TI: 0.1% [3/2061]). The prevalence of trichiasis in adults was 0.1% (2/2061). When
adjusted for age and sex, the prevalence of TT was 0.04% (95% CI: 0–0.3%). The field team did
not recall one case of trichiasis and the other was documented as mild, with a single lash con-
tacting the globe away from the cornea.
Photographs were taken from 3110/3674 (85%) of participants. Preliminary quality control
yielded 2418 (78%) photographs that were unsuitable for grading due to quality issues. A total
of 692 photographs from study participants of all ages (238 in children aged 1–9 years) were
evaluated by an independent grader. Photo-grading according to the simplified grading system
agreed with TF in 94% of cases leading to Fleiss’ kappa agreement scores of 0.88, which indi-
cated excellent agreement between photo grader and field grading in TF calls. Cases of TS were
noticed in the photo set, although the evidence was insufficient to determine the population
prevalence of this sign.
Fig 1 shows exemplars of both mild and more severe TF in Solomon Island children, as well
as a normal conjunctiva for contrast. The age-specific prevalence of TF cases is shown in Fig 2.
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Conjunctival infection
Swabs were collected from 1076/1135 (94.8%) child participants aged 1–9 years, along with 41
field controls. Of those, 1002 (93.1%) passed quality control by testing positive for the
Fig 1. Photographs of conjunctivae showing (A) no evidence of active trachoma, (B) mild trachomatous inflammation-follicular (TF) and (C) more severe TF.
All three photographs were taken of conjunctival C. trachomatis infection-negative children aged 1–9 resident in Temotu, Rennell or Bellona, Solomon
Islands, October-November 2013, in whom the photo grade and field grade matched.
doi:10.1371/journal.pntd.0004863.g001
Fig 2. Age-specific prevalence (grey bars) and 95% confidence interval (arrows) of trachomatous inflammation—follicular (TF) in
individuals aged 1–15 years, recorded during a trachoma survey of Temotu, Rennell and Bellona, Solomon Islands, October-November
2013.
doi:10.1371/journal.pntd.0004863.g002
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endogenous control gene H. sapiens RPP30. All blank field controls and all known-negative
extraction and PCR controls tested negative for endogenous control and microbial targets. Evi-
dence of Ct infection was found in 13 (1.3%) of 1002 specimens. Of those who tested positive
for plasmid on diagnostic screen, 9 also tested positive for Ct chromosomal target omcB.
Of the individuals whose swab was positive for the endogenous control RPP30, 257/1002
(25.7%) had TF and/or TI in the right eye (Table 2). The prevalence of Ct infection was 10/257
(3.9%) in those with TF and/or TI, and 3/745 (0.4%) in those without. Active disease status was
highly significantly associated with current infection (odds ratio: 10.0, p = 0.0005).
While TF was observed in all 32 villages that were surveyed, we observed Ct infection in just
eight villages. While the study was not designed to detect sub-EU-level differences in preva-
lence, post hoc analysis indicated there were significantly more cases of infection per capita in
Rennell and Bellona than in Temotu province (6/131 [4.6%] versus 7/871 [0.8%], respectively;
MannWhitney U: p = 0.0004). TF levels in the 1–9 year old indicator group were in excess of
10% in both provinces included in the EU, but significantly lower in Rennell and Bellona
(27.3% in Temotu versus 17.2% in Rennell and Bellona; Mann Whitney U: p = 0.0001).
Load of infection
The mean load of endogenous control target was 12,560 copies/swab (IQR: 872–13,980 copies/
swab). In positive swabs, the median load of Ct plasmid was 13,840 copies/swab (IQR: 3599–
84,990 copies/swab). There was a large difference in median load between Ct positive samples
from children with active disease when compared to those without active disease, although the
difference was not statistically significant (median 13,840 versus 782 copies/swab; MannWhit-
ney U test p = 0.81). The median omcB load was 7725 copies/swab (IQR: 1696–22,110 copies/
swab) and the mean plasmid:genome ratio (i.e., plasmid copy number per bacterium) was 4.4
(IQR: 3.7–5.6) which is similar to that described elsewhere [24].
Genome sequencing
Sequencing was successful in 11/13 strains. The mean number of paired reads per specimen
was 2.3 million (IQR: 2.1–2.7 million; Table 3). The median percentage of reads mapping to A/
HAR-13 reference genome was 10.1% (IQR: 1.5–24.4%) per specimen. The median percentage
of reads mapping to B/Jali20/OT reference plasmid was 2.1% (IQR: 0.3–4.8%) per specimen.
Complete genome sequences (>95% coverage) were obtained from five of 13 specimens,
whilst partial genome sequences (<95% coverage) were obtained from six specimens. Com-
plete (>95%) or partial (<95%) plasmid sequences were obtained from eight and three speci-
mens, respectively. One specimen failed to sequence. The median coverage of at least 1× read
depth of the reference genome was 51.5% (IQR: 12.4–98.2%); the median coverage of at least
1× of the reference plasmid was 99% (IQR: 61.4–99.7%).
Table 2. Frequency of conjunctivalC. trachomatis infection and active trachoma during a trachoma
survey in Temotu, Rennell and Bellona, Solomon Islands, October-November 2013.
ddPCR result No TF/TI (%) TF/TI (%) Total
Positive 3 (0.4) 10 (3.9) 13 (1.3)
Negative 742 (99.6) 247 (96.1) 989 (98.7)
Total 745 257 1002 (100)
ddPCR: droplet digital polymerase chain reaction; TF: trachomatous inﬂammation—follicular; TI:
trachomatous inﬂammation—intense.
doi:10.1371/journal.pntd.0004863.t002
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BLASTn analysis of five complete Solomon Islands Ct consensus genome sequences against
archived Ct genome sequences revealed that all five had closest sequence homology and align-
ment to serovar A type ocular strains. BLASTn analysis of eight complete Solomon Islands
plasmid consensus sequences revealed highest sequence homology with published serovar B
ocular strain plasmids.
Phylogenetic analysis of the complete Solomon Islands Ct genomes showed that these sam-
ples formed a single clade of closely related genotypes that formed a sub-clade of the ocular
strains. The five complete genomes were more closely related to each other than they were to
the nearest reference neighbour (A/HAR-13). Strains from the Solomon Islands were most
closely related to the ocular serovars in the T2 chlamydial clade, as shown in Fig 3. Bootstrap-
ping supported our phylogram by indicating resampling did not alter the branch position in
>80% of bootstrap runs.
Outer membrane protein A (ompA) sequences from the ocular reference strains do not clus-
ter in a single clade, as has been described previously [37]. OmpA orthologs from the five Solo-
mon Island sequences were more closely related to each other than to their nearest neighbour
which was the C-TW3 strain. Their relationship to other reference sequences is shown in S2A
Fig. Additionally, tryptophan synthase alpha subunit (trpA) orthologs in Solomon Island
sequences were most similar to ocular strains (S2B Fig) and featured a single nucleotide
Table 3. Sequencing parameters and results of BLASTn analysis of consensus sequence. Conjunctival C. trachomatis genomes obtained from
Temotu, Rennell and Bellona, Solomon Islands, in October-November 2013.
Sample Genetic
component
Total paired
reads
Number of paired reads mapped to
reference (%)
% reference
covered*
Serovar of closest NCBI BLASTn
match
SB000209 Genome 1,948,968 445 (0.02) 0.2 F
Plasmid 173 (0.01) 15.5 D
SB002563 Genome 1,838,502 513 (< 0.01) 0.5 I
Plasmid 35 (< 0.01) 12.4 F
SB002739 Genome 2,530,443 403,672 (16.0) 95.8 A
Plasmid 61,345 (2.4) 99.7 B
SB006908 Genome 2,594,512 34,663 (1.3) 18.5 J
Plasmid 3857 (0.1) 76.7 D
SB006930 Genome 2,630,055 1,743,718 (66.3) 98.9 A
Plasmid 293,102 (11.1) 99.8 B
SB008107 Genome 2,269,697 485,840 (21.4) 98.0 A
Plasmid 79,314 (3.5) 99.8 B
SB011363 Genome 3,878,711 75,326 (1.9) 16.3 I
Plasmid 17,375 (0.4) 99.2 B
SB011759 Genome 3,044,398 52,165 (1.7) 16.3 A
Plasmid 11,707 (0.4) 96.0 B
SB011836 Genome 313 0 (0) 0.0 -
Plasmid 0 (0) 0.0 -
SB012441 Genome 2,996,613 301,482 (10.1) 84.5 A
Plasmid 63,827 (2.1) 99.5 B
SB013112 Genome 2,274,168 1,345,864 (59.2) 98.9 A
Plasmid 332,462 (14.6) 99.8 B
SB013321 Genome 2,128,740 584,834 (27.5) 98.8 A
Plasmid 127,976 (6.0) 98.8 B
* At least 1× read depth
doi:10.1371/journal.pntd.0004863.t003
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deletion leading to a premature stop codon and truncation of the open reading frame when
compared to urogenital sequences. Finally, the relationship between the plasticity zone (PZ) of
Solomon Island sequences compared to references was evaluated and is shown in supplemen-
tary Fig 2C.
Fig 3. Maximum likelihood phylogram of (A) genome and (B) plasmid sequences from clinical specimens collected in the Solomon Islands in October and
November 2013, assembled toC. trachomatis A/HAR-13 and B/Jali20/OT reference, respectively. All branches had bootstrap values over 85/100.
doi:10.1371/journal.pntd.0004863.g003
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Literature search
A low prevalence of TT has been observed in other populations in which TF was highly preva-
lent. Fig 4 shows data taken from published PBPSs in Nigeria [38–44], Niger [45], Sudan [46],
Kenya [16], Ethiopia [47] and Cameroon [48,49] comparing the prevalence of TF in those aged
1–9 years with the prevalence of TT in 15+ year-olds in the same EUs, all of which were treat-
ment-naïve. Of 58 identified EUs with comparable prevalence of TF in the 1–9 year olds (10%
< TF< 40%) to that observed in the current study, 50% had a TT prevalence greater than 1%
in those over the age of 15 years; the median TT prevalence was 1%, compared to 0.1% in our
survey. Our population had a high TF prevalence when compared to other districts in this anal-
ysis with<1% TT.
Published data from studies in Ethiopia [50], Niger [50], Tanzania [18], Gambia [18], Cam-
eroon [48], Mali [51] and Brazil [52] indicate that in other trachoma-endemic populations, the
highest age-specific TF prevalence is generally in those aged 3–4 years. When published age-
specific TF profiles from other parts of the world are compared to the age distribution in this
study (Fig 5), the peak age-specific TF prevalence in our data is shown to be in an older age
group.
We identified a number of previous studies have reported concomitant Ct infection and
active trachoma prevalence estimates [19–21,53–70] in children aged 0–9 years or a subset of
that group in 35 districts. At the population level there is a good correlation between the two
(R = 0.84) (Fig 6). Our Ct infection estimate does not conform to the patterns observed in
those other populations, with infection being substantially less prevalent than might be
expected given the TF prevalence.
Discussion
We report an apparently mild trachoma phenotype in which TF is moderately prevalent yet Ct
infection, TI and TT are rare. The findings reflect those of other studies; over 2300 adults were
Fig 4. Comparison of unadjusted prevalence of trachomatous trichiasis (TT) in 15+ year olds, and
trachomatous inflammation—follicular (TF) in 1–9 year-olds, in treatment-naïve trachoma-endemic EUs for
which data have previously been published (n = 58), and in which the TF prevalence in 1–9 year-olds was
10–40%.Correlation coefficient (R) is 0.40 for this subset, but 0.77 if including studies from areas of any
prevalence.
doi:10.1371/journal.pntd.0004863.g004
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surveyed in Makira, Isabel and Central provinces yet only 3 cases of TT identified, indicating
an unadjusted prevalence among those adults of 0.1% despite 22.2% of the 1–9 years popula-
tion in the same survey having signs of TF [12]. The TF prevalence in Temotu, Rennell and
Bellona is the highest of the populations surveyed during GTMP mapping. Choiseul province
had low levels of both TF (6%) and TT (0%). Interestingly, Western Province had more TT
cases than Temotu, Rennell and Bellona [71]. Further studies are warranted to determine
whether infection prevalence is also higher in that region. The prevalence of TF in these com-
munities qualifies this EU for priority implementation of the A, F and E components of the
SAFE strategy (surgery to treat TT, mass antibiotic distribution to treat infection, promotion of
facial cleanliness and environmental improvement to reduce transmission [72]), but the trichi-
asis data suggest the elimination target for TT has already been met. The evidence of this survey
suggests that prevalence of TF in children may not be an appropriate marker of disease burden
in this setting. Prolonged infection with Ct, intense transmission of Ct, presence of TI and
other markers of inflammation have been associated with progression to TS [3,73–75], the pre-
cursor of TT. It is therefore feasible that the low prevalence of TI and Ct are related to the pau-
city of TT in this population.
In Fig 4 we demonstrate that the correlation between reported TF and TT prevalence is
weak, suggesting that high TF prevalence is not always indicative of a significant TT burden.
This is not an unexpected finding; the signs of TF are transient, being instigated and cleared
Fig 5. Published age-specific trachomatous inflammation—follicular (TF) prevalence data in studies undertaken in districts with >10%
TF in overall child population (dotted and dashed lines), compared to the same in Temotu, Rennell and Bellona, Solomon Islands,
October-November 2013 (grey columns).
doi:10.1371/journal.pntd.0004863.g005
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over the course of weeks or months, whereas TT has a much longer-term onset and is influ-
enced by an accumulation of a lifetime of microbiological and immunological stimuli. Field
grading has not previously been standardised across studies and must therefore be compared
between studies with caution. TF is used in part for ease and uniformity of field grading rather
than specificity for chlamydial infection, and Fig 6 shows that there is a moderate correlation
between population Ct infection prevalence and population TF prevalence in most districts
studied to date. The search criteria for this literature search were relatively lenient; controlling
for field grading discrepancy, sample collection methodology, and diagnostic test would likely
result in a stronger correlation.
At the individual level, TF and Ct prevalence do not always correlate well; for example in a
rural Tanzanian community where the TF prevalence was>10%, only 6.1% of those with TF
had Ct infection and no association was found with clinical signs disease [74]. Follicular
inflammation of the conjunctiva can have many different causes, such as viruses, nonchlamy-
dial bacteria, chemical exposure and allergic reactions [76]. While detailed eyelid examination
may be able to distinguish these infections phenotypically, the WHO simplified grading system
is not sufficiently detailed to do so. Streptococcus pneumoniae and Haemophilus influenzae
have been shown to be significantly associated with TF in the Gambia and Tanzania [74,77].
Numerous other species of the Staphylococcus, Streptococus,Moraxella,Hameophilus and Cor-
ynebacteria genera among others have been cultured from the conjunctivae of children and
adults living in trachoma-endemic areas. Although many have not been shown to associate
with clinical signs of TF, there are indications that in adults these bacteria can drive
Fig 6. Relationship between the prevalence of conjunctival C. trachomatis infection (diagnosed by nucleic acid amplification test) and
trachomatous inflammation—follicular (TF) in the total 0–9 year-old population or a subset of that group at the district level (n = 35
districts).Correlation coefficient (R) is 0.84.
doi:10.1371/journal.pntd.0004863.g006
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inflammation which leads to increased scar tissue deposition [78] or recurrent TT after surgery
[79,80]. It is therefore likely that a proportion of all TF cases globally may not be chlamydial in
origin; it seems that in this Pacific Island setting, this proportion is high and this is translated
into a reduced prevalence of end-stage trachomatous disease. Fig 4 also indicates that this may
also be true of other parts of the world, where districts with sufficient TF to qualify for inter-
vention under WHO guidelines do not necessarily have a significant TT burden. Exposure to
circulating Ctmay modulate the immune response at the conjunctiva to increase inflammation
in response to otherwise commensal organisms. In turn this could drive the immunopathology
that leads to scarring. It is possible that the low prevalence of Ct observed in this population is
insufficient to drive intense transmission, and children are exposed less frequently than in
other trachoma-endemic populations and therefore are not as susceptible to such intense or
regular periods of inflammation.
The highest age-specific TF prevalence in this study was in those aged 6 years (Fig 1). The
difference between that and other published data, as documented in Fig 5, may imply a differ-
ent mode or intensity of transmission, or may reflect reduced accumulation of partial immu-
nity. It is not possible to determine the true mechanism without intensive longitudinal study,
but this observation supports the case that the epidemiology of TF in our population is
atypical.
While the majority of our Ct-positive swabs were taken from eyes with active trachoma, we
consider the low absolute number of infections insufficient to drive the moderate burden of
TF. It is not clear from our cross-sectional study whether a non-chlamydial microbial agent is
causing TF, or whether those with TF had suffered a relatively recent Ct infection and had per-
sistent inflammatory disease causing the follicular inflammation we observed. The use of
ddPCR has not yet become widespread in infectious disease studies. While it is not suitable for
all applications, it offers the significant benefit of reference-free quantification of nucleic acids.
In the present study, the load of Ct in positive samples was substantial, which are thought to be
more transmissible than low-load infection. There was also substantially higher infection load
in those with TF as compared to those without TF, although this difference was not statistically
significant.
Despite recent advances in culture-free sequence methodologies, low-load infections are
known to yield poor quality or no sequence data. The technique we used in this study report-
edly provides high quality sequence data (20× read depth over at least 95% of the genome)
when the input specimen has above ~12,000 and ~98,000 chlamydial genome copies in vaginal
swab and urine samples, respectively [25]. A lower load limit for ensuring high quality
sequencing in ocular samples is not yet known, but we were encouraged that partial or com-
plete sequence data were yielded from 11/13 Ct positive swabs strains that were sequenced.
Those where complete genome coverage (>95%) was achieved appeared to be most closely
related to ocular serovars, and appeared to be very closely related to each other. The sequence
information suggested that, at trpA and the wider PZ, the Solomon sequences were closely
related to ocular strains, and ocular and urogenital strains were distinct from each other at
these loci. The trpA open reading frame was truncated in these sequences. This region contains
key determinants of Ct tissue tropism and further supports the close relationship of these
strains to classical ocular references. The small number of sequences available makes it difficult
to identify differences potentially related to pathogenicity. Urogenital strains are known to be
able to infect conjunctival epithelium [81], and given the high prevalence of sexually transmit-
ted Ct infections in the Solomon Islands [82], we may have expected some contamination of
the conjunctivae with urogenital chlamydial strains. Our data did indicate urogenital strains
were present in several conjunctivae, but the quality of those sequences aligning to urogenital
references was uniformly low. It is not possible to determine whether this was because these
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were urogenital strains that had not established a sufficiently fulminant infection to yield
enough material for sequencing, or whether the matches obtained were an artefact of the low
sequence coverage. We can say, though, that our next generation sequencing confirmed that
strains with high sequence homology to well-defined ocular Ct strains are present in the con-
junctivae of children in the Solomon Islands.
One limitation of our study is the absence of an alternative explanation for the discrepancy
between Ct and TF levels. Only samples for which testing passed various quality control steps
were included in this paper and our test had been previously validated against an external stan-
dard. We therefore do not believe that simple diagnostic failure has significantly influenced our
data. Of the four signs of trachoma described in this paper (TF, TI, TT and current infection),
three (infection, TI and TT) are present at low levels in this population. Further studies are
underway to test for potential alternative pathogens such as S. pneumoniae andH. influenzae,
and we are investigating longer-term markers of Ct infection by screening the population of
Temotu, Rennell and Bellona for both trachomatous scarring and antibodies against chlamyd-
ial pgp3 antigens. We have not addressed the genetics of the population in this study and while
host genetic factors have been shown to associate with an increased risk of scarring [83,84]
very little is known about diversity in immune response genes in the Solomon Islands. The lim-
ited amounts of immunogenetic typing data that are available indicate that some HLA epitopes
associated with increased risk of scarring (e.g. HLA-C2) are moderately prevalent in the Pacific
region, while other putative protective alleles (e.g. the HLA-B"08:01~C"03:04 haplotype) are
almost absent (data taken from allelefrequencies.net, search March 2016). Investigating this is
beyond the scope of this study, but accumulated evidence on the genetics of trachoma indicate
that both pathogen and host are sufficiently well adapted to coexistence that a host polymor-
phism that makes the host entirely refractory, or pathogen variation that completely amelio-
rates the infectivity and/or pathogenicity of Ct seems unlikely. Polymorphisms in key immune
genes such as IL-10 and gamma-interferon have been shown to be more frequent in cases with
severe trachoma than in normal controls [85], although these were not replicated in genome-
wide association screening. It is possible that variation in immune responsiveness may influ-
ence the susceptibility of this population to Ct infection but a specific immune pathway that is
expressed significantly differently between those in whom scarring progresses and those in
whom it doesn’t has yet to be identified [75].
In addition to ocular Ct infection, we observed signs of both active trachoma and trachoma-
tous conjunctival scarring in this sample indicating trachoma is or has recently been endemic
in these islands. However, the prevalence of Ct infection appeared to be too low to be the sole
explanation for the high burden of TF, while TI and TT were curiously scarce given the sub-
stantial amount of TF that was present. Whilst Ctmay account for some of the TF in this popu-
lation, we expect that the majority of TF-like disease is either caused by a single as-yet
undetermined factor, or by multiple contributory aetiologies. This form of disease, if not
unique to the Solomon Islands, might inflate estimates of trachoma burden and could lead to
unwarranted mass drug administration in other world populations. In several European set-
tings, there has been a steady increase in incidence and reinfection rates of urogenital Ct despite
enhanced detection and treatment, which some have hypothesised could be attributed to inter-
ruption of the natural acquisition of immunity [86]. We do not have good markers of what
constitutes ‘acquired immunity to Ct’ to measure this, but it is relevant in this context to con-
sider the possibility of negative effects of MDA in addition to the potential positive ones. The
findings of this study may have profound impacts on approaches to trachoma programme
monitoring in the peri-elimination period.
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Manuscript supplementary figure 1. Maximum likelihood phylogram of (A) genome and (B) plasmid sequences 
from clinical specimens assembled using Chlamydia trachomatis E/Bour reference.  
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Manuscript supplementary figure 2. Phylogram illustrating relationship of Solomon Islands sequences to 
reference sequences at (A) ompA, (B) trpA and (C) PZ regions. 
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Manuscript supplementary table 2. Sequence accession numbers. 
Participant ID Chromosome GenBank accession number Plasmid GenBank accession number 
SB002739 CP016418 CP016419 
SB006930 CP016420 CP016421 
SB008107 CP016422 CP016423 
SB013112 CP016424 CP016425 
SB013321 CP016426 CP016427 
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CHAPTER 5: NOTES AND ADDITIONAL INFORMATION 
 
5.3 Note A: Effect of variable storage temperature on swab DNA   
 
5.3.1 Introduction 
 
During the study in section 5.2, swabs were collected into RNAlater (Thermo Fisher Scientific, 
Carlsbad, USA) and stored for up to 48 hours before freezing. The islands are geographically 
isolated, have no electricity outside of the provincial capital Lata, and can take several hours of 
sea travel in outboard-motor canoes on the open ocean to move between islands. It is therefore 
very difficult to keep specimens frozen. This was achieved by carrying a portable freezer, a 
generator and 200L barrels of fuel between islands. However, this meant that, for some periods 
the freezer was closed but not actively being cooled so may have led to some fluctuation in 
temperature. The internal temperature changed between -60°C and -15°C according to the 
freezer monitor, therefore never defrosting and justifying the methodology statement in the 
manuscript. Specimens were transferred to permanent frozen storage at least once every week. 
However, large variations in temperature, particularly freeze–thaw cycles can damage cells and 
nucleic acid material, and render them undetectable by NAATs. I set out to ensure that the 
changes in frozen temperature did not result in specimen degradation sufficient to render them 
undetectable by PCR. The impact of temperature change on chlamydial material was assessed 
to determine whether minor cycles of rising and falling frozen temperature caused a significant 
drop in detected Ct load and explain the low Ct prevalence.  
 
5.3.2 Methods 
 
5.3.2.1 Swab preparation 
 
Mock positive suspension of Ct was prepared as described in section 4.2.3.1. 50µL of 1:500 µL 
homogenized suspension of serovar A Ct EBs and their human host HEp-2 cells was pipetted 
directly onto 20 sterile swab heads which were immediately placed into RNAlater. The swabs in 
RNAlater were refrigerated overnight then randomly allocated to one of four storage treatment 
groups as described in figure 5.3.2.1, five swabs per group. Swabs were variously stored at and 
cycled between different frozen temperatures (-20°C and -80°C) and defrosting temperature 
(4°C) depending on the treatment group. The experiment ran for 2 weeks, and then all 
specimens were allowed to equilibrate to room temperature prior to extraction. 
 
5.3.2.2 Nucleic acid extraction and detection 
 
DNA was extracted using the AllPrep DNA/RNA mini kit, according to manufacturer’s 
instructions. The diagnostic ddPCR assay was carried out as described in the manuscript in 
section 5.1.    
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5.3.2.3 Data analysis 
 
Variance and means between groups were compared with one-way analysis of variance 
(ANOVA).  
 
Figure 5.3.2.1. Temperature profiles of treatments for DNA resistance to freeze–thaw study.   
 
5.3.3 Results 
 
Droplet digital PCR failed in one specimen (stored under treatment 4) which was excluded from 
the analysis. The load detected in swabs stored under the four treatment regimens are 
displayed in figure 5.3.2.2. There was no significant difference in variance between- and within-
groups for either endogenous control load or Ct plasmid load (F-statistic = 0.44 and 1.1, 
respectively) and no significant difference in means overall (p = 0.516 and 0.309, respectively). 
The null hypothesis for the ANOVA was that all groups have equal variance and means; as no 
significant differences were found in the overall model, no pairwise t-test was conducted.  
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5.3.4 Discussion 
 
I am confident that minor fluctuations in the frozen temperature would not lead to diagnostic 
failure. The low prevalence of detectable Ct in this study should not be attributed to changes in 
storage temperature during specimen collection.  
 
Figure 5.3.2.2. Recovered loads from freeze–thaw study. According to ANOVA testing, none of the differences in the 
model were significant. Random jitter was added to the x-coordinate of each point to separate points that would 
otherwise be superimposed.   
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5.4 Note B: Clustering of clinical trachoma 
 
When calculating the sample size required to assess a given parameter with a specified 
precision, the sample required from a simple random selection is inflated by a design effect to 
account for disease clustering (307). The GTMP methodology utilized a general design effect of 
2.65 taken from amalgamated previous trachoma surveys (15). From the age profile of TF and 
the low prevalence of ocular Ct, disease transmission and clustering may be expected to differ 
from that observed in other trachoma-endemic settings. Also, given the geographic isolation of 
the islands, and even villages within the same island, the spatial distribution of trachoma in this 
population may also be unique. The inter-cluster correlation coefficient (ICC) was calculated 
from the between-village, between-household and population-wide variance in TF proportions, 
where ICC is defined as (307): 
 
ICC = sB / (sB + sW)  
 
Where sB is the between-cluster variance and sW is the within-cluster variance. The ICC of TF at 
the village level was 0.74, and at the household level was 0.55. Both suggest clinical disease is 
clustered at the household and the village level; more so at the village level. Importantly, this 
suggests prevalence is unlikely to be homogenous throughout the EU (this is commonly 
observed in trachoma-endemic areas (232)). The most frequent transmission of infection would 
be expected at the household level as that would be where most contact took place, however, 
the higher village-level ICC and the later peak age-specific prevalence could suggest 
transmission at the community level rather than in the household, such as at school or church.   
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5.5 Note C: Organism load and genome sequencing success 
 
When the Ct genome and plasmid were first sequenced (161), the sequencing technology used 
required large amounts of input DNA to be able to determine individual bases with confidence. 
The organisms had to be cultured to generate sufficient genomic material. Culture can take 
several days per passage and may require several passages from clinical samples. It is time 
consuming and may lead to some in vitro genetic change. As isolates are continuously 
replicated in the absence of immune pressure and negative selection pressures related to the 
burden of maintaining such factors, culture can lead to their functional attenuation. Concurrent 
development of methods for the enrichment of chlamydial DNA without culture and high-
throughput, low-cost sequencing (167,168,308) has enabled sequencing of clinical strains 
directly from diagnostic specimens. In this study, despite the small absolute number of 
infections, the sequencing success rate from Ct-positive samples was relatively high (5/13; 
39%). The ddPCR technique provided good estimates of genome copy number in these 
specimens, this data was therefore used to assess whether a load cutoff for sequencing 
success could be established in this sample set. 
 
Table 5.5.1 shows a number of indicators of the amount of material collected onto a swab. In 
the table, more specimens with high Ct omcB and plasmid loads appear to have been 
successfully sequenced than those with low Ct loads. The small numbers involved prohibits 
useful multivariate analysis in this context. This reflects findings from other groups that the 
absolute number of genome copies, rather than the ratio of Ct to other (mostly human, but also 
other microbial) nucleic acid (167), is the most important factor in determining sequencing 
success. However, the stated lower limit of reliable successful sequencing for urogenital 
specimens is between ~12000 and 90000 total genome copies, depending on specimen type 
(167). In the lowest load specimen to achieve a complete genome sequence, there were an 
estimated 454 genome copies. This low number might reflect a reduced sample complexity 
when compared to a urogenital specimen, with fewer microbes and amplification inhibitors than 
found in the urogenital tract. This should encourage the use of direct sequencing of specimens 
from ex-diagnostic specimens in trachoma research, as the role of chlamydial genetic 
polymorphisms in pathogenicity is poorly understood compared to other pathogens (160,166). 
This is not a reliable limit of detection; reads from two of these specimens with ~24,000 and 
~26,000 genome copies, respectively, covered less than 20% of the genome when assembled.   
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Table 5.5.1. Metrics describing amount of material obtained from swab sample, and their relationship to 
complete coverage. 
Indicator Median 
≥ 95% coverage  
at 1X depth 
<95% coverage  
at 1X depth 
Endogenous control  
Above 3 4 
Below 2 3 
C. trachomatis plasmid load  
Above 4 2 
Below 1 5 
C. trachomatis omcB load 
Above 4 2 
Below 1 5 
DNA concentration 
Above 1 5 
Below 4 2 
 
 
Figure 5.5.1. Genome copies in specimens from which sequence coverage was partial and complete. Genome 
copies considered equivalent to omcB copies. The difference was not significant upon regression testing (p = 0.8). 
Boxes represent median and inter-quartile range, and the whiskers represent 1.5-times the inter-quartile range.  
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6. LONG-LIVED SIGNS OF CHLAMYDIA TRACHOMATIS 
TRANSMISSION AND TRACHOMA PATHOGENESIS  
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6.1 Introduction 
 
In chapter five, the moderate prevalence of the clinical sign TF was not concurrent with highly 
prevalent infection or TT. This result questions the utility of the WHO simplified grading scheme 
in the Solomon Islands, and requires further investigation.  
 
The late-stage sequelae of trachoma (i.e. TS, TT) are thought to be more common in people 
who have had several rounds of recurrent and prolonged Ct challenge and inflammation (10). 
Cross-sectional point estimates of prevalence of transient markers such as TF and Ct infection 
cannot provide insight into historical exposure. In this chapter, two features of trachoma were 
examined that may reflect historical challenge.  
 
6.2 Anti-Pgp3 ELISA validation: within- and between-assay performance  
 
6.2.1 Introduction 
 
The performance of anti-Pgp3 ELISA is difficult to assess, because true previous-exposure 
‘positives’ and ‘negatives’ are hard to define. Many Ct infections are asymptomatic (227), so it is 
hard to identify whether a seronegative individual has truly not been exposed to the bacterium. 
There is also likely to be heterogeneity in production and maintenance of antibody response, so 
it is difficult to know whether all individuals exposed to Ct will become seropositive. Additionally, 
Pgp3 immunogenicity is not biovar-specific, so there is likely to be an underlying positive rate in 
any population from urogenital infection and exposure in parturition. TF and infection are not 
suitable ‘gold standards’ for traditional diagnostic comparison purposes as they measure 
transient processes. Additionally, serum level of anti-Pgp3 antibodies is a continuous rather 
than discrete variable, so the threshold between positive and negative sera is not always clear. 
The assay was developed at CDC and has been evaluated as part of their work (D Martin et al., 
manuscript under preparation) therefore this section will not focus on the comparability of this 
data to published datasets, the majority of which have been generated using a multiplex bead 
array system described elsewhere (243). Prior to rolling the technique out on clinical samples, I 
set out to determine the intrinsic variability to the ELISA protocol used to increase our 
confidence in any results generated with the technique.  
 
6.2.2 Methods 
 
6.2.2.1 Dried blood spot collection, preparation and test ELISA 
 
Specimen collection, handling and elution are described in section 6.3. The ELISA protocol 
used in this study is described in section 6.3. 
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6.2.2.2 Within-technique reproducibility 
 
The ELISA protocol includes a serial dilution of high anti-Pgp3 titre serum (presumed positive) 
in low anti-Pgp3 titre serum (presumed negative) on each plate, both sera being supplied by the 
developing laboratory alongside other reagents. The dilution levels are shown in table 6.2.3.1. 
Baseline absorbance is removed by running three wells with PBST-milk alone on each plate 
and subtracting the mean OD from the OD of the other wells of the plate. A successful test was 
defined as testing on a plate where the OD of standard dilutions fell within 20% of the previously 
determined mean acceptable values. 
 
This standard dilution series was run in triplicate wells on each of the 20 plates required to run 
our sample set. The reproducibility of the assay was measured by assessing the variance of 
these repeated specimens.  
 
All clinical data reported were the first successful result from single extensions from the filter 
paper wheel eluted in PBST-milk. For 465 specimens randomly selected from the whole 
specimen set, dried blood was eluted from a second extension and re-tested using the same 
protocol. The same criteria for eligibility of the test result as described above were applied. The 
comparison between specimens tested on different plates is enabled by normalization to 200U 
standard, for which the mean OD value is around 1. Therefore, repeat-tested specimens were 
normalized prior to comparison. 
 
6.2.2.3 Between-technique reproducibility 
 
A randomly selected subset of 160 specimens were eluted into PBST-milk. An aliquot of PBST-
milk was assessed with the protocol developed by the CDC (as described in section 6.3) and 
then a second aliquot from the same eluate was tested using an independent ELISA technique 
also assessing Pgp3 reactivity, developed at LSHTM by Harry Pickering. 
 
Pgp3 for the LSHTM ELISA was prepared by culturing Escherichia coli transfected with a 
glutathione S-transferase (GST)-tagged Pgp3-encoding plasmid overnight in 2YT media 
supplemented with isopropyl β-D-1-thiogalactopyranoside (IPTC) to induce expression. Bacteria 
were lysed, resuspended in PBS supplemented with 1% Triton X-100 and pelleted to remove 
cell debris. Soluble GST-tagged proteins were isolated from the supernatant using glutathione 
sepharose beads, which were then purified by washing from the beads using 5mL 
polypropylene spin columns. GST tags were removed by incubating with cleavage buffer 
supplemented with 8% PreScission Protease, and resulting protein eluate purified with 
chromatography. 
 
A 50-μL aliquot of 1μg/mL Pgp3 in 0.1M sodium bicarbonate (pH 9.6) was added to Immulon 4 
HBX microtitre plates (Fisher Scientific, Loughborough, UK) and incubated overnight at 4°C to 
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bind the antigen. The following day, plates were rinsed twice with washing buffer (PBS with 
volume/volume 0.05% tween-20, PBSTLSHTM), and blocked with 100μL blocking buffer 
(PBSTLSHTM supplemented with 2.5% weight/volume nonfat milk power) at room temperature for 
4 hours. After two washes, one 50μL aliquot of dried blood spot eluted overnight in PBST-milk 
was added to each well and incubated at room temperature for 4 hours. After four washes, 
100μL anti-human IgG-peroxidase antibody diluted 1/30000 in blocking buffer were added per 
well and incubated at room temperature for 1 hour. After a final four washes, 100μL 1-Step Ultra 
TMB-ELISA substrate (Fisher Scientific, Loughborough, UK) was added per well and incubated 
at room temperature for 10 minutes. The reaction was stopped by addition of 100μL 2M 
sulphuric acid per well and the OD measured at 450nm for detection and 700nm for background 
correction.  
 
6.2.2.4 Data analysis 
 
Coefficients of variation (CoVs) were defined as the standard deviation of the mean divided by a 
mean of repeat-test OD estimates. Intrinsic thresholds for each analysed dataset were predicted 
using an expectation maximization finite mixture model in the ‘mixtools’ R package (309,310), 
whereby a sample was considered positive if the OD was more than three standard deviations 
above the mean OD of the presumed-negative specimens. 
 
6.2.3 Results 
 
Table 6.2.3.1 shows the variability of repeat testing of ELISA standards. Within plates, the CDC 
ELISA methodology was highly reproducible across all OD levels, with specimens with ODs 
above baseline having a mean CoV of 5%. The baseline measurements were more variable 
with a CoV of 17%. The between-plate variability in standards is a much greater source of 
variation in assay result. 
 
Table 6.2.3.1. Reproducibility of repeat testing of dilutions of high anti-Pgp3 and low anti-Pgp3 sera. 
Standard 
High anti-Pgp3 
serum 
Low anti-Pgp3 
serum 
Mean* OD 
Mean* within-plate 
CoV 
Between-plate 
CoV 
1000U 100% 0% 1.98 5.1% 24.2% 
500U 50% 50% 1.50 4.1% 23.9% 
200U 20% 80% 1.03 4.5% 24.6% 
50U 5% 95% 0.43 6.6% 27.8% 
0U 0% 100% 0.13 17.1% 165.6% 
CoV: Coefficient of variance; OD: Optical density at 450nm; U: Arbitrary units 
*Means determined from mean value across 20 plates of clinical specimens. 
 
Figure 6.2.3.1 depicts the correlation between blood eluted from different blood spots collected 
consecutively from the same participant. The CoV between different blood spots tested using 
this assay was 24.8%. The similarity with the between-plate variation estimate suggests the 
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majority of difference in repeated tested blood spot ODs comes from the assay’s inherent inter-
plate variation. Upon re-testing, the Spearman’s rho correlation coefficient between first and 
second estimate of Pgp3 level was 0.88, suggesting good agreement. When thresholds were 
assigned to both datasets independently, 38/465 (8.2%) repeat tested specimens had 
discrepant results between first and second test, a kappa agreement score of 0.84.  
 
Figure 6.2.3.1. Antibody response to Pgp3 compared between blood spots collected consecutively from the 
same participant on a single filter wheel. Tested on consecutive days using an identical protocol. Spearman’s rho 
correlation is 0.84, kappa agreement for diagnostic result is 0.84. 
 
Figure 6.2.3.2 demonstrates the correlation between two aliquots of the same blood spot eluate 
tested using two independent methodologies. The correlation is, in general, good (Spearman’s 
rho 0.88). When thresholds are assigned independently to each dataset, 20/160 (12.5%) 
specimens tested were discrepant, a Cohen’s kappa agreement score of 0.74. Most (19/20) of 
the discrepant specimens were called positive by the CDC protocol, but negative by the LSHTM 
ELISA protocol, reflecting higher estimates of OD by the CDC ELISA in the intermediate 
reactivity range.  
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Figure 6.2.3.2. Comparison of eluate optical density estimated by two independent ELISA protocols. Eluate 
aliquots were tested side-by-side on the same day. Spearman’s rho is 0.88, kappa agreement score is 0.74. 
 
6.2.4 Discussion 
 
The estimation of anti-Pgp3 antibody concentration recovered from dried blood spots is 
inherently variable. The largest contributor to assay variation is between-plate variation, 
therefore it is appropriate to use a normalization step in the data analysis to ensure the data is 
comparable to OD data generated by ELISA at other laboratories. Diagnostically, repeat testing 
samples in this context is likely to create difficulty in defining the result of borderline specimens 
which intermittently test positive and negative (311). Given the inherent variability of the immune 
response and the inter-plate variability of the assay, a single well per specimen was considered 
to be sufficient to estimate reactivity to Pgp3. The comparison with an external ELISA suggests 
that the estimate of anti-Pgp3 antibodies is generally reliable. However, the CDC protocol 
generates a slight overestimation of intermediate ODs, leading to a small number of positives 
that were negative by alternative test. As described above, it is not possible to determine from 
these data which test is more accurate; it is possible that a number of small protocol differences 
between the ELISA techniques compared (for example, cleavage of GST tag [LSHTM protocol] 
compared to nonremoval of the GST tag [CDC protocol] and blocking in PBST-milk [LSHTM 
protocol] rather than PBST [CDC protocol]) may cumulatively lead to higher absorbance in the 
CDC protocol. To date, the PPV of IgG anti-Pgp3 antibodies for non-IgG anti-Pgp3 antibodies, 
or antibodies to other Ct antigens has not been assessed. I was satisfied that agreement within- 
and between-assay was appropriate to estimate the population-level Pgp3 seroprevalence with 
sufficient accuracy to support the conclusions made in section 6.3. 
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6.3 Manuscript 
 
In the Solomon Islands, lower age-specific prevalence of anti-Pgp3 antibodies and scarring 
were found than in comparator regions, and, interestingly, no association was identified 
between clinical signs of disease and prior Ct exposure. A large proportion of TF cases were 
seronegative and a number of physiologically typical TS cases occurred in seronegative 
individuals. 
 
We observed relatively little increase in TS cases with age and did not find of evidence of 
accumulating severe scars with age. Combined with lack of increase in Pgp3 response, this is 
consistent with a low prevalence of ocular Ct infection and low rate of transmission. Both, 
however, are inconsistent with over 30% of the children in these villages having TF 6 months 
previously. It is unclear whether the scars observed in Solomon Island children will progress to 
TT in some individuals. It may be that these scars are caused by acute challenges not related to 
trachoma and that the immunopathology that leads to TT is not triggered.  
 
Ocular infection with Ct is present in the Solomon Islands but the burden appears to be much 
lower than indicated by the prevalence of TF. Clinical signs of TF and TS are observed in 
individuals who have no historical exposure to Ct. A key unanswered question is what is 
causing this follicular inflammation if we assume, as the data suggest, that the majority of cases 
are not related to Ct. This will be addressed in chapter seven.   
Trachoma in the Pacific Islands 
 
 
RESEARCH PAPER COVER SHEET 
SECTION A – Student Details 
Student Robert Butcher 
Principal Supervisor Chrissy h Roberts 
Thesis Title Using alternate indicators to define need for public health 
intervention for trachoma: Evidence from the Pacific 
Islands 
If the Research Paper has previously been published, please complete Section B, if not 
please move to Section C 
 
SECTION B – Paper already published 
Where was the work published? NA 
When was the work published? NA 
If the work was published prior to 
registration for your research degree, give a 
brief rationale for its inclusion 
NA 
Have you retained copyright for the work?* NA Was the work subject to academic 
peer review? 
NA 
*If yes, please attach evidence of retention. If no, or if the work is being included in its published 
format, please attach evidence of permission from the copyright holder (publisher or other 
author) to include this work. Work published under Creative Commons Attribution 4.0 
International Open Access License.  
 
SECTION C – Prepared for publication, but not yet published 
Where is the work intended to be published? Lancet Infectious Diseases 
Please list the paper’s authors in the intended 
authorship order: 
Robert M R Butcher, Oliver Sokana, Kelvin Jack, Leslie 
Sui, Charles Russell, Suzanne Tetepitu, Matthew J 
Burton, Anthony W Solomon, David CW Mabey, Chrissy 
h. Roberts. 
Stage of publication Under peer review 
 
SECTION D – Multi-authored work 
For multi-authored work, give full details of your role 
in the research included in the paper and in the 
preparation of the paper. 
I supported Anthony Solomon in securing funding for this 
project. I worked with Chrissy Roberts to design this 
study. I obtained ethical approval for the study. I 
coordinated the fieldwork with the help of Oliver Sokana, 
Kelvin Jack, Eric Kalae, Leslie Sui and Suzanne Tetepitu. 
I conducted the laboratory work independently. I analysed 
the data with the help of Chrissy Roberts. I prepared the 
figures and tables, and wrote and revised the manuscript 
following feedback from co-authors.  
 
Student signature:                                       Date: 09/12/16 
 
Supervisor signature:                                        Date: 19/12/16              
 
Running header: Chlamydial serology and scarring in the Solomon Islands 
	
Signs of trachoma are prevalent in Solomon Islanders who 
have no evidence of prior infection with Chlamydia 
trachomatis. 
 
Robert M R Butcher1*, Oliver Sokana2, Kelvin Jack2, Diana L Martin3, Matthew J Burton1, 
Anthony W Solomon1, David CW Mabey1, Chrissy h. Roberts1. 
 
1 Clinical Research Department, London School of Hygiene & Tropical Medicine, Keppel Street, 
London, WC1E 7HT, UK 
2 Eye Department, Solomon Islands Ministry of Health and Medical Services, P.O. Box 349, 
Honiara, Solomon Islands 
3 Division of Parasitic Diseases and Malaria, US Centers for Disease Control and Prevention, 
Atlanta, GA, USA 
 
* Corresponding author: robert.butcher@lshtm.ac.uk, +44 207 927 2419 
 
Keywords 
Trachoma; ocular Chlamydia trachomatis; ddPCR; anti-Pgp3 antibodies; trachomatous scarring; 
Solomon Islands 
 
Running header 
Chlamydial serology and scarring in the Solomon Islands  
Running header: Chlamydial serology and scarring in the Solomon Islands 
	
Key Messages 
• In the Solomon Islands we have identified a disease which has signs that closely 
resemble those of trachoma (TF, TS) but which occurs in many individuals without 
serological evidence of prior Ct infection.  
• The conjunctival scarring process does not appear to progress to severe scarring and 
TT, and no consequent threat to vision is evident.  
• Clinical grading of TF is shown to be a poor tool to guide MDA in this context. This may 
have resulted in mass antibiotic distribution here that was not necessary for the 
purposes of a public health threat from trachoma.  
• International guidelines for trachoma elimination should be reassessed in the light of this 
evidence.  
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Abstract 
Background 
The prevalence of trachomatous inflammation-follicular (TF) in the Solomon Islands is moderate, 
but the prevalence of trachomatous trichiasis (TT) and ocular Chlamydia trachomatis (Ct) infection 
is low.  
Methods  
We enrolled 1511 people aged ≥1 year from randomly selected households in 13 villages in which 
>10% of the population had TF prior to a single round of azithromycin MDA undertaken six months 
previously. Presence or absence of signs of trachoma, digital photographs and dried blood spots 
were collected from each participant. Conjunctival swabs were collected from children aged 1–9 
years who had TF. Photographs were analysed for scarring using the modified WHO trachoma 
grading system. Blood spots were screened for anti-Pgp3 antibodies using enzyme-linked 
immunosorbent assay. Tests for Ct infection were performed on conjunctival swab DNA using 
droplet digital PCR. 
Results 
The prevalence of TF in 1–9 year olds decreased to 13.1% from its pre-MDA level of 26.1% 
(p<0.0001). Conjunctival scars were visible in 13.1% of photographs and most severely scarred 
cases were children. 10% of severe scars had morphology that was atypical for trachoma. Mild 
(p<0.0001) but not severe (p=0.149) scars increased in prevalence with age. Anti-Pgp3 antibody 
prevalence was 18% in 1–9 year olds, sharply increasing around the age of sexual debut, to reach 
69% in over 25s. Anti-Pgp3 seropositivity was not associated with scarring in children (p=0.472) 
or TF in children (p=0.581). The prevalence of Ct infection in TF cases before and after MDA did 
not differ significantly (3.1% pre-MDA versus 9.8% post-MDA; p=0.08).  
Conclusions 
Signs of trachoma are common in the Solomon Islands but occur frequently in individuals who 
have no serological evidence of prior ocular infection with Ct. WHO recommendations for district-
level assessment and MDA provision based on signs alone may have led to inflated estimates of 
the trachoma burden and mass distribution of antibiotic treatment that was unnecessary for 
trachoma elimination in this context.  
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Introduction 
Trachoma is responsible for approximately 1.9 million cases of visual impairment or blindness 
globally.(1) International partners have committed to elimination of trachoma as a public health 
problem by the year 2020. The causative agent, Chlamydia trachomatis (Ct), induces specific 
immune responses at the conjunctiva during an infection(2) which include the polyclonal 
production of antibodies to Ct antigens.(3) Repeated infectious stimuli and the immunological 
response to them can cause a gradual accumulation of scar tissue in the tarsal conjunctivae.(4)  
Scarring typically begins to develop in late childhood(5) and can reach a prevalence of 25% in 
10-year-olds in hyperendemic populations.(6) Scarring progresses throughout a lifetime and, in 
severe cases, can lead to entropion, trichiasis, abrasion of the cornea, corneal opacity and 
blindness.(7) 
Global elimination strategies are guided by the signs “trachomatous trichiasis” (TT) and 
“trachomatous inflammation—follicular” (TF). The World Health Organization (WHO) 
recommends mass drug administration (MDA) with azithromycin in districts with >5% TF 
prevalence in 1–9 year-olds.(8) As trachoma control reduces prevalence, the positive predictive 
value of TF as a Ct infection marker drops and phenotypically similar diseases with other 
aetiologies will be unmasked.(9) We have previously reported data from a 2013 population-based 
prevalence survey covering the two provinces of Temotu and Rennell & Bellona of the Solomon 
Islands, which showed the prevalence of TF in those aged 1–9 years was moderately high 
(26.1%), but TT (0.1%) and ocular infection with Ct (1.3%) were rare.(10) In accordance with 
WHO guidelines, MDA took place in these provinces in 2014.  
It was unclear whether the high TF prevalence in these provinces was accompanied by significant 
burden of trachomatous scarring (TS), whether TF occurred exclusively in those who had 
previously been infected with Ct, or whether MDA would reduce or eliminate TF. Six months after 
MDA, we revisited villages that previously had high proportions of children with TF and assessed 
prior exposure to Ct infection and age-specific prevalence of scarring.  
 
Methods 
Ethics 
Study approval was from the London School of Hygiene & Tropical Medicine (LSHTM; 8402) and 
Solomon Islands National Health Research Ethics Committee (HRC15/03). Subjects aged 18+ 
years gave written informed consent to participate. A parent/guardian provided consent for those 
aged under 18 years.  
Study design 
Thirteen villages in Temotu and Rennell & Bellona provinces were selected because over 10% of 
the community (all ages) had signs of TF.(10) Due to their small respective populations (Temotu: 
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21,362; Rennell & Bellona: 3041), the two provinces were combined into one evaluation unit 
during baseline mapping. The number of villages in each province surveyed as part of this study 
were selected to reflect the relative population proportion (Temotu: 11 villages; Rennell & Bellona: 
2 villages). The survey took place in June-July 2015, six months after a single round of 
azithromycin MDA had been delivered by the Solomon Islands National Trachoma Elimination 
Program. The program administered approximately 24000 doses of azithromycin and achieved 
coverage of approximately 80% in Rennell & Bellona, and 85% in Temotu. After the baseline 
survey, the National Program also used billboard posters and regular radio spots to promote facial 
cleanliness and raise awareness of trachoma elimination. The current survey was powered to 
estimate the prevalence of anti-Ct antibody seropositivity in children aged 1–9 years. Based on 
the low prevalence of ocular Ct infection prior to MDA (1.3%), we expected the seroprevalence 
to be approximately 10%, in line with other communities with low Ct prevalence.(11) To estimate 
seroprevalence with ±5% precision at the 95% confidence level, 367 children were required.(12) 
In our 2013 survey, we examined a mean of 1.1 children per household and therefore needed 25 
households in each of 13 clusters to reach our sample size. All residents aged 1 year or above 
living in households drawn at random from a list of all households in a study cluster were eligible 
to participate. 
Trachoma grading 
Grading using the WHO simplified system(13) for TF, ”trachomatous inflammation—intense” (TI) 
and TT was performed in the field by one of two Global Trachoma Mapping Project (GTMP)-
certified graders, wearing 2.5× binocular magnifying loupes.(14) High-resolution digital 
photographs of the right tarsal conjunctivae were graded for TS using the modified WHO 
trachoma grading system (Table 1).(15) Photographs were graded by two photo-graders who had 
previously achieved kappa scores for inter-observer agreement of >0.8 for F, P and C (follicles, 
papillae and cicatricae) grades, compared to a highly experienced trachoma grader. Photograph 
grading was undertaken masked to field grading, laboratory results, and the other photograph 
grader’s assessment. Discrepant grades were arbitrated by a third highly experienced grader.  
Specimens 
Sterile lancets (BD Life Sciences, Oxford, UK) were used to collect 10 µL of blood onto filter paper 
(CellLabs, Sydney, Australia) which was air-dried for 4–12 hours before being sealed in ziplock 
bags with desiccant sachets. These were refrigerated for up to one week and then stored at -
20°C before shipping at ambient temperature to LSHTM. 
Using standard methods,(16) right conjunctival swabs were collected from any children aged 1–
9 years who had signs of TF and/ or TI. Swabs were frozen to -20°C within one week of collection 
and shipped to LSHTM on dry ice for processing.  
Serological and nucleic acid testing 
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Previous exposure to Ct infection was measured by detection of anti-Ct Pgp3 antibodies using an 
enzyme-linked immunosorbent assay (ELISA).(17)(18) Optical density (OD) at 450 nm was 
measured using SpectraMax M3 photometric plate reader (Molecular Devices, Sunnyvale, USA).  
DNA was extracted from swabs with the QIAamp DNA mini kit (Qiagen, Manchester, UK). We 
tested samples for Homo sapiens ribonuclease subunit (RPP30 endogenous control) and open 
reading frame 2 of the Ct plasmid (diagnostic target) using a droplet digital PCR assay(19) with 
minor modifications.(20)  
Data analysis 
All data analyses were conducted using R 3.2.3.(21) Pre- and post-MDA proportions were 
compared using Wilcoxon’s rank sum test. ddPCR tests for current ocular Ct infection were 
classified into negative and positive populations according to methods described previously (19). 
ELISAs for antibodies to Ct were classified as negative or positive using an expectation-
maximisation fixed mixture model (Migchelsen et al, in press). Using this method, the threshold 
normalised OD value for positivity was 0.7997.  
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Results 
Study demographics 
In total, 1511 people (46.3% male; 466 1–9 year-olds) aged 1 year and over were examined in 
382 households from the 13 selected study villages. By comparison, the pre-MDA survey of the 
same villages yielded 1534 people (490 1–9 year-olds) in 394 households. Data on non-
participation were not collected in June 2015, but the number enrolled was similar to that for the 
pre-MDA survey, suggesting a similar participation rate (~90%) on both occasions. In this study, 
there was a mean of 4 people per household aged 1 year and over, and a mean of 1.2 children 
per household aged 1–9 years, which, after accounting for non-participants, are similar to the 
means in the 2009 Solomon Islands National Census (4.9 people of any age and 1.4 children 
aged 1–9 years per household in Temotu, 4.4 people of any age and 1.1 people aged 1–9 years 
per household in Rennell & Bellona).(22)  
Active trachoma and TT 
Prior to MDA, there were 165/489 (33.7%) cases of TF in either eye and 1/489 (0.2%) case of TI 
in those aged 1–9 years in study villages.(10) Following MDA, we observed 66/466 (14.2%) cases 
of TF and no cases of TI in either eye, representing a decrease in TF of 58% (p<0.0001). A similar 
pattern was observed in right eyes considered alone – the eyes from which swabs were collected 
if indicated (Table 2). 56% of TF cases following MDA were bilateral. No cases of TT were 
identified during this study. 
In the two enrolled villages of Rennell & Bellona, a slight increase in the prevalence of TF in either 
eye in those aged 1–9 years following MDA was noted, but it was not statistically significant (11/60 
[17.9%] before MDA to 14/78 [18.3%] after MDA; p=0.956). In contrast, in the 11 enrolled villages 
of Temotu, a substantial decrease in TF (from 155/430 [36.0%] before MDA to 52/388 [13.4%] 
after MDA; p<0.0001) was observed.  
Trachomatous scarring 
Of the right eye photographs collected, 1440/1511 (95.3%) were suitable for grading. 188/1440 
(13.1%) photographs were graded as C>0, of which 127 were C1, 53 were C2 and 8 were C3. 
Exemplars of scarring that resembled normal trachoma phenotypes are shown in Figures 1A and 
1B. The photo-graders noted that some conjunctivae met the criteria for C3, with clear bands of 
scarring, but also showed clear features not typically associated with trachomatous pathology. In 
some cases, these were characterised by boundaries demarcating heavily scarred from 
apparently healthy conjunctiva (Figure 1C and 1D). Photograders noted atypical scars in 4/53 
(7.5%) C2 cases and 3/8 (37.5%) C3 cases. Of the scarred eyelids classed as typical for 
trachoma, 36/54 (67%) were seropositive, whereas 2/7 (29%) of those classed as ‘atypical’ were 
seropositive, although the difference in proportions was not significant (chi-squared test p=0.123).  
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Figure 1. Photographs from adults graded as C3. (A and B). Conjunctivae with features meeting the criteria for C3 
characteristic of trachoma (C and D). Conjunctivae with features meeting the criteria for C3 but thought not to be 
trachomatous in origin. Study IDs were SB113564, SB108878, SB107613 and SB108669. All taken of residents in 13 
selected communities of Temotu and Rennell & Bellona Provinces, Solomon Islands, June-July 2015.   
The age-specific prevalence of scarring is shown in Figure 2. Of 435 photographs graded from 
children aged 1–9 years, 25 (5.7%) were graded as C>0. In 311 adults aged >40 years who were 
examined, 74 (23.8%) had C>0 (65 cases of C1, 9 cases of C2, 0 cases of C3). Of 8 cases of C3 
in the population, 4 (50%) were in children aged 1–9 years, although 2 of these were classed as 
‘atypical’.  
The proportion of people with C1 increased with age (logistic regression p<0.0001) but the 
proportion of people with more severe scarring (C2 or C3) did not increase with age (logistic 
regression p=0.149). There was no significant association between having C>0 and gender (chi-
squared test p=0.80). In Rennell & Bellona, 25/225 (11.1%) of photos were graded C>0, whereas 
in Temotu, 163/1215 (13.4%) of photos were graded C>0; the difference in scarring between 
provinces was not significant (Wilcoxon Rank Sum test p=0.289).  
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Figure 2. Age-specific prevalence of scarring (defined as C>0), as identified by photographic grading, in 13 
selected communities of Temotu and Rennell & Bellona Provinces, Solomon Islands, June-July 2015. Bar labels 
represent total number of people in each age group.   
 
Anti-Pgp3 serology 
Dried blood spots were collected from 1499/1511 (99.2%) people of all ages during the post-MDA 
survey; the other 12 people declined finger-prick. Overall,  anti-Pgp3 seroprevalence was 
633/1499 (42.2%). In children aged 1–9 years, the prevalence of anti-Pgp3 antibodies was 83/462 
(18.0%); in 1-year-olds alone, it was 5/47 (10.6%). The mean seroprevalence in those aged 6–
10 years was not significantly higher than in those aged 1–5 years (20.3% compared to 16.6%, 
Wilcoxon rank sum p=0.276). The largest increase in seroprevalence was observed between 
those aged 16–20 years and 21–25 years when the seroprevalence rose significantly from 30.4% 
to 71.6% (Wilcoxon rank sum p<0.0001). Of those aged over 25 years, 67.4% were seropositive 
(Figure 3). In the 16–20-year-old age group, the prevalence of seropositivity amongst females 
was higher than in males (13.9% versus 41.1%, Wilcoxon rank sum test p<0.0001). The 
seroprevalence among children in Rennell & Bellona was significantly higher than that in Temotu 
(38.5% versus 13.8%; chi-squared p<0.0001).  
There was no association between seropositivity and signs of TF in children aged 1–9 years 
(19.7% seropositive in those with TF in either eye compared to 17.7% seropositive in those 
without TF, p=0.581). In those younger than the median self-reported age of sexual debut (18 
years (23)), there was no association between C grade and anti-Pgp3 OD (linear regression 
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adjusted for age and gender p=0.453) or anti-Pgp3 positivity (logistic regression adjusted for age 
and gender p=0.472). 
 
Figure 3: Age-specific seroprevalence of anti-Pgp3 antibodies, separated by gender. Pale blue bars represent 
proportion of seropositive females in each age group (optical density over 0.7997), dark blue bars represent proportion of 
seropositive males. Dried blood specimens collected from 13 selected communities of Temotu and Rennell & Bellona 
Provinces, Solomon Islands, June-July 2015. 
 
Ocular C. trachomatis infection  
Swabs from all 61 children aged 1–9 years with TF in the right eye that were tested for Ct had a 
positive endogenous control result; the median load of the human RPP30 target was 83,000 
copies, equivalent to over 40,000 conjunctival cells. In this study, 6/61 (9.8%) of children with 
active trachoma had Ct infection. Of the 6 specimens from children positive for Ct, the median 
load was 104,100 plasmid copies/swab. We previously showed that before MDA, 5/160 (3.1%) of 
those with active trachoma in study villages had evidence of infection with Ct. The median pre-
MDA load of Ct infections in these villages was 51,880 plasmid copies/swab.(10) Neither the 
difference between the pre- and post-MDA Ct prevalence nor pre- and post-MDA Ct load was 
statistically significant (Wilcoxon rank sum test p=0.08 and p=0.22, respectively). The relationship 
between Ct infection, signs of trachoma and seropositivity was examined in children aged 1–9 
years and is summarised in Table 3. All six cases of active trachoma in which infection was also 
detected were in seropositive individuals (Figure 4). All study villages had at least one case of TF, 
but infections were limited to three of the 13 villages studied. Two villages in Rennell & Bellona 
housed five of the six Ct infections identified during this study.  
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Figure 4: Anti-Pgp3 antibody titre from children aged 1–9 years in 13 selected communities of Temotu and Rennell 
& Bellona Provinces, Solomon Islands, June-July 2015. Those with trachomatous inflammation—follicular (TF) and/or 
trachomatous inflammation—intense (TI) but no infection are highlighted in blue, those with TF and/or TI and infection are 
red and those with neither TF nor TI nor infection are grey. The horizontal dotted line represents the threshold for 
seropositivity. Random jitter was applied to the x-coordinate of each data point to separate points that would otherwise 
overlap.    
Running header: Chlamydial serology and scarring in the Solomon Islands 
	
Discussion 
The Solomon Islands, along with other Pacific Island states, has been identified as trachoma-
endemic based on moderately high province-level prevalences of TF. Whilst measures for 
trachoma elimination have already been deployed in Temotu and Rennell & Bellona, we have 
previously noted that TI, ocular Ct infection and late-stage disease (TT) are rare.(10) If the findings 
from these study villages were replicated throughout the district, TF would still be sufficiently 
prevalent to warrant intervention. However, using a suite of non-TF tools (clinical photography for 
evaluation of conjunctival scarring, nucleic acid infection testing and serological testing), we have 
demonstrated here that ocular Ct is scarce and is not being widely transmitted, and that TF is not 
concurrent with prevalent severe scarring or TT in this population.  
We would not expect to see large numbers of individuals with TF who have not previously been 
infected with Ct, but in this population, the majority (80.3%) of individuals with TF were 
seronegative, and participants with TF were no more likely to be seroreactive to Pgp3 than their 
peers without TF. We found a small and non-significant increase in age-specific seroprevalence 
between young children (0–5 years) and older children (6–10 years), which suggests that there 
is limited horizontal transmission of Ct strains among children. This is concordant with our 
previous data, which suggested that although ocular Ct strains are present in the Solomon 
Islands, they are rare.(10) The increase in seropositivity with age in this group was modest 
compared with that seen in hyperendemic villages of the United Republic of Tanzania, where 
seropositivity has been observed to increase from approximately 25% to 94% between the ages 
of 1 and 6 years.(17) In the current dataset, there was a rapid increase in age-specific 
seroprevalence around the age of 18 years, the self-reported median age of sexual debut in a 
nearby population.(24) The prevalence of urogenital Ct infection is known to be high in women 
attending antenatal clinics in the Solomon Islands (24), which may account for the high 
seroprevalence in adults, and exposure during parturition may also be a major contributor to the 
10% of 1-year-olds in our study who had evidence of prior Pgp3 exposure.(25)  
Antibodies to Pgp3 have recently been suggested for monitoring Ct transmission in trachoma 
programmes,(26,27), but there is still much to learn about the dynamics of these responses.  For 
example, it is not clear whether anti-Pgp3 responses are detectable in all individuals previously 
infected with Ct, or if multiple exposures are required to develop sustained anti-Ct responses. In 
this study, only 19.7% of children with TF were positive for anti-Pgp3 antibodies, but all six 
children with current infection were seropositive. There was also a high prevalence of Pgp3 
reactivity in adults living in Temotu and Rennell & Bellona, a proportion of whom are likely to have 
had a previous urogenital Ct infection.(24) While seroreversion due to clearance of infection by 
MDA is a possible explanation for the low seroprevalence and absence of association of anti-
Pgp3 antibodies with TF, there is currently no evidence for complete seroreversion for Pgp3-
specific antibodies(17,28) after clearance of infection. We are therefore confident that Pgp3 is an 
appropriate antigen for serosurveillance in this population. 
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Analysis of the age-specific prevalence of conjunctival scarring illustrated that, while the 
proportion of people with mild scars increased with age, the proportion of those with more 
extensive or eyelid-distorting scars did not increase with age. Contrary to what might be expected 
in a trachoma-endemic community,(29) no eyelid-distorting scars were found in 311 adults >40 
years. There does appear to be severe scarring among children, but some cases are atypical 
(Figure 1) and are in children who lack Pgp3 reactivity (Table 3), so other causes of scarring may 
be contributing to this (presumed) ongoing incidence. There are a number of inflammatory 
conditions (e.g. adenoviral, acute haemorrhagic or membranous conjunctivitis) which may result 
in conjunctival scarring, although the pathology, incidence and prevalence of these are poorly 
understood.(30) It is currently unclear whether the TF that we observed is directly linked to 
conjunctival scarring in this setting. Currently in Temotu and Rennell & Bellona, the low 
prevalence of severe scars suggests that the proportion of the population at risk of developing TT 
is very low, although we cannot determine how this might change temporally.  
Prior to intervention with MDA, more than 15% of children living in the selected villages had TF. 
The 13 communities included here were the most highly endemic of those surveyed in Temotu 
and Rennell & Bellona during the GTMP. In this study, we showed that the burden of TF in many 
of these villages dropped significantly following a single round of MDA, but still remains above the 
threshold for continued intervention. The drop in clinical disease was not reflected by a drop in 
ocular Ct in children with TF, which increased, albeit statistically insignificantly. From interventions 
in other settings, we might expect TF prevalence to drop by approximately 50% six months after 
a single round of MDA, given 80% population coverage.(31,32) Azithromycin has anti-
inflammatory and broad-spectrum antibiotic effects, which may help explain the observed 
decrease in clinical disease. We observed regional variation across the study villages. Compared 
to Temotu, we noted more children were seropositive, more children with TF had infection, and 
MDA did not have as significant an impact on TF levels in Rennell & Bellona. Our survey was not 
prospectively designed to assess these differences, and the subgroup size in Rennell & Bellona 
precludes more detailed analysis. Temotu is much more similar to the rest of the Solomon Islands 
in terms of the geology of the islands, and the lifestyle and ethnicity of the majority of the 
inhabitants. Further studies on the localisation of trachoma in the islands are warranted. 
The complex, multistage nature of trachoma makes it difficult to predict the outcome of a given 
intervention.(33) Data from cross-sectional surveillance tools used in isolation can be hard to 
interpret, especially given the prolonged persistence of TF after clearance of infection.(34) Some 
features of conjunctivitis in the Solomon Islands resemble trachoma, particularly the prevalent 
follicular inflammation and some of the severe conjunctival scarring. Crucially, these clinical 
features were not co-endemic with TT at a prevalence that indicates a public health problem. In 
this setting, tests for infection gave a better indication of the public health threat from trachoma 
than TF. A combined approach in which various age-specific markers of trachoma are assessed 
together across the complete age range of the population, may prove useful for prioritising areas 
for intervention where the prevalence of TF alone does not coherently reflect trachoma’s public 
health importance.  
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Our data provide compelling evidence that trachoma is not a public health problem in these 
villages. Whilst there have been substantial collateral benefits to local residents from having 
received MDA (such as on genital Ct(35) and yaws(36)), further rounds of azithromycin MDA do 
not appear to be indicated for the purposes of trachoma elimination. WHO recommendations for 
implementation of MDA and the SAFE strategy should be reviewed in the light of this evidence.  
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Tables 
Table 1. Grading system for conjunctival scarring, reproduced from Dawson and colleagues (15). 
Grade Classification Definition 
C0 Absent No scarring on the conjunctiva 
C1 Mild Fine scattered scars on the upper tarsal conjunctiva, or scars on other parts of the 
conjunctiva 
C2 Moderate More severe scarring but without shortening or distortion of the upper tarsus 
C3 Severe Scarring with distortion of the upper tarsus 
 
Table 2. Population characteristics of study populations before and after MDA, 13 selected communities of Temotu and 
Rennell & Bellona Provinces, Solomon Islands. 
Characteristic Pre-MDA (October–
November 2013; 
(10)) 
Post-MDA 
(June–July 
2015: this 
study) 
p-value* 
Number examined, all ages 1534 1511 - 
Number examined aged 1–9 years 490 466 - 
Number of households enrolled 394 382 - 
% male of those examined 46.5 46.3 0.836 
TF in either eye in 1–9 year olds 33.7% 14.2% <0.0001 
Active trachoma in swabbed eye  
(right eye field assessment) 
160 (32.7%) 61 (13.1%) <0.0001 
Ct infection in those aged 1–9 years 5 (3.1%) 6 (9.8%) 0.08 
Median Ct infection load in positive specimens  
(plasmid copies/swab) 
51,880 104,100 0.219 
Ct: Chlamydia trachomatis 
* t-test 
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Table 3. Serological status compared to other tests for trachoma, 13 selected communities of Temotu and Rennell 
& Bellona Provinces, Solomon Islands, June–July 2015 
Comparator 
1–9 year-olds ³10 year-olds 
Seronegative Seropositive Total Seronegative Seropositive Total 
Ct  infection 
by ddPCR* 
Positive 0 6 6 - - - 
Negative 48 7 55 - - - 
TF Positive 53 13 66 13 9 22 
Negative 326 70 396 474 541 1015 
TI Positive 0 0 0 0 1 1 
Negative 379 83 462 487 549 1036 
Scarring C0 333 77 410 414 418 832 
C1 15 1 16 36 75 111 
C2 3 2 5 16 32 48 
C3 3 1 4 1 3 4 
Ct: Chlamydia trachomatis; ddPCR: droplet digital polymerase chain reaction; TF: trachomatous inflammation—
follicular; TI: trachomatous inflammation—intense.  
* presence or absence of infection only assessed in children with TF and/or TI. 
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CHAPTER 6: NOTES AND ADDITIONAL INFORMATION 
 
6.4 Note A: Exemplars of photographs graded for follicles, papillae and cicatricae 
 
 
Figure 6.4.1. Exemplars of photographs graded as F, P and C. While the more severe grades are more 
reproducible, the milder grades can be subjective. Additionally, features not relevant for trachoma grading schemes are 
visible in some images, for example concretions visible in image C2 or light artefacts in image C1. The photograder can 
judge whether these are related to trachoma, but the assigned grade is based on the visible features, whether the 
grader thinks they are related to trachoma or not.   
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6.5 Note B: Scarring trachoma in a comparative population  
 
The prevalence of conjunctival scars in these villages of the Solomon Islands increases with 
age, suggesting incident scars are still emerging. However, the proportion of older people with 
scarring is low, and the relative proportion of severe compared to mild scarring is similar 
throughout the age groups, suggesting progression is not taking place. This is consistent with 
the low levels of ocular infection observed. Mild scars are expected to start in childhood and 
progress to severe scars with age, but relatively few datasets have been generated which 
explore the process in detail as the most commonly used grading system is the simplified 
system, which doesn't differentiate between mild and severe scarring. A study conducted in 
Guinea Bissau in 2013 which graded all participants of any age in the field using the FPC 
system provided a useful comparator dataset with a high prevalence of Ct infection (26). The 
Solomon Island and Guinea Bissau studies were similar in size; approximately 1500 people of 
all ages living in randomly selected households in tropical island settings. The baseline 
unadjusted prevalence of TF/TI in 1–9 year olds in Guinea Bissau was 22% compared to 33.7% 
in the Solomon Islands. The prevalence of ocular Ct infection according to ddPCR in children 
aged 1–9 years in Guinea Bissau was 25%, whereas in the Solomon Islands the baseline 
prevalence of infection was 3.1% (26). Both studies utilised the FPC system. Figure 6.5.1 
demonstrates the prevalence of severe scars in older age groups to be much lower in the 
Solomon Islands than in Guinea Bissau. This is consistent with the hypothesis in section 6.3 
that progression of trachoma is relatively mild in the Solomon Islands compared to other 
trachoma-endemic regions. It is also evident that the prevalence of scars of any severity, and 
particularly eyelid-distorting scars, are more prevalent in the childhood age groups in Solomon 
Islands than in Guinea Bissau. This pattern of scars in children but not in adults could suggest 
that trachoma is increasing, and children are experiencing infectious stimuli that their parents 
have not. There is also likely to be an increased burden of neonatal conjunctivitis in the 
Solomon Islands due to the very high prevalence of sexually transmitted infections which can, in 
severe cases, lead to conjunctival scarring and entropion, therefore potentially inflating 
estimates of severe scarring from trachoma. However, as we demonstrate in figure 2 of section 
6.3, those scars graded as C3 were noted upon grading not to look typically trachomatous due 
to significant sub-epithelial edema. This exposes a weakness of the grading system whereby 
distortion of the conjunctiva is graded as C3, even though the graders acknowledge the clinical 
presentation is not typical of trachoma. 
 
These striking differences in age-specific scar prevalence are in populations with similarly 
striking differences in ocular Ct prevalence. Key distinctions between the studies should be 
considered as potential sources of bias when comparing these two plots. Firstly, the Guinea 
Bissau and Solomon Islands studies were carried out in populations that are likely to have very 
distinct genetic profiles, which is known to have an impact on scarring risk (263). The impact of 
host genetics on scarring risk is likely to be very complicated as described in the discussion of 
section 5.2, but may contribute to the discrepancy seen. Secondly, the Guinea Bissau data was 
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generated before MDA, whereas the Solomon Island data was generated 6 months after one 
round of MDA. That round of MDA 6 months previously is not likely to have altered our scarring 
prevalence estimates, as the process of scarring is not thought the be reversible and is thought 
to take years to develop; thus any reduction of scarring caused by MDA are likely to need 
longer to be observable (34). Thirdly, villages enrolled in the Guinea Bissau study were 
randomly selected, whereas in the Solomon Islands study villages were specifically selected for 
trachoma endemicity. This is unlikely to have led to an underestimation of age-specific scar 
prevalence in the Solomon Islands. Finally, the Guinea Bissau grades were generated in the 
field whereas in the Solomon Islands they were generated from photographs. Due to the two-
dimensional nature of photographs, marginal cases of distortion of the conjunctiva (required to 
meet criteria for C3) are not always clear. Similarly, very fine scars may be more easily 
observed during clinical examination where the grader can adjust their position and the lighting 
on the conjunctiva to identify very fine changes to the texture or structure of the epithelial tissue. 
This is not possible from photographic examination. Both of these issues constitute limitations of 
photograph grading, which may be overcome using techniques that were unavailable during this 
study, such as in vivo confocal microscopy. However, in the case of these two comparator 
populations we do not expect those marginal cases to account for the gross differences in C3 
prevalence between studies.  
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Figure 6.5.1. Age-specific prevalence of scarring in (A) Guinea Bissau (moderate trachomatous inflammation – 
follicular (TF), moderate ocular Chlamydia trachomatis (Ct) infection) and (B) the Solomon Islands (moderate 
TF, low ocular Ct infection). The numbers above each column represent the total number of people in each group. 
Height of bars shows total percentage of population with scars graded C1-C3. Colours indicate the proportion of each 
age group with C1 (grey), C2 (blue) and C3 (green) scars. Guinea Bissau fine scar grade data kindly shared by Anna 
Last.  
A 
B 
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6.6 Note C: Association between scarring and anti-Pgp3 antibody titre 
 
Most adults in the study population were seropositive. However, the wide range of anti-Pgp3 
antibody ODs and the significant increase in those over 18 years suggests a nontrachomatous 
origin to seropositivity which may confound estimates of relationship with scar grade (figure 
6.7.1). It is therefore not appropriate to compare the Pgp3 level with scar grade in adults. 
 
Figure 6.6.1. Normalised anti-Pgp3 optical density of specimens from Solomon Islanders of all ages showing 
wide range of responses in those aged over 18 years. Boxes illustrate inter-quartile range, and whiskers represent 
up to 1.5-times the inter-quartile range. 
 
However, in children, ocular Ct should be the primary driver of Pgp3 seropositivity where it is 
present, therefore reducing the confounding effects of urogenital exposure. In the manuscript 
(section 6.3), a linear regression model of scar grade compared with Pgp3 level in children in 
the Solomon Islands is used to demonstrate that detectable levels of Pgp3 reactivity do not 
increase with scar grade. This is well illustrated by the normalised OD data from these children, 
as shown in figure 6.6.2. The anti-Pgp3 antibody level in children with conjunctival scarring in 
the Solomon Islands is no different to those without, suggesting no difference in prior exposure 
with Ct. This is further evidence that the scars in children, although unusually prevalent 
compared to areas with highly prevalent Ct infection (demonstrated in section 6.5), are unlikely 
to be a result of Ct infection. 
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Figure 6.6.2. Relationship between optical density (OD) value and photograph C score in children aged 1–15 
years. No difference in median Pgp3 level is observed between those with and those without scarring meeting the FPC 
grading system for trachoma. Red lines indicate median OD values for each scar grade.  
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7. AETIOLOGY OF TRACHOMATOUS INFLAMMATION – 
FOLLICULAR IN THE SOLOMON ISLANDS  
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7.1 Introduction 
 
Internationally standardized mapping techniques demonstrated that the prevalence of clinical 
signs of trachoma in Melanesia is unusual. In the Solomon Islands, two independent measures 
of infection (ddPCR and ELISA) have indicated that the prevalence of Ct low, and is unlikely to 
explain the burden of TF. Antibody responses to Ct antigens, which are generated in response 
to ocular infection (239), were absent in most (80.3%) of the children with TF who were living in 
trachoma-endemic villages of the Solomon Islands. Furthermore, the prevalent conjunctivitis 
was not concurrent with severe scarring in adults, suggesting the chronic immunopathogenesis 
associated with repeated Ct infection may not be widespread in this population. A non-Ct cause 
for TF was suspected. 
 
A number of potential candidate pathogens have been identified by the studies summarized in 
Table 1.7.2. Although numerous bacteria have been isolated from the conjunctivae of children 
with clinical signs of trachoma, S. pneumoniae (Sp) and H. influenzae (Hi) (both capsulated and 
noncapsulated subtypes) were the most likely suspects, as they have both been shown to 
correlate closely with TF in some populations. 
 
In this chapter, I set out to determine whether common pathogens of the conjunctival, auricular 
and oral mucosae were associated with inflammation in this population. In section 6.3, the 
markers under investigation were long-lived and examining specimens from children after a 
round of MDA was appropriate. Infection, meanwhile, is transient and likely to be affected by 
MDA regardless of whether the organism itself is directly susceptible to azithromycin. Therefore, 
the pre-MDA specimen set described in chapter five was revisited and tested for the presence 
of several specific bacterial causes and one viral cause of conjunctivitis. 
 
7.2 Manuscript 
 
Whilst bacteria are detected in many (19%) of the specimens, none showed any statistically 
significant association with disease. A subset of these specimens was then tested using a less-
targeted sequencing-based screening of poly-microbial communities, which has recently been 
applied to ocular specimens. Both the richness and diversity of bacteria at the conjunctiva are 
similar between those with visible follicular inflammation and those without. This was initially 
surprising given how different the mucosal environments must be at the molecular level, but 
other studies of diseased and nondiseased eyes have also failed to detect disease-associated 
shifts in microbiome (185,186).  
 
These studies indicate that no bacterial species, genus or community structure appears to be 
sufficiently strongly linked to TF to explain the disease that was observed in the Solomon 
Islands. The final conclusion is that a nonbacterial cause is the most likely explanation of TF 
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and this further adds to the case against the continued use of TF as an indicator for MDA in the 
Solomon Islands.   
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Abstract 
 
Background  
Several non-chlamydial microbial pathogens are associated with clinical signs of active 
trachoma in trachoma-endemic communities with a low prevalence of ocular Chlamydia 
trachomatis (Ct) infection. In the Solomon Islands, the prevalence of Ct among children is low 
despite the prevalence of active trachoma being moderate. We therefore set out to investigate 
whether active trachoma was associated with a common non-chlamydial infection or with a 
dominant polymicrobial community dysbiosis in the Solomon Islands. 
 
Methods 
We studied DNA from conjunctival swabs collected from 257 Solomon Islanders with active 
trachoma and matched controls. Droplet digital PCR was used to test for pathogens suspected 
to be able to induce follicular conjunctivitis. Polymicrobial community diversity and composition 
were studied by sequencing of hypervariable regions of the 16S ribosomal ribonucleic acid gene 
in a subset of 54 cases and 53 controls. 
 
Results 
Although Ct was associated with active trachoma, the number of infections was low (cases: 
3.9%, controls: 0.4%). Estimated prevalence (cases, controls) of each non-chlamydial infection 
was as follows: S. aureus (1.9%, 1.9%), Adenoviridae (1.2%, 1.2%), coagulase-negative 
Staphylococcus (5.8%, 4.3%), H. influenzae (7.4%, 11.7%), M. catarrhalis (2.3%, 4.7%) and S. 
pneumoniae (7.0%, 6.2%). There was no statistically significant association between clinical 
signs of trachoma and presence or load of any of the non-Ct infections that were assayed. Inter-
individual variations in the conjunctival microbiome were characterised by differences in the 
levels of Corynebacterium, Proprionibacterium, Helicobacter and Paracoccus, but diversity and 
relative abundance of these specific genera did not differ significantly between cases and 
controls.  
 
Discussion 
It is unlikely that the prevalent trachoma-like follicular conjunctivitis in the Solomon Islands has a 
dominant bacterial aetiology. Before implementing community-wide azithromycin distribution for 
trachoma, policy makers should consider that clinical signs of trachoma can be observed in the 
absence of any detectable azithromycin-susceptible organism.   
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Introduction 
 
Trachoma, caused by Chlamydia trachomatis (Ct), is the leading infectious cause of 
preventable blindness (1), and is targeted for elimination as a public health problem by 2020 
through the SAFE strategy (Surgery, Antibiotics, Facial cleanliness and Environmental 
improvement). The decision to implement community-wide trachoma control interventions, 
which include mass drug administration (MDA) with azithromycin, is based on population 
prevalence estimates of one clinical sign of active trachoma (trachomatous inflammation–
follicular [TF]) in the 1–9-year-old age group (2). In the Solomon Islands, the prevalence of TF is 
sufficient to warrant MDA but the prevalence of trachomatous trichiasis (TT) suggests trachoma 
may not pose a significant public health problem. A recent trachoma survey in a treatment-naïve 
population of the Solomon Islands estimated 26% of 1–9-year-olds to have TF but, surprisingly, 
conjunctival Ct infection was detected in only 1.3% of that age group (3). Whilst Ct infection is 
not always detectable in TF cases (4, 5), infection prevalence in the Solomon Islands is far 
lower than is seen in other countries with similar TF prevalence (3).  
 
Ct is not the only pathogen to associate with signs of TF. A number of differential diagnoses for 
follicular conjunctivitis are described (6), some of which are rare and distinguishable by patient 
history (such as Parinaud’s oculoglandular syndrome). Other causes of conjunctivitis which can 
present with follicles are Streptococcus pneumoniae, Haemophilus influenzae (7), and 
adenovirus (8). Non-ocular Chlamydia serotypes (9) and non-trachomatis Chlamydia species 
(10) have also been suggested as possible causes of TF. A number of studies have examined 
conjunctival microbiology in trachoma-endemic settings. A greater diversity of pathogens can be 
cultured from the conjunctivae of people with TF compared to counterparts without TF (7). 
Among bacterial species isolated during a study in Tanzanian children, Streptococcus 
pneumoniae, Haemophilus influenzae B and Haemophilus influenzae non-type B associated 
more strongly than Ct with clinical signs of active trachoma (7). In The Gambia, S. pneumoniae 
and H. influenzae type B infection correlated closely with signs of active trachoma in 
communities which had received MDA, whereas Moraxella catarrhalis and Staphylococcus 
aureus did not (11). Common non-chlamydial pathogens have associated with trachomatous 
scarring (TS) (12) and recurrence of TT after surgery (13) in some, but not all (14, 15), studies.  
 
Although traditionally thought to be ‘sterile’, several studies have now described polymicrobial 
communities colonising the conjunctival epithelium (16, 17). Staphylococcus, Streptococcus, 
Haemophilus and Moraxella genera can be readily cultured from swabs taken from the inferior 
fornix (7, 11, 12). Attempts to detect bacteria from the conjunctiva have shown community 
diversity and composition to vary significantly between individuals. It is unclear whether a ‘core’ 
microbiota persists at the conjunctiva, but profiles closely related to that of the skin have been 
reported (18). Corynebacterium, Propionibacterium, Staphylococcus and Streptococcus have 
been consistently dominant, whereas other genera such as Acinetobacter, Brevundimonas, 
Pseudomonas, Bradyrhizobium, Sphingomonas, Bacillus, Simonsiella and Elizabethkingia have 
been identified more sporadically (19–21). Conjunctival polymicrobial community composition is 
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known to vary with age and season (22) and appears to be responsive to external stimuli such 
as regular contact lens wear (23), The conjunctival microbiome varies significantly between 
people with trachomatous scarring and those without, however, significant associations 
between microbiome and follicular conjunctival inflammation or microbiome and other diseases 
have yet to be described (22, 24). 
 
We hypothesised that clinical signs of active trachoma in the Solomon Islands where ocular Ct 
is uncommon could be explained by a common non-chlamydial infection or by a dominant 
polymicrobial community dysbiosis.  
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Methods 
 
Study ethics 
 
Ethical approval was granted by the London School of Hygiene & Tropical Medicine 
(6319/6360) and the Solomon Islands National Health Research (HRC13/18) Ethics 
Committees. A parent or guardian provided written consent for each child participant. 
 
Study population 
 
The samples tested during this study were a sub-set of specimens from a population-based 
trachoma prevalence survey of 3674 people (1135 children aged 1–9 years) in 32 clusters from 
Temotu and Rennell & Bellona Provinces, Solomon Islands; data from that survey are 
presented elsewhere (3). At the time of the survey, no trachoma interventions had been 
implemented in the Solomon Islands. Sterile swabs were passed three times over the right 
conjunctiva of every child before storage in 300 µL RNALater® (Life Technologies). Swabs 
were kept cool in the field for up to 24hrs then frozen (3). Inclusion criteria for cases (n = 257) 
were age 1–9 years, detectable human DNA in the conjunctival swab and a field grade of TF or 
trachomatous inflammation—intense (TI) in the right eye. An equal number (n = 257) of age-, 
gender- and island-matched controls without TF or TI were selected using the ‘e1071’ R 
package. A random subset of cases (n = 54) and controls (n = 53) were further characterized 
using V1-V3 16S rRNA gene sequencing. Field controls (clean swabs passed within 20 cm of 
seated participants, without touching them, and then treated identically to subjects’ specimens), 
extraction controls (extraction carried out in the absence of a specimen and PCR carried out on 
the eluate) and PCR controls (PCR carried out in the absence of any added material) were used 
to determine background levels of microbial contamination in the 16S rRNA gene sequencing 
protocol. 
 
Droplet digital PCR  
 
DNA was extracted from conjunctival swabs using the Qiagen AllPrep DNA/RNA kit. We chose 
not to use mechanical lysis on these low biomass specimens due to the reported lower yields 
compared to chemical lysis (25). All specimens have previously been tested for Ct and Homo 
sapiens Ribonuclease P protein subunit p30 (RPP30, acting as endogenous control) using a 
validated assay (26); the community prevalence of ocular Ct infection is described elsewhere 
(3).  
 
Duplex ddPCR assays were developed for (1) Adenoviridae (27) and S. pneumoniae (28), (2) 
H. influenzae (29) and M. catarrhalis (30, 31), and (3) S. aureus and coagulase-negative 
Staphylococcus (32, 33) based on published assays. Each assay contained 10 µL 2 ddPCR 
Supermix for probes (Bio-rad, Hemel Hempstead, UK), primers and probes at custom 
concentrations (Table 1) and 8 μL of template DNA. Thermal cycling was 10’00’’ at 95°C then 
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40x (0’15’’ at 95°C | 1’00’’ at 60°C) then 12’00’’ at 98°C (26). A positive result for a clinical 
specimen was defined as >95% confidence of non-zero target load, as described previously 
(26). Assay performance was assessed by repeat testing of PCR product dilution series’ and 
cultured pathogen material before rolling out to clinical samples. The reproducibility, linearity 
and limits of detection of each assay were considered appropriate (Supplementary Table 1) and 
were also similar to published performance of the Ct assay used (26).  
 
16S rRNA gene sequencing 
 
An approximately 530-bp region of the 16S ribosomal RNA (rRNA) gene (variable regions 1-3) 
was amplified using forward (modified 27F; 5'-[adaptor]-AGAGTTTGGATCCTGGCTCAG-3') 
and custom barcoded reverse primers (534R; 5'-[adaptor]-[barcode]-
AGTCAGTCAGCCATTACCGCGGCTGCTGG-3'). Each 15 μL reaction contained 7.5 μL 2x 
Phusion High Fidelity Master Mix (New England Biosciences, MA, USA), 0.45 μL DMSO, 0.1 
μM primers and 5.55 μL DNA. The thermal cycling conditions were 0’30’’ at 98°C then 31x 
(0’10’’ at 98°C | 0’30’’ at 62°C | 0’15’’ at 72°C) then 7’00’’ at 72°C. Amplicons were cleaned 
using 0.6 v/v AMPure XP beads (Beckman Coulter, CA, USA), quantified using Qubit (Thermo 
Fisher Scientific, MA, USA) then pooled at equimolar concentrations. The 4 nM sequencing 
library was mixed 0.75 v/v with a 4 nM Phi-X control library (Illumina, CA, USA). 3 µL of 100 µM 
custom read primers were mixed in to wells 12 (Read 1; 
CTACACTATGGTAATTGTAGAGTTTGGATCCTGGCTCAG), 13 (Index; 
CCAGCAGCCGCGGTAATGGCTGACTGACT) and 14 (Read 2; 
AGTCAGTCAGCCATTACCGCGGCTGCTGG) of the MiSeq reagents cartridge before 2 x 300 
bp paired-end sequencing with the 600-cycle MiSeq v3 sequencing reagent kit on the MiSeq 
platform using a standard protocol (Illumina, CA, USA). 96 uniquely barcoded specimens were 
run in multiplex on each MiSeq run. 
 
Data analysis 
 
ddPCR data were analysed using R version 3.2.2 (34). Binomial univariate regression was used 
to test the relationship between each individual infection and active trachoma. The most 
accurate final multivariate model, determined by lowest Akaike Information Criterion (AIC) 
value, was determined by step-wise removal of variables from a binomial multivariate 
regression model incorporating all tested pathogens. The chance of the Ct association occurring 
due to chance was assessed by counting the number of significant results obtained from 
randomly re-ordering the Ct data 1000 times.  
 
Raw 16S amplicon sequences were directly assigned to genera using Illumina BaseSpace ‘16S 
Metagenomics’ app version 1.0.1.0, which uses algorithms from Wang and colleagues (35). 
Two clinical specimens yielded fewer than 1000 reads in total and were removed from the 
analysis. Amplicons were sequenced from six no-template control (NTC) specimens (two ‘field’ 
controls, two ‘extraction’ controls, two ‘PCR’ controls, defined above) to identify any 
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contaminants endogenous to the collection, PCR or sequencing process. Any genera 
represented by more than 600 reads in the six combined NTCs (average 100 reads per NTC) 
were eliminated from the clinical specimen analysis. This resulted in the removal of 21 genera, 
which accounted for 95.1% of the reads from NTCs and 88.3% of the reads from clinical 
specimens. The genera removed included common contaminants of reagent kits (36) such as 
Pelomonas, as well as some previously described conjunctival microbiota constituents such as 
Brevundimonas, Staphylococcus and Streptococcus (19, 22). 
 
Between-group differences in the Shannon Diversity Index (a measure of diversity which 
increases with increasing species abundance and evenness) and Inverse Simpson Index 
(another measure of diversity where 1 is infinite diversity and 0 is no diversity) were compared 
using a t-test. Discriminant Analysis of Principal Components (DAPC), a multivariate clustering 
method to analyse highly dimensional datasets, was performed using the ‘adegenet’ package in 
R (37) and cross-validation was used to determine the optimal number of principal components 
to include in a discriminant function aimed at separating cases from controls on the basis of 
their polymicrobial community structures. 
 
 
Results 
 
Specimen set demographics 
 
A total of 257 cases and 257 controls (n = 514) were tested. All 257 cases had TF, and one also 
had TI. Case status was defined by clinical signs in the right eye but respectively 236/257 
(91.8%)  and 8/257 (3.1%) of the cases and controls had TF in the left eye. Both case and 
control groups were 38% female. Mean age was 5.6 years (cases) and 5.5 years (controls, 
student’s t test p = 0.76). There was no significant difference between cases and controls in 
terms of the clusters represented (Kolmogorov-Smirnov test p = 0.97) and all 32 clusters were 
represented. The case specimens had higher loads of human DNA than the controls (18030 
versus 9354 copies/swab; p = 0.00003). There were no significant differences in age, gender or 
location within the subset selected for 16S-amplicon sequencing.  
 
Quantitative PCR tests for ocular pathogens 
 
In this study, 19.8% of children had evidence of infection with at least one of the targeted 
organisms (Table 2). We considered the prevalence of Ct in this sample set to be too low 
(96.1% of TF cases were Ct-infection negative) to account for the level of active disease. The 
prevalence of Adenoviridae (1.2%) and S. aureus (1.9%) were both very low. There was no 
association between active trachoma and infection with H. influenzae, S. pneumoniae, S. 
aureus, coagulase-negative Staphylococcus or M. catarrhalis. Ct infection was associated with 
active trachoma (logistic regression p = 0.026; odds ratio: 10.4). The association between Ct 
and active trachoma was still significant in a multivariate analysis (p = 0.025). The permuted p-
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value for the association between Ct and active trachoma was highly significant (p = 0.001). 
Active disease was neither associated with infection with at least one pathogen (any pathogen, 
p = 0.185) nor the number of concurrent infections in the same eye (number of concurrent 
pathogens, p = 0.207). Infection loads of those who tested positive are shown Figure 1. Despite 
some numerical differences between groups, none of the differences were statistically 
significant.  
 
Figure 1. Target copies per swab of each pathogen identified in conjunctival swabs collected from children with and 
without active trachoma in the Solomon Islands. Numbers show p-values for logistic regression comparison between 
active trachoma case and control groups for each pathogen. None of the differences observed were statistically 
significant. 
 
16S rRNA gene sequencing 
 
The total number of genera identified across all clinical specimens and NTCs was 659, 
however, 125/659 (19%) had a cumulative total of ten reads or fewer. The median number of 
reads per clinical specimen was 55,104 (IQR: 40,705 – 89,541) and the median percentage of 
reads mapped to genus level was 51.9%. The median number of genera identified was 151 
(IQR: 117 – 212) per clinical specimen. Following removal of presumed contaminants, 
approximately 40% of cleaned reads were assigned to genera that each constituted less than 
1% of the total polymicrobial community. 40 genera were represented by at least 1% of 
remaining reads in clinical samples.  
 
The diversity of bacterial communities was in general low; the mean Inverse Simpsons Diversity 
index over all specimens was 0.061 (IQR: 0.046 – 0.092). The median Inverse Simpson’s 
Diversity index in cases was 0.061 [IQR: 0.048 – 0.095] versus controls 0.060 [IQR: 0.044 – 
0.078] (Student’s t-test p = 0.56). The median Shannon Diversity Index was 3.38 in cases and 
3.37 in controls (Student’s t-test p = 0.96). There was no significant difference in alpha-diversity 
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between cases and controls by either measure of diversity. In cases of active trachoma, the 
most dominant bacterial genera were Corynebacterium (12.0% of total reads), 
Proprionibacterium (6.2%) and Helicobacter (4.8%). In controls, the most dominant genera were 
Corynebacterium (13.9%), Paracoccus (5.2%), Proprionibacterium (4.7%), and Neisseria (4.1%) 
(Supplementary Figure 1). The genus level membership of the bacterial community varied 
between cases and controls. Of 21 genera found in specimens from those with active trachoma, 
10 were not found in controls, including Helicobacter, Mesoplasma, Brachybacterium and 
Haemophilus. Of 23 genera found in controls, 12 were not found in cases, including Neisseria, 
Prevotella, Rhodococcus and Porphyromonas.  
 
Principal Components (PC) Analysis (Figure 2, Supplementary Figure 2) revealed that 
Corynebacterium (PC1), Paracoccus (PC2), Propionibacterium (PC2, PC3) and Helicobacter 
(PC3) are major contributors to the variation in the conjunctival microbiomes of children in the 
Solomon Islands. While individual cases or controls have distinctive profiles dominated by these 
genera, the majority of cases and controls are indistinguishable (Figure 2) using the first three 
PCs (explaining 45% of total variation). We condensed PCs 1-20 into a single discriminant 
function, which explained 87% of variation in the data. In this analysis, the genus-level 
polymicrobial community structure is significantly different between cases and controls (logistic 
regression p = 0.0000062) (Figure 3). That discriminant function was dominated by a number of 
genera such as Curvibacterium and Mesoplasma (Supplementary Figure 3). Cross validation to 
predict group membership using discriminant functions of between 10 and 90 PCs had a low 
success rate (median 53.3% success, range: 50.1 – 62.3%). This suggests that while 
differences do exist between the polymicrobial communities in cases and controls, they are too 
subtle and varied to be predictive of phenotype, at least when working with this number of 
specimens.  
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Figure 2. (A) First and second and (B) second and third principal components describing variation between the 16S 
sequences identified in Solomon Island children with and without active trachoma. Dark blue spots indicate controls. 
Light blue spots indicate cases. Red arrows show principal component loadings. 
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Figure 3: Discriminant analysis of the association of 20 combined principal components with active trachoma, showing 
a significant discrimination of phenotype groups (p = 0.000006).  
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Discussion 
 
Follicular conjunctivitis meeting criteria for the trachoma phenotype TF is highly prevalent in the 
Solomon Islands, but the prevalence of Ct infection is curiously low. Although Ct was the only 
pathogen to associate with TF in this study, the prevalence was much lower than may be 
expected of a population with this level of TF (3). Both S. pneumoniae and H. influenzae were 
detected at moderate prevalence in our population, whilst we found very few cases of 
Adenoviridae and M. catarrhalis infection. Comparator data from other populations are scarce, 
but it is clear that staphylococcal species were detected in the conjunctivae in the Solomon 
Islands at a substantially lower prevalence (7%) than in children in either Tanzania (14.8% S. 
epidermidis) (7), Sierra Leone (20% S. aureus, 29% coagulase-negative Staphylococcus) (38) 
or The Gambia (post MDA, 14.7% S. aureus) (11). By ddPCR testing for a number of bacteria 
and viruses that have previously been linked to TF, we can discount the possibility that any of 
them can account either singly or en masse for the high TF prevalence.  
 
Through 16S amplicon sequencing and community profiling, we have shown that there is 
apparently no dominant bacterial genus associated with this disease. The dominant features of 
variation in conjunctival bacterial communities in Solomon Islands children (Corynebacterium, 
Propionibacterium) have consistently been identified in other studies. Other genera (e.g., 
Paracoccus, Helicobacter, Haemophilus) have not previously been identified in 16S studies, 
whilst some reported in other studies (e.g., Simonsella, Pseudomonas) were not found in these 
specimens (19–22). Many studies have sequenced the V3-4 region of the 16S gene whereas 
we targeted V1-3. V region choice has been shown to have an impact on the genera identified 
at other mucosal sites (39) and, while no data have yet emerged on how this affects profiles 
from the eye, it is possible this could account for some of the differences. Consistent with 
previous studies (36), we found a background of genera that amplified in NTCs that also 
appeared in clinical specimens. The microbiological biomass at the conjunctiva is known to be 
very low, even compared with other nearby sites such as skin or oral mucosa (20). When true 
resident bacteria are scarce, 16S rRNA gene PCR readily amplifies reagent contaminants. We 
took stringent measures to exclude reagent contaminants, but this resulted in the removal of 
some important genera such as Staphylococcus and Streptococcus. Among the biggest 
contributors to between-conjunctiva variation were Corynebacterium and Propionibacterium, but 
these genera did not differentiate TF cases from controls (Figure 2). Previous investigations of 
the role of the conjunctival microbiome in ocular disease have also not shown significant 
differences. In The Gambia, there was an increased abundance of Haemophilus in cases of TF, 
as compared to controls, although this difference was not significant (22). People with ocular 
manifestations of rosacea, Sjögren’s syndrome and healthy controls did not have significant 
differences in diversity or relative abundance of key phyla identified across all three groups (24). 
However, other disease associations have been identified. For example, the abundance of 
Corynebacterium and Streptococcus varied significantly between individuals with and without 
conjunctival scarring (22). 
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The microbiota of these children were heterogeneous and had subtle variations that appeared 
to reach significant association with TF when the full community structure was considered in 
comparative statistical models. It remains possible (though perhaps unlikely) that a multitude of 
factors, operating at the level of single bacterial species, polymicrobial communities or viral 
species, all contribute to the presentation of the phenotype. It is perhaps more likely that as yet 
unidentified viral or allergic causes could explain the prevalence of TF in the Solomon Islands.  
 
There are some limitations to our study. Firstly, although the ddPCR assays are based on 
validated assays and appear to be accurate (Supplementary Table 1), they have not been 
formally evaluated in this format. Secondly, by not using mechanical lysis in our extraction 
process, the absolute prevalence of some difficult-to-lyse Gram positive genera (e.g., 
Staphylococcus) may have been under-estimated. This would not impair the comparison of 
cases to controls, between which protocols were consistent. Thirdly, 16S amplicon sequencing 
of low biomass samples is known to result in amplification of reagent and environmental 
contaminants (36). This study focused on gross differences in community structure between 
those with and without disease and these should be independent of contaminating reads. We 
also employed stringent quality control measures to ensure data were not confused by artefacts 
of the sequencing process.  
 
Given the current international commitment to trachoma elimination, further characterisation of 
the role of non-Ct stimuli in TF is important. We might expect those with TF in the absence of Ct 
to be at lower risk of progression to TS and TT than those with repeated Ct infection and 
inflammation (40), however, such individuals have not been studied longitudinally to assess 
outcomes therefore it is unclear how these cases should be managed. Furthermore, years after 
MDA has been administered, TF persists at levels above the threshold for elimination (>5%) in 
communities where Ct infection is not readily detectable (41, 42). The public health risk of 
trachoma in these communities is also unclear. 
 
Public health scenarios such as the one in the Solomon Islands will become increasingly 
common as trachoma elimination programmes reduce the global prevalence of Ct, and the 
positive predictive value of TF for ocular Ct infection declines as a result (43). MDA might be 
inappropriately delivered when clinical signs of trachoma are the only indicator used for 
programmatic decision making. While MDA is effective for the treatment of trachoma (44), mass 
antibiotic exposure may increase macrolide resistance in nonchlamydial bacteria (45) and 
theoretically could make the population more susceptible to later infections by preventing 
accumulation of acquired immunity to Ct (46). Decisions to undertake such a program should 
therefore be carefully considered. The case for using tests for Ct infection during trachoma 
surveys is strengthened by our data. The value of nucleic acid amplification tests for detecting 
non-chlamydial infection remains questionable, as multiple infectious agents might be important, 
and these are likely to differ between populations.   
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Supplementary information 
 
 
Supplementary table 1: Each PCR product for dilution into standards was prepared using TaqMan Universal II PCR 
mix (Life Technologies, Paisley, UK), cleaned with Qiagen MinElute PCR product kit (Qiagen, Manchester, UK) and 
serially diluted from 1:106 to 1:1012 in ten-fold dilution steps. Each series was tested in five technical replicates with 
duplex ddPCR assays to determine the reproducibility of the assay. Target concentrations between one and 10 
copies/μL were reproducibly detected by all six assays. The coefficient of determination for all assays was in excess of 
0.99 when fitted to a linear regression model. All six assays were highly reproducible, and the mean coefficient of 
variance (CoV) was 12.1% (range: 7.8 – 14.7%). 
 
Assay 
Standard curve * 
LoD R2 CoV (%) 
S. aureus 4.0 0.991 14.4 
Coagulase-negative Staphylococcus 1.2 0.994 14.7 
S. pneumoniae 9.9 0.998 11.9 
H. influenza 2.3 0.997 14.7 
Adenoviridae 3.0 0.997 9.1 
M. catarrhalis 1.0 0.993 7.8 
CoV: Coefficient of variation; LoD: Limit of detection: R2: Coefficient of determination 
* Values calculated from 10-fold dilution series of PCR product between approximately 105 and 101 copies per target per 
test with 5 technical replicates at each dilution point. 
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Supplementary figure 1. Relative taxa abundance in age-, sex- and location-matched children with TF/TI (n = 54) and 
without (n = 53). Relative taxa abundance is expressed as percentage of total reads per specimen group. Genera with 
reads representing less than 1% of the total number of reads were combined into a group entitled ‘Other’. 
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A 
B 
Supplementary figure 2. First and second principal components coloured by (A) age group and (B) gender. Spots 
indicate individuals. Red arrows indicate loadings. 
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Supplementary figure 3. Relative contributions of genera driving difference between active trachoma cases and 
controls. 
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CHAPTER 7: NOTES AND ADDITIONAL INFORMATION 
 
7.3 Note A: Comparison of extraction technique for organism detection by PCR 
 
7.3.1 Introduction 
 
A critical step in detection of pathogen DNA with NAATs is release of the genomic material from 
bacterial bodies. One weakness of PCR diagnostics for bacteria is that the differing chemical 
composition of bacterial cells walls make them variably resistant to chemical lysis techniques. 
Lysis procedure has been shown to influence the evenness of species recovery in microbiota 
studies (316). This issue can be compounded by the complexity of the specimen, which may 
further inhibit DNA release, although this is unlikely to be the case for low-biomass conjunctival 
specimens. A DNA and RNA co-purification protocol was used in this study in order to provide 
the option for future experiments on host gene expression. RNA is highly susceptible to 
degradation and, as a result, the lysis technique does not involve harsh lysis steps such as 
bead-beating or prolonged incubation at elevated temperatures. Cell wall disruption is achieved 
with proprietary detergent-based lysis buffer. Ct has been detected at high loads in swabs 
extracted using RNA-tolerant lysis buffers in this and other previous studies (74,312,313), 
however, publications using this particular lysis technique followed by detection of other 
common pathogens are lacking. I therefore set out to compare nucleic acid recovery from key 
bacteria from our technique compared to another commonly used protocol with more severe 
lysis methodology to assess whether it may have influenced diagnostic performance.  
 
7.3.2 Methods 
 
7.3.2.1 Preparation of bacterial isolates 
 
Cultured isolates of Sp, Hi, Mc, Staphylococcus epidermidis (representing CoNS, chosen as the 
most commonly found CoNS on the skin and eyes) and Sa were grown from laboratory stocks 
using standard microbiological techniques.  
 
Lysis of adenovirus particles was not assessed during this study because viral DNA is readily 
available in the cytoplasm of host cells during an infection, and the lysis of human cells with this 
technique was already confirmed by detection of the H. sapiens RPP30 endogenous control 
target. 
 
7.3.2.2 Nucleic acid extraction and detection 
 
Each of the antecedent studies from which these assays were taken utilized different extraction 
protocols for isolation of DNA from cultured colonies and clinical specimens. The techniques are 
outlined in Table 7.3.2.2.1. The QIAamp DNA mini kit was selected as a comparator kit because 
Trachoma in the Pacific Islands 
 
 
it was commonly used, similar in protocol to the spin column kits used in many of these studies, 
and included enzymatic digestion of material for lysis prior to heating with proteinase K.  
 
Table 7.3.2.2.1. Lysis and extraction techniques used during qPCR assay validation.  
Test Specimen type Extraction kit  Lysis Ref 
H. influenzae fucK 
Cultured reference strains, 
blood, CSF 
Gentra 
PureGene 
Extraction kit 
Not specified – manufacturer 
recommends incubation in 
proprietary Cell Lysis Solution at 
80°C for 5 mins. 
(314) 
M. catarrhalis copB 
Cultured reference strains, 
nasopharyngeal swabs 
QIAamp tissue 
kit 
Lysed using 0.5% SDS, 
proteinase K, heated to 55°C for 
1 hour. 
(315) 
S. pneumoniae lytA 
Cultured reference strains, 
serum, middle ear fluid, 
CSF. 
QIAamp DNA 
kit 
Triton X100/mutolysin/lysozyme-
supplemented lysis buffer 
heated to 37°C for 1 hour 
(316) 
S. aureus SpA Cultured references strains, 
lab-confirmed staph positive 
blood cultures. 
Custom 
Colonies resuspended in water 
and heated at 98°C for 15 
minutes and then centrifuged to 
remove bacterial debris 
(317) Coagulase-negative 
Staphyloccocus tuf 
CSF: cerebrospinal fluid; SDS: sodium dodecyl sulfate (detergent). 
 
Approximately 20μL of bacterial cultures were scraped from culture plates and resuspended in 
1X PBS. Four ten-fold dilutions of resuspended bacterial cultures were prepared and each was 
aliquotted into six separate 200-μL aliquots. These aliquots were randomly allocated to Qiagen 
AllPrep DNA/RNA kit (Qiagen, Manchester, UK) extraction and Qiagen QIAamp DNA mini kit 
(Qiagen, Manchester, UK) extraction with manufacturers recommendations for lysis.  
 
The lysis procedure for the Qiagen AllPrep DNA/RNA kit involved vortexing for one minute in 
proprietary RLT Plus buffer (Qiagen, Manchester, UK) supplemented with β-mercaptoethanol 
followed by incubation for five minutes at room temperature. Lysis for the Qiagen QIAamp DNA 
mini kit involved lysis with 10mg/mL lysozyme (Sigma Aldrich, Gillingham, UK) for 20 minutes at 
37°C followed by 60 minutes incubation at 56°C with proprietary buffer AL (Qiagen, Manchester, 
UK) supplemented with proteinase K.  
 
For both procedures, the lysed material was subsequently bound to the column, washed and 
eluted into 100μL of 0.1 Tris EDTA as per respective recommendations for each kit.  
 
Equal volumes of eluate were tested with ddPCR as described in the manuscript in section 7.2. 
 
7.3.3 Results 
 
Figure 7.3.3.1 illustrates the difference in yield recovered from bacterial isolates lysed using 
differing lysis methods. Both lysis procedures lysed all bacterial suspensions effectively 
regardless of input concentration. For Mc, Sp and Hi, the AllPrep DNA/RNA kit consistently 
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offered improved recovery of genomic targets as compared to the QIAamp DNA kit with the 
exception of the highest concentration Hi where recovery was similar. For Sa and S. 
epidermidis, there were consistently fewer targets recovered in those samples extracted using 
the AllPrep DNA/RNA kit than from those extracted using the QIAamp DNA kit at high and 
medium load input. At highest input load, both kits yielded the same number of target copies for 
both Sa and S. epidermidis. However, across all loads, the mean reduction in S. epidermidis 
load was 47.7%, and the mean reduction in Sa load was 33%.    
 
7.3.4 Discussion 
 
It is possible the loss of material from the incomplete lysis may impact on targeted 
staphylococcal assay sensitivity. During validation of the qPCR protocol from which these 
oligonucleotide sequences were taken, the study authors purified DNA by resuspending 
colonies in water and heating at 98°C for 15 minutes and then centrifuging them to remove 
bacterial debris, a relatively crude technique which still resulted in successful release of genetic 
material for PCR (317). Adding mechanical lysis to chemical/enzymatic lysis is recommended 
for optimal evenness of representation of phyla, however, it is known to impact DNA yield (318). 
The prevalence of some difficult-to-lyse bacteria may have been under-represented on both the 
targeted testing and the community profiling. However, the lysis method was consistent 
between cases and controls therefore comparison between those two groups is still appropriate. 
As the lysis technique does not result in complete loss of any of the ddPCR targets, the assays 
would still be able to detect high-load targets, which are those most likely to be causing 
inflammation.  
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Figure 7.3.3.1. Comparative load recovered from bacteria targeted in this study. (A) Staphylococcus aureus, (B) 
Haemophilus influenzae, (C) Staphylococcus epidermidis, (D) Moraxella catarrhalis and (E) Streptococcus pneumoniae 
when extracted using Qiagen AllPrep Mini DNA/RNA kit (red boxes) and Qiagen QIAamp DNA mini kit (blue boxes). 
Boxes represent mean and interquartile range, and whiskers represent 1.5-times the interquartile range. RLT Plus and 
AL are proprietary lysis buffers.  
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7.4 Note B: Agreement between droplet digital PCR and 16S gene sequence 
representation 
 
7.4.1 Introduction 
 
Both 16S amplicon sequencing and ddPCR utilize thermocycling and DNA polymerase to 
amplify gene sequences to detect bacteria. ddPCR specifically targets conserved gene regions 
which should make the reaction more efficient and predictable, whereas even the conserved 
regions of the 16S gene where primers bind do have some diversity. Additionally, the V-regions 
within the 16S amplicon are highly variable in terms of length and sequence, and therefore the 
efficiency of amplification will not be equal across all species. The individual characteristics of 
each process is appropriate for their purpose in this study; ddPCR must be specific as a 
diagnostic, whereas it is necessary for 16S amplicon sequencing to misrepresent some 
peripheral genera because it profiles the community composition as a whole.  
 
Both techniques were applied to the subset of specimens from which 16S gene sequences 
were amplified, thereby allowing comparison between the two. ddPCR was used to test for 
bacterial species in four different genera: Staphylococcus, Streptococcus, Moraxella and 
Haemophilus. Staphylococcus and Streptococcus were excluded from the primary analysis of 
clinical specimens as they were found in the 16S negative controls. Neither Haemophilus nor 
Moraxella had significant influence on the first, second or third principle components identified in 
the dataset. None of the bacteria tested with ddPCR were significantly associated to clinical 
status. 
 
7.4.2 Methods  
 
16S amplicon sequencing and ddPCR was conducted as described in the manuscript in section 
7.2.  
 
16S sequence read number was compared to ddPCR result. For the purposes of the 
comparison, the ddPCR result was considered the ‘true’ result. Diagnostic comparison was 
conducted using varyingly stringent diagnostic criteria. Two ddPCR diagnostic criteria were 
tested: any load above 0 copies/μL (including those where the load is so low our confidence in 
non-zero estimate is below 95%; less stringent), and any ddPCR positive result (where only 
those with sufficient load to give us over 95% confidence in non-zero load; more stringent). 
These diagnostic criteria have been outlined previously (231). Three thresholds for classification 
of 16S amplicon positivity were set (>0 [least stringent], >10, >100 [most stringent]). 
Subsequently, Fleiss’ unweighted kappa was calculated to determine agreement between 
specimens. Chi-squared tests were employed to determining whether there was a significant 
association between ddPCR positivity and 16S read number at each level of stringency. 
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The number of genus-specific reads were compared in all ddPCR negative versus all ddPCR 
positive specimens. Logistic regression was used to test whether there was a relationship 
between ddPCR positivity and 16S read number. 
 
7.4.3 Results  
 
Table 7.4.3.1 provides a summary of diagnostic comparisons between the two techniques. 
None of the results show a significant association between number of genus-specific 16S reads 
and ddPCR result. For all four genera, there was a large number of specimens with 16S reads 
for each genera but ddPCR negative (16S>0/ddPCR- Staphylococcus: 85; Streptococcus: 85; 
Moraxella: 28; Haemophilus: 59). This was reflected by very poor specificity and PPVs. The 
overall diagnostic potential of 16S sequencing is very poor Kappa agreement indicated mostly 
ddPCR and 16S sequence presence had no better than random agreement. Some (albeit poor) 
agreement was reached at the most stringent diagnostic criteria (ddPCR 95% confidence in 
non-zero load, >100 genera-specific 16S sequences), suggesting the need for cautious quality 
control with this technique. However, even at the most stringent level, diagnostic performance 
was far below the level normally required for use. This was true across all four genera. 
 
Box plots comparing number of 16S reads in all ddPCR-negative (at the 95% confidence level) 
specimens to all ddPCR-positive specimens tested. In general, the number of reads was higher 
in ddPCR-positive specimens, but this was hugely variable, and the group sizes were too small 
for meaningful analysis. Many of the ddPCR-negative specimens which detected a target load 
below the threshold for positivity also had 16S reads detected at variable levels. There were 
several ddPCR+/16S- specimens in the (Hi fucK: 3; Mc copB: 1), although the vast mojrity of 
discrepant results were ddPCR-/16S+. 
 
7.4.4 Discussion 
 
There was no agreement between ddPCR and 16S. This was true regardless of how stringent 
the diagnostic criteria. There was also no association between load detected by PCR and 
number of 16S sequences matching that genus. This finding is surprising, however, it does not 
detract from the overall message of the manuscript presented in section 7.2 which uses these 
two techniques to address completely different questions. ddPCR was used as a sensitive and 
specific diagnostic in the absence of available culture facilities, and 16S was used to 
characterise the overall structure of microbial communities at the conjunctiva.  
 
The ddPCR target for three of the genera (Streptococcus, Moraxella and Haemophilus) are 
species-specific, yet other species in those genera are also common components of the skin 
microbiota. These other species may explain the number of reads in some of the 16S+/ddPCR- 
specimens. For example, viridans-group Streptococci and non-influenzae Haemophilus species 
have frequently been cultured from the conjunctivae. Many earlier culture-based studies do not 
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go into species-specific differentiation of these groups, and there is likely to be some 
commensal bacteria within the genera which generate genera-specific 16S sequences, but do 
not amplify with species-specific primers. However, for Staphylococcus, we specifically used 
broad spectrum primers which detect a number of different Staphylococcus species in the 
coagulase-negative group (317). These are frequently classed among the most prevalent 
members of the normal ocular flora (319). Several specimens were identified where a positive 
load of Staphylococcus was recorded, but the diagnostic result was deemed negative because 
the concentration was too low to be classified as a positive PCR result. This may be an artifact 
of the extraction process, as described in the manuscript and in Note A. This is especially 
relevant as the prevalence of CoNS was much lower than might have been expected in this 
group. Alternatively, staphylococcal contamination was present in the no-template controls, 
suggesting it might also be an artifact of the sequencing process. When the criteria for 
classification as a positive result are relaxed, 16S sequence number becomes more specific for 
ddPCR result. However, this is reflected in a compromise in sensitivity. Other aspects of the 
assay therefore seem likely to be causing multiple false positive 16S results, perhaps related to 
species not targeted by the PCR assays. Optimisation of the 16S library preparation and 
bioinformatics pipelines may improve correlation between sequence data and targeted PCR, 
which would enable us to study the constituents of these communities with more accuracy. 
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Table 7.4.3.1. Diagnostic correlation between 16S reads and droplet digital PCR positivity. In all of the diagnostic 
analyses, ddPCR was treated as the ‘true’ result and 16S read number as the comparator. Using Bonferroni’s correction 
for multiple testing, a p-value of 0.002 was considered significant. 
Genera ddPCR 16S reads Sensitivity Specificity PPV NPV 
Cohens 
Kappa 
Chi-
squared 
p-value 
Staphylococcus 
Load >0 
copies/μL 
>0 0.940 0.043 0.516 0.400 -0.017 1.000 
>10 0.739 0.140 0.315 0.429 -0.060 0.680 
>100 0.500 0.391 0.472 0.419 -0.109 0.387 
Positive 
>0 1.000 0.056 0.066 1.000 0.007 1.000 
>10 0.833 0.300 0.074 0.964 0.023 0.817 
>100 0.667 0.456 0.075 0.953 0.026 0.874 
Streptococcus 
Load >0 
copies/μL 
>0 1.000 0.025 0.181 1.000 0.009 1.000 
>10 0.762 0.063 0.178 0.833 0.002 1.000 
>100 0.882 0.532 0.288 0.955 0.229 0.005 
Positive 
>0 1.000 0.023 0.096 1.000 0.004 1.000 
>10 1.000 0.069 0.100 1.000 0.014 0.928 
>100 0.889 0.494 0.154 0.977 0.122 0.065 
Haemophilus 
Load >0 
copies/μL 
>0 0.706 0.380 0.197 0.857 0.043 0.698 
>10 0.039 0.937 0.375 0.841 0.143 0.295 
>100 0.059 0.987 0.500 0.830 0.071 0.785 
Positive 
>0 0.400 0.352 0.033 0.914 -0.040 0.518 
>10 0.400 0.934 0.250 0.966 0.260 0.072 
>100 0.200 0.989 0.500 0.957 0.264 0.203 
Moraxella 
Load >0 
copies/μL 
>0 0.167 0.700 0.036 0.926 -0.049 0.817 
>10 0.000 0.989 0.000 0.937 -0.011 1.000 
>100 0.000 0.989 0.000 0.937 -0.011 1.000 
Positive 
>0 0.000 0.705 0.000 0.985 -0.021 1.000 
>10 0.000 0.989 0.000 0.989 -0.011 1.000 
>100 0.000 0.989 0.000 0.989 -0.011 1.000 
ddPCR: droplet digital PCR; PPV: positive predictive value; NPV: negative predictive value. 
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8. DISCUSSION  
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Evidence on the sensitivity and specificity of TF for Ct infection strongly suggests that after 
MDA, or in low prevalence environments, the PPV of TF is low (126). In this thesis, we present 
data suggesting in the Solomon Islands the PPV is also low, even though the level of TF is 
moderately high, and no treatment has yet been administered. This might be attributable to the 
unmasking of phenotypically similar diseases as the global prevalence of ocular Ct infection 
drops and as an increasing number of people from different parts of the world are examined. 
Research into the appropriateness of diagnostic tools for monitoring and evaluating public 
health programs is therefore critical. Interventions for trachoma were developed largely based 
on data generated in sub-Saharan Africa, and the appropriateness of tests that work well in 
endemic African countries should be explored in other world populations. The study of trachoma 
in the Pacific is therefore justified, and the outcomes have important implications locally and for 
other countries considering elimination.  
 
8.1 Data synthesis 
 
The first hypothesis for this study was that TF meeting the criteria for intervention is not 
concurrent with sufficiently prevalent TT to be classed as a public health threat; we suspect the 
clinical phenotype in the Pacific Island small states to be unusual. Vanuatu and Solomon 
Islands were shown to have TF present at levels that require A, F and E intervention, but TT 
prevalence is too rare to be counted as a public health threat according to WHO thresholds. In 
rejecting the null for the first hypothesis of this study, we find a paradox in Melanesia – the TT 
prevalence suggests trachoma is not a public health problem in Solomon Islands, Vanuatu and 
Fiji, but treatment is indicated based on the prevalence of TF. TF is not sight-threatening in its 
own right, nor even symptomatic in most cases. It is also possible that this is isolated to the 
region. However, the presentation of trachoma in endemic populations is likely to be diverse as 
a result of the life-long accumulation of stimuli required to develop scarring and TT, therefore 
the relationship between TT and TF is not expected to be linear. In figure 1.3.2, there are a 
small number of studies where a similar pattern is observed (TF ≥10% in those from 1–9 years, 
TT < 0.2% in those aged 15+ years). However, these estimates were not, for the most part, 
generated using standardised study design and grading, nor were they age standardised in 
most cases. They also included single districts in studies where many of the other districts did 
have a public health threat from TT (for example, Cameroon (52)). The GTMP is expected to 
identify further districts where the work presented in this thesis may be relevant; infection testing 
may be warranted in those areas. Elsewhere in the Pacific, more cases of TT were found in one 
survey in Kiribati than the other three surveys in Solomon Islands, Vanuatu and Fiji combined. 
Kiribati met the WHO criteria for intervention, and should be reviewed for capacity to implement 
the S component of the SAFE strategy immediately in addition to implementation of A, F and E 
components of trachoma control. These are a multitude of differences between Melanesia and 
Micronesia that might lead to differing trachoma endemicity; this may be an area of interest for 
future studies but beyond the scope of this study.  
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The second hypothesis of this study was that in these areas where TT is rare, there was no 
association between ocular Ct and TF. The population prevalence of TF and Ct are well 
correlated in many endemic districts, but situations are emerging (e.g., low prevalence, post-
treatment) where TF is not closely associated with Ct. As an increasing number of districts 
embark on control programmes and others consider whether elimination goals have been met, 
the diagnostic specificity of trachoma for Ct infection should come under increased scrutiny. 
Prior to this study, the prevalence of TF and TT was not clear in Fiji; recent reports had 
conflicting evidence. More recent studies have indicated the high TT prevalence estimate to be 
an artefact of the WHO simplified system and social practices of eyelash epilation among 
Fijians (304), and suggest the prevalence in the Western Division to be 0%. We have now 
demonstrated ocular Ct infection to be scarce and not associated with TF, thereby addressing 
the second hypothesis in Fiji. Subsequently, the seroprevalence of anti-Pgp3 antibodies was 
found to be low in Fiji and did not increase with age (305). The second study hypothesis was 
further investigated in the Solomon Islands. Ct was associated with TF in this population; 
however, TF was observed in more than a quarter of children surveyed, yet over 95% of them 
did not have Ct infection. Independent, long-lived antibody markers of Ct infection are less 
susceptible to artefacts from seasonal or temporal fluctuations in transient infection - these did 
not suggest accumulation of Ct exposure. The clinical signs of progressive conjunctival fibrosis 
were not prevalent in adults, suggesting the trachoma was not progressing as severely as it 
does elsewhere. Therefore, in the Solomon Islands, several indicators (TI, severe scars, Ct 
infection, anti-Pgp3 antibodies and TT) are practically absent, yet TF is still present at levels 
that warrant intervention. The implications for Melanesia have been that two rounds of MDA 
have been reconsidered, giving Ministries the opportunity to invest resources and staff 
elsewhere. The cost of MDA in the Pacific Islands is known to be high, in part due to their wide 
geographic distribution, and this could represent a significant saving.  
 
The third study hypothesis was that an alternative pathogen may be more closely associated 
with TF than Ct. The evidence did not suggest that the prevalence of nonchlamydial pathogens 
was disproportionately higher in the eyes of those with TF compared to those without, therefore 
the null hypothesis could not be rejected. Non-Ct infections are thought to contribute towards 
inflammation that causes scarring to progress (11,39), therefore this finding is consistent with 
the low prevalence of severe scars in the population. Upon examination of the full bacterial 
community at the conjunctiva no shift in the richness or diversity of genera represented was 
observed when comparing cases of TF with matched counterparts, suggesting bacterial 
dysbiosis is not associated with TF here, and therefore unlikely to be the cause of active 
disease in people with no serological evidence of Ct exposure. Together, the data suggest there 
is a low prevalence of trachoma in the Solomon Islands that is attributable to Ct infection. This 
accounts for the low prevalence of severe scars and TT cases. It is possible the burden of TF is 
being inflated by a viral or allergic cause, although the epidemiology and presentation of those 
types of conjunctivitis are well characterised and distinct from those of trachoma. Figure 8.1.1 
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presents a summary of the data presented in this paper, and a proposed model for trachoma 
progression in the Solomon Islands resulting in low prevalence of TT.  
 
The underlying reasons for the proposed difference in pathogenesis are hard to speculate. The 
genetics of the pathogen are broadly similar to other serovars that cause trachoma. Even at 
those loci thought to have disproportionate influence on virulence (mostly found in the PZ), the 
Solomon Island strains are similar to other ocular strains. Cases of TF in the absence of 
detectable Ct is not unprecedented; studies have found the PPV of TF for NAAT positivity to be 
low in areas where TF prevalence  exceeds 10% (31), but this is not commonly observed in a 
treatment-naïve population. Has this community previously been exposed to antibiotics? There 
is no suggestion of mass macrolide distribution or increased availability compared to other 
trachoma-endemic environments in the academic literature. Trachoma is typically associated 
with arid areas where water is so limited that it restricts face washing behavior. Fresh water is 
commonly available in the Solomon Islands due to the regular, year-round rainfall (figure 1.9.5). 
Therefore, the environment is clearly different to many (although not all) trachoma-endemic 
countries, yet 60-70% of children in some provinces have visible oculonasal secretions upon 
examination (‘dirty face’) (287). Greater distance to nearest source of water for washing or 
drinking was not associated with trachoma in the Solomon Islands during the GTMP survey in 
2013 (290). According to recent surveys, approximately 60% of households in Solomon Islands 
do not have access to improved latrines, suggesting availability of fly breeding sites near 
houses, but there was no association between absence of latrines and trachoma (290). It is 
possible our surveys have taken place in at a seasonal nadir of infection transmission, however, 
the consistency of the weather depicted in figure 1.9.5 suggests the Solomon Islands do not 
experience seasonality in rainfall and temperature, and therefore trachoma may also not be 
subject to profound seasonal variation on that basis. Host genetics may have a role to play as 
the population of the Solomon Islands is genetically isolated, but as mentioned in the discussion 
of the manuscript in section 5.2, some of the alleles that have associated with increased risk of 
scarring are present at high frequency throughout the Pacific. Urogenital infections are also 
highly prevalent, suggesting they are not impeded by local host resistance to Ct infection.  
 
The profile of age-specific TF prevalence in the pre-MDA survey could suggest an alternative 
transmission pattern. It is possible that ocular Ct infections are being transmitted but do not 
establish infections of sufficient duration or intensity to drive antibody responses and 
immunopathology. It is tempting to consider whether the high prevalence urogenital Ct 
infections in expectant mothers may have an impact on susceptibility to Ct infection, or the 
inflammatory response to a single episode of Ct exposure. The prevalence of urogenital Ct 
infections in Melanesia is among the highest in the world. In chapter 6, this is suggested as a 
potential reason for the high proportion of 1-year olds in this study with antibodies to Pgp3. 
While antibodies alone to Ct are insufficient to provide protection against infection, sustained 
antibody levels throughout childhood may be indicative of a broader immune response that may 
give children in these communities an immunological ‘head start’ against ocular Ct infection. 
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There may also be a herd effect of high proportion of seropositive young children in the 
community acting as ‘barriers’ to widespread transmission, perhaps even a critical mass of 
seropositive individuals within a population. There are critical limitations to this hypothesis; 
firstly, any relationship between exposure in partum and either protection against subsequent 
infection or attenuation of response to single infection stimuli would be expected to show some 
association (either negative or positive) with high anti-Pgp3 antibody titre. This is not the case in 
this population. Secondly, the formation of lymphoid centres to facilitate B-cell maturation, class 
switching to IgG and plasma cell formation may not be possible at such a young age with such 
transient exposure. Thirdly, in endemic settings, multiple infections are thought to be needed to 
induce scarring, and the accumulation of exposure enhances risk of scarring. Therefore, the 
concept of early exposure attenuating response to future challenge seems counterintuitive. 
Ultimately, the current understanding of the basic biology of protective immunity to Ct is 
insufficient to speculate whether this is plausible. Further research into the antibody status of 
children born to mothers with active urogenital infection, longitudinal short- and long-term follow-
up might provide better understanding of how this affects an individual’s response to 
subsequent Ct stimuli.   
 
8.2 Limitations and future opportunities 
 
The islands in this study are separated by hundreds of kilometers of open ocean, and the 
majority of the populations are rural and isolated. The geographical isolation promotes 
microclimates throughout the archipelago, therefore the likelihood of disease being 
homogenous throughout the region is low. This is demonstrated by the difference observed 
between Temotu and Rennell & Bellona, political neighbors with differing dominant ethnicities, 
very little migration between the two, and apparently differing levels of trachoma and infection. 
The effect of MDA is also not apparently consistent between the two provinces; surprisingly, in 
villages in Rennell & Bellona where infection and TF were more closely correlated, the impact of 
MDA was negligible, whereas in Temotu where over 95% of TF cases do not have detectable 
Ct infection, TF was reduced by over 50%. Preliminary estimates of MDA coverage were 
approximately 70% in Rennell & Bellona and 90% in Temotu. The study was not powered to 
detect differences between provinces, and the number of villages is so low, it is likely to be 
susceptible to inaccuracies due to disease clustering. It is also not surprising that a broad 
spectrum antibiotic with immunomodulatory effects should reduce an inflammatory phenotype 
such as TF even in the absence of a detectable macrolide susceptible causative agent. 
However, this does suggest that, as long as suitable coverage is achieved, MDA is likely to be 
effective at reducing TF in this population. While cases of TT may be rare in Temotu, six cases 
were found in the Western province of the Solomon Islands during the GTMP, and others have 
been referred to central clinics from Malaita province (figure 1.9.3). There is likely to be 
substantial geographical variation in trachoma prevalence, therefore data collected from 
surveys of one island group should be applied cautiously to other areas. Further work is 
warranted to extend the geographic coverage of the Pacific trachoma programme, and support 
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national programmes in directing their trachoma elimination efforts to pockets of trachoma 
which may remain on some islands. 
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It remains unclear whether nonchlamydial pathogens are an independent causative agent for 
TF or whether they are opportunistic pathogens of conjunctivae that have previously been 
conditioned to be more susceptible to repeated Ct infection. The data in section 7.2 support the 
latter hypothesis, but the TF in the absence of antibodies to Pgp3 support the former. No 
relationship was found between clinical signs and pathogens commonly isolated from trachoma-
endemic settings, yet the ocular Ct endemicity of study populations where the majority of data 
have been generated may introduce bias that precludes comparison to the Solomon Islands. 
Because TF is present in Melanesia children and declines into adulthood, a single cause seems 
more likely, as acquired partial immunity to a mixture of causes may develop more slowly. 
However, in the absence of a definitive pathogen associated with follicular inflammation, there is 
no ‘smoking gun’ upon which to form further hypotheses about a potential different cause. 
Microarray or sensitive amplification-free deep sequencing technologies could shed light on a 
potential causative agent, and longitudinal investigations would be warranted to determine 
causality.  
 
In trachoma-endemic environments, the vast majority conjunctival scarring is considered to be a 
result of Ct infection. However, nonchlamydial and noninfectious causes of scarring are 
intermittently mentioned in the literature (320,321). Although many adults with scarring are also 
seropositive for anti-Pgp3 antibodies, we have presumed that most of the anti-Pgp3 signal is 
those adults is caused by previous urogenital infection. The accumulation of minor scars with 
increasing age in seronegative individuals suggests there may be other causes of incident 
scarring that do not progress to scarring severe enough to distort an eyelid, but without a 
longitudinal study of scarring, it is not possible to definitively declare the risk of progression. 
Although no trachoma intervention is directly aimed at treating scarring, it is the primary cause 
of entropion and therefore improving our understanding of the causes and mechanisms of 
scarring is critical. In the peri-elimination period, TS may prove a useful short-term indicator of 
whether A, F and E interventions are likely to lead to reduced risk of developing TT (34,100). 
There are also likely to be parallels between eyelid scarring and pelvic organ scarring (a 
complication of vaginal Ct infection that can lead to infertility and ectopic pregnancy), therefore 
improved understanding of scarring pathogenesis could help us identify what aspects of Ct 
infection are critical to inducing ongoing immunopathogenesis. 
 
In these communities, TF appeared to be successfully treated by MDA where coverage was 
sufficient. A final issue for consideration is whether the communities would benefit from 
trachoma-targeted interventions for reasons other than trachoma control. There has already 
been a positive impact of the first MDA round on yaws (102) and sexually transmitted infections 
(322); other beneficial impacts of MDA are described in section 1.5. In Fiji, yaws does not 
appear to be endemic (305), so the collateral benefit of azithromycin MDA may be limited in that 
respect. The potential benefit of F and E implementation in parts of Melanesia is significant, 
where many still live traditional subsistence lifestyles and there is social stigma associated with 
insufficient infrastructure for basic hygiene practices. The negative implications of MDA should 
also be considered. Some commentators have suggested that disrupting the natural 
Trachoma in the Pacific Islands 
 
 
accumulation of partial immunity within the community could theoretically have negative knock-
on effects to the prevalence of Ct, however, this is yet to be empirically proven (114). The most 
pressing risk from MDA is the emergence of macrolide-resistant pathogens. Resistance to 
macrolide antibiotics among, for example, Mycoplasma genitalium (323), Treponema pallidum 
(324) and Neisseria gonorrhoeae (325) isolates is emerging worldwide at an alarming rate 
(326). Current published data from trachoma studies has not demonstrated significant drop in 
antibiotic susceptibility among most pathogens studied. Where macrolide-resistance has been 
observed, it seems to decrease after the removal of antibiotic pressure (113). However, 
prospective, long-term studies in communities where MDA is undertaken for a prolonged period 
are lacking. These would be especially valuable in communities where more intensive regimens 
(e.g., biannual treatment) are under consideration.  
 
On balance, this candidate feels that the momentum of the trachoma community could be 
effectively leveraged to provide holistic benefit to the lives of Pacific Islanders, particularly from 
the F and E components of SAFE strategy. In the absence of compelling evidence that 
trachoma MDA specifically drives resistance, this candidate feels this should include the A 
component, pending urgent studies on the potential negative implications of MDA. No doubt 
those struggling to eliminate trachoma with already over-stretched budgets may disagree.  
 
8.3 Conclusions  
 
In the Solomon Islands, the prevalence of TF was moderate before MDA, but was poorly 
predictive of Ct infection positivity. TF was reduced by approximately 50% after MDA, yet ocular 
Ct prevalence did not change. TF was not associated with exposure to Pgp3, and adults in the 
same population did not have a high prevalence of severe scarring, nor sufficient TT to be 
classed as a public health problem. Does TF therefore represent the burden of ocular Ct 
endemicity in this area, or the need for trachoma intervention? The evidence suggests not. 
International guidelines recommend basing decisions about the implementation of A, F and E 
on TF alone; in this context, that guideline has led to significant spending on interventions 
aimed at treating an infection that does not appear to be prevalent.  
 
To the credit of the GET2020 community, MHMSs in the Pacific and international partners have 
embraced the findings of this study and adopted a pragmatic approach to trachoma elimination. 
The Pacific Trachoma Initiative, assembled in response to these data, has curtailed the MDA 
programme pending more data and has integrated pre-, short-term (6 months) post- and long-
term (24 months) post-MDA operational surveillance of ocular Ct infection into the Trachoma 
Action Plans of Solomon Islands, Vanuatu, Fiji and Kiribati. This will provide additional data to 
Ministries to inform their decisions about whether additional rounds of MDA are warranted after 
the first is complete.  
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As many as eight annual MDA treatments have incompletely controlled TF in some settings in 
Africa and this may be an indication that the situation in the Pacific region is not unique. Whilst 
the ‘unusual’ clinical presentation that triggered this study has not yet been described outside of 
the Pacific, the completion of GTMP may identify other districts in which a similar mismatch 
between the prevalence of TF and TT could indicate that MDA might not be warranted. The 
approach taken here may encourage other nations to include operational surveillance of ocular 
Ct infection in trachoma elimination programmes. A combined approach such as ours would be 
optimal, but may be unrealistic on the global scale of trachoma elimination. Infection testing has 
been shown to be cost–effective in low-prevalence areas (135) and the data here demonstrate 
the high information gain that can be achieved through application of this highly specific marker 
of current ocular Ct infection. The introduction of at least one test for infection into the WHO 
guidelines for trachoma assessment, alongside clinical grading, may prevent rounds of MDA 
that could be otherwise directed at hyper-endemic districts.  
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Introduction: Both yaws and trachoma are endemic in several countries in the Paciﬁc. In co-endemic coun-
tries there may be potential synergies between both control programmes.
Methods: We undertook a cluster randomised trachoma and yaws seroprevalence survey of children in the
Western Division of Fiji. Children were examined for skin lesions consistent with active yaws. A dried blood
spot was collected which was tested using the Treponema pallidum particle agglutination (TPPA) test and an
ELISA to detect antibodies against Pgp3.
Results: A total of 607 children from 305 households across 23 villages were recruited into the survey. On skin
examination, no child had clinical evidence of yaws, and the TPPA assay was negative in all children (0%, 95%
CI 0.0–0.6). The seroprevalence of Pgp3 antibodies was 20.9% (95% CI 17.8–24.6%).
Discussion: In this study there was neither clinical nor serological evidence that transmission of yaws was
ongoing. The Pgp3 seroprevalence pattern was consistent with either low level transmission of ocular
Chlamydia trachomatis or exposure to C. trachomatis in the birth canal which is consistent with a survey con-
ducted in the same region in 2013. These data suggest neither yaws nor ocular chlamydia infection are a sig-
niﬁcant public health problem in the Western Division of Fiji.
Keywords: Fiji, Neglected tropical diseases, Scabies, Trachoma, Yaws
Introduction
Yaws, caused by Treponema pallidum subsp. pertenue, is
endemic in several countries in the Paciﬁc.1 Trachoma, caused
by ocular infection with Chlamydia trachomatis, is the leading
infectious cause of blindness and is also endemic in the
Paciﬁc.2,3 Both diseases are classiﬁed as neglected tropical dis-
eases (NTDs) by WHO. WHO has targets for both the global
eradication of yaws and elimination of blinding trachoma as a
public health problem by 2020.4,5 Central to the strategy for
both of these targets is the use of community mass treatment
with azithromycin, which is an effective therapy for both
organisms. In countries where both yaws and trachoma are
endemic there may be potential synergies between the control
programmes at multiple levels including survey, intervention
and surveillance.6,7
Of the countries where yaws remains endemic, three of the
most high-burden countries are in the Paciﬁc, including Papua
New Guinea, the Solomon Islands and Vanuatu.8 Yaws has pre-
viously been reported in many other countries in the Paciﬁc,
including Fiji, but there are no current data from Fiji on the
prevalence of active disease or the seroprevalence of infection.9
Accurate data on both clinical and serological prevalence of
yaws in Fiji are needed to guide programmatic decision making.
Trachoma has been reported to be endemic in a number of
countries in the Paciﬁc, although population-based mapping
studies have suggested a relatively low number of cases of
trichiasis – the late, blinding, stage of the disease – in the
© The Author 2016. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.
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region. A recent survey completed in the Western Division of
Fiji reported a low prevalence of ocular infection with C. tra-
chomatis among children, and similar ﬁndings have been
reported from other Paciﬁc countries, including the Solomon
Islands.10
Serology has recently emerged as a potential surveillance
tool for trachoma programmes. Current measures of ocular
infection (directly by PCR, or indirectly by clinical examination)
provide only a cross-sectional snapshot of community preva-
lence, without necessarily giving any information about the
changing exposure in a population over time. For trachoma,
antibodies to Pgp3 are thought to be a long-lived and speciﬁc
marker for prior C. trachomatis exposure.11,12 Serology is also a
major tool in surveillance for yaws. Treponemal antibodies per-
sist for life and cannot distinguish between yaws and syphilis.
A prevalence of treponemal antibodies greater than 1% amo-
ngst children has been suggested as a possible trigger for more
detailed yaws mapping studies.13
The collection of dried blood spot samples in prevalence
surveys have recently emerged as a practical tool to allow col-
lection and storage of a large number of ﬁnger-prick blood
samples from which the seroprevalence of several infections
can be assessed. This has notable advantages in facilitating
integrated NTD mapping and surveillance activities.14,15 Prior
to this study implementation of the SAFE strategy for elimin-
ation of trachoma had not yet commenced in Fiji and there
had not been any azithromycin mass drug administration con-
ducted in the country. We conducted an integrated survey to
assess the seroprevalence of antibodies to T. pallidum and
C. trachomatis in order to evaluate the need for further inter-
ventions for these NTDs in Fiji.
Methods
We conducted a population-based cluster-randomised sur-
vey in the Western Division of Fiji in July and August 2015,
where we had previously documented a low prevalence of
both clinical signs of active and ocular infection with C. tra-
chomatis.2 No mass distribution of azithromycin for trach-
oma or yaws has previously been carried out in this region,
nor any recent penicillin-based mass treatment campaigns
for yaws, to the best of the authors’ knowledge. Data are
reported in line with the STROBE guidelines for cross-
sectional surveys (Supplementary File 1). Study data are
available in Supplementary File 2.
Survey methodology
This was a two-stage cluster-randomised survey. Each cluster
consisted of a single village. Villages were selected randomly,
using probability proportional to size sampling, from a list of all
communities in the Western Division of Fiji. On the day on the
survey, in collaboration with local leaders, a list of all households
was enumerated and 30 households selected using simple ran-
dom sampling. All children aged 1–14 at sampled households
were eligible for inclusion.
Data collection
A nurse was trained in standardised dermatology. Examinations
included the head and neck, limbs and trunk but excluded the
genitals and buttocks. Individual-level data were collected on
age, gender, and the presence or absence of skin lesions. For
each skin lesion we recorded the location, clinical appearance
and whether the lesion was consistent with yaws or an alterna-
tive diagnosis. A clinical case of yaws was deﬁned on the basis
of typical clinical ﬁndings of papillomatous or chronic, painless
ulcerative skin lesions and using the WHO pictorial guide to
yaws.16 The clinical diagnosis of scabies was based on features
including morphology (burrows, papules, nodules, vesicles) and
body distribution of rash; presence of pruritus on history or evi-
dence of excoriation; contact history with individuals with a
similar rash and itch; and consideration of differential diagnoses.
The distribution of scabies lesions was noted using nine pre-deﬁned
body regions. Scabies severity was classiﬁed by the number of
lesions present as mild (≤10 lesions), moderate (11–49 lesions)
or severe (≥50 lesions or crusted scabies).
Active impetigo was diagnosed on the basis of discrete papu-
lar, pustular or ulcerative lesions with associated erythema,
crusting, bullae or frank pus. Inactive impetigo was diagnosed
by the presence of discrete, non-conﬂuent healed superﬁcial
skin lesions. Severity of active impetigo was classiﬁed as very
mild (≤5 lesions), mild (6–10 lesions), moderate (11–49 lesions)
or severe (≥50 lesions).
All data were entered directly into Android smartphones
using the OpenDataKit software package.17 Individuals with a
skin condition requiring treatment were referred to the local
health clinic where they were treated free of charge in line with
Ministry of Health guidelines.
A ﬁnger-prick blood sample was collected onto a ﬁlter paper
from all children regardless of clinical features. Filter papers were
air-dried and stored in a sealed bag with a desiccant sachet. In
individuals with ulcerative or papillomatous skin lesions consist-
ent with yaws we also collected a swab sample of lesion exud-
ate. Exudate was transferred to a FTA Elute Micro Card (GE
Healthcare, Chalfont St Giles, UK) using three ﬁrm side-to-side
motions of the swab across the card. Each card was placed in its
own re-sealable plastic packet with an individual desiccant
sachet. All samples were transferred to Lautoka Hospital and fro-
zen at −20°C and then shipped to the London School of Hygiene
& Tropical Medicine (LSHTM), London, UK for testing.
Laboratory testing
Blood samples were tested at LSHTM. All laboratory testing was
performed by individuals masked to the clinical ﬁndings. For
yaws, a single extension of each ﬁlter paper sample was eluted
as previously described and the elute tested using the T. pallidum
particle agglutination test (TPPA; Mast Diagnostics, Bootle, UK).18
For trachoma, a separate extension of each ﬁlter paper was
tested using an ELISA for Pgp3 developed by the US Centres for
Disease Control (Diana Martin, personal communication). Dried
blood spots were eluted into 250 µL of 1× phosphate-buffered
saline (PBS) with 2.5% weight-for-volume milk powder plus 0.3%
volume-for-volume tween 20 (PBST-milk). Immunolon 2HB plates
were coated overnight with 50 ng per well glutathione S-transferase
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(GST)-tagged Pgp3 then blocked for 1 hour with PBST. Plates
were bound for 2 hours with 50 µL of the elution mixture, then
incubated at room temperature with rabbit anti-IgG for 1 hour.
Plates were then incubated in the dark for 10 minutes with tetra-
methylbenzidine (TMB) and the absorbance read at 450 nm. Plates
were washed four times with PBST between steps. A series of posi-
tive serum diluted in negative serum was run on each plate. Plates
were re-run if the mean of each point in the dilution series fell
more than 20% outside of pre-determined normal range. All
specimens on the plate were normalised to a 20% dilution of
presumed-positive material as that typically gave optical density
(OD) readings around 1.
Statistical analysis
We calculated the clinical prevalence of yaws and other com-
mon skin infections. A positive cut-off value for the Pgp3 ELISA
was deﬁned using a mixtures model.19 For the purposes of ana-
lysis we grouped age into 1–5 years, 6–10 years and 11–14
years of age. We categorised ethnicity as iTaukei, Indo-Fijian
(the predominant ethnic groups in Fiji) or other. We calculated
the seroprevalence of antibodies against T. pallidum and C. tra-
chomatis. Random effects logistic regression was used to assess
associations between age, sex, ethnicity and gender with both
clinical ﬁndings and seroprevalence data controlling for the
effect of clustering at household and village-level. Analysis was
conducted in STATA 13.1 (StataCorp LP, College Station, TX, USA)
and R 3.2.3 (the R Project for Statistical Computing).20
Sample size
We calculated that a sample size of 1005 children was needed
to detect a seroprevalence of both treponemal antibodies and
Pgp3 antibodies of 5% in 1–14 year-olds with a degree of preci-
sion of ±2%, a design effect of 2, and a 10% non-response rate.
Based on the Fiji national census we calculated that 30 house-
holds in each of 30 villages would be sufﬁcient to reach this
sample size.
Ethical approval
Written informed consent was obtained from each participating
child’s parent or guardian by a member of staff ﬂuent in the
local dialect. Assent was obtained from all children with a signa-
ture or thumb print. Ethical approval for the study was granted
by the ethics committees of the Fiji Ministry of Health (2015.65.
WES) and LSHTM (10359).
Results
A total of 607 children from 305 households across 23 villages
were recruited into the survey. The median age was 6 years
(IQR 4–9), 312 children were male (51.4%). There were 493
individuals of iTaukei descent (81.2%), 91 individuals were
Indo-Fijian (15.0%) and 23 children were of another ethnicity
(3.8%).
On examination 184 children (30.3%) had at least one skin
lesion. No skin lesions were considered to be clinically consistent
with yaws. The most common skin lesions noted were scabies
without secondary bacterial infection (n=59, 9.7%), scabies with
bacterial skin infection (n=31, 5.1%) and impetigo without
underlying scabies (n=24, 3.9%). Scabies was more common
amongst children of iTaukei ethnicity (OR 2.9, p=0.015) and was
the major risk factor for the presence of impetigo (OR 10.30,
p<0.0001) with a population attributable fraction of 51.2%.
Eczema (n=18, 2.9%), tinea corporis (n=16, 2.6%) and mollus-
cum contagiosum (n=14, 2.3%) were also common (Figure 1).
Dried blood spots were collected from 593 children (96.7%).
The TPPA was negative in all children enrolled in this study (95%
CI 0–0.6%). Because no yaws-like lesions were identiﬁed no
swabs for PCR were collected. Using the mixtures model an OD
threshold of 0.72 was deﬁned for the Pgp3 assay. Based on this
cut-off the overall seroprevalence of Pgp3 antibodies was
20.9%. Seroprevalence increased with age from 15% in children
aged 1 year to 22% amongst children aged 14 years. In univari-
ate analysis both age and ethnicity were signiﬁcantly associated
with a positive Pgp3 ELISA (p=0.043 and p<0.001 respectively)
but there was no association with gender (p=0.71). In multivari-
able analysis iTaukei ethnicity was associated with a signiﬁ-
cantly increased risk of Pgp3 seropositivity (aOR 9.82, 95% CI
2.94–32.79, p<0.001) (Table 1 and Figure 2).
Discussion
We found no evidence that yaws was still endemic in the
Western Division of Fiji. No children were identiﬁed with clinical
evidence of yaws and treponemal antibody testing was nega-
tive in all children. As these tests reﬂect lifetime exposure to
T. pallidum this represents strong evidence that transmission of
yaws is not ongoing in the communities where this study took
place. Approximately one-ﬁfth of children in the study had evi-
dence of exposure to C. trachomatis. In a previous study in the
Western Division of Fiji we reported a trachomatous inﬂamma-
tion – follicular (TF) prevalence of 2.8% and an ocular chlamydia
infection prevalence of 2.3%.2 These serology data are compar-
able to other settings where there is a low prevalence of both TF
and ocular chlamydia infection.21 Steeply increasing age-speciﬁc
anti-pgp3 prevalence in children aged between 1 and 10 years
is thought to be indicative of intense transmission of ocular
Figure 1. Clinical prevalence of common skin infections.
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C. trachomatis; in this population the prevalence of anti-pgp3
antibodies was already high in the 1-year age group, suggesting
the majority of seropositivity was acquired at in the ﬁrst year of
life.12,21 As Pgp3 is conserved between urogenital and ocular
strains of C. trachomatis we cannot discount the possibility that
the Pgp3 seroprevalence may reﬂect transmission in the birth
canal as well as, or indeed more than, ocular transmission of
chlamydia. The prevalence of urogenital C. trachomatis infection
amongst pregnant women has previously been reported to be
high in Fiji and community prevalence surveys in other Paciﬁc
countries have also reported high rates of urogenital C. tracho-
matis.22,23 In a study of pregnant women in Suva, Fiji, native
Fijian women were found to have higher rates of urogenital
infections, including C. trachomatis, than Indo-Fijian women.24
Based on the current data it is unclear whether ocular C. tracho-
matis infection or transmission in the birth canal is the major
driver of Pgp3 seropositivity in these communities. These data
highlight the potential challenges of using Pgp3 as a sero-marker
for trachoma in communities where the prevalence of genital
chlamydia infection is also high.
Skin problems were common in this study population with
scabies and impetigo the most commonly identiﬁed conditions.
These ﬁndings are consistent with a national scabies prevalence
survey that was previously conducted in Fiji.25 As previously
noted scabies was more common amongst iTaukei than indo-
Fijians and was the major risk factor for impetigo.25 The absence
of both chronic ulcerative lesions and papillomatous lesions
consistent with yaws is supported by our serological data show-
ing an absence of treponemal antibody positivity. Anecdotally,
health care staff in the Western Division of Fiji reported that
they did not see children with skin lesions consistent with yaws
presenting to health care clinics.
Our study has a number of limitations. Whilst survey clusters
were chosen in advance, we did not achieve our desired sample
size because of logistical difﬁculties on the days of surveys of
particular communities and the time limitations of the survey
team. This may have limited our ability to detect rare cases of
yaws amongst these communities. This is of particular import-
ance as yaws is known to be highly focal even in regions where
it is endemic. However the absence of any positive treponemal
antibody tests in children enrolled in this study provides strong
evidence that transmission is not ongoing in the communities
included in this study. The appropriate methodology for conﬁrm-
ing yaws elimination has not yet been agreed but it is likely that
large-scale seroprevalence surveys will be required. The reduced
sample size also reduced the statistical power to assess asso-
ciations between demographic variables and Pgp3 antibody sta-
tus. Secondly, the study was conducted in only a limited
geographic region of Fiji. Further studies in other parts of the
country should be undertaken. Finally we did not collect linked
clinical data on active trachoma or ocular swabs for PCR during
this survey. We had conducted a previous survey in this region
of Fiji two years earlier where we have demonstrated a low
prevalence of TF (2.8%) and ocular C. trachomatis infection
Table 1. Factors associated with Pgp3 antibody positivity
Variable Indicative prevalence data Adjusted odds ratioa (95% CI) p-valueb
Age (years)
1–5 (n=267) 16.9% 1 p=0.0133
6–10 (n=218) 23.3% 1.83 (1.10–3.02)
11–14 (n=99) 25.2% 2.20 (1.17–4.15)
Ethnicity
Indo–Fijian (n=86) 3.5% 1 p<0.0001
iTaukei (n=476) 24.8% 10.88 (3.12–37.92)
Other (n=22) 9.1% 2.89 (0.39–21.05)
Gender
Male (n=308) 20.5% 1 NS
Female (n=276) 21.7% 0.89 (0.57–1.38)
NS: not signiﬁcant.
aAll odds ratios are adjusted for age, gender and ethnicity.
bLikelihood ratio test.
Figure 2. Seroprevalence of Pgp3 antibodies by age and ethnicity. Data
are seroprevalence and 95% CIs. Only data for iTaukei and Indo-Fijian
children are shown due to the small number of children of other
ethnicities.
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(2.3%) amongst children2 and where no cases of trachomatous
trichasis were seen.
There is a need for better data to inform programmatic decision
making and integrated approaches to NTDs in the Paciﬁc. Our study
has conﬁrmed that yaws and trachoma mapping activities can be
integrated and that it may be possible to expand this to other NTDs
such as scabies. There is also scope for cooperation between mass
treatment programs, for example co-administration of ivermectin,
albendazole and azithromycin, where more than one treatment is
indicated and appropriate safety and efﬁcacy data exist.26 Our data
add to existing data suggesting that yaws is no longer a public health
problem in Fiji and that trachoma is not likely to be one of the major
causes of blindness in Fiji. Given the mixed ﬁndings of trachoma sur-
veys conducted in Fiji early impact assessments should be conducted
to guide Ministry of Health trachoma elimination activities.
Supplementary data
Supplementary data are available at Transactions online (http://
trstmh.oxfordjournals.org/).
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Abstract
Background
The WHO definition of trachomatous trichiasis (TT) is “at least one eyelash touching the
globe, or evidence of recent epilation of in-turned eyelashes”, reflecting the fact that epilation
is used as a self-management tool for TT. In Fiji’s Western Division, a high TT prevalence
(8.7% in those aged 15 years) was reported in a 2012 survey, yet a 2013 survey found no
TT and Fijian ophthalmologists rarely see TT cases. Local anecdote suggests that eyelash
epilation is a common behaviour, even in the absence of trichiasis. Epilators may have been
identified as TT cases in previous surveys.
Methods
We used a preliminary focus group to design an interview questionnaire, and subsequently
conducted a population-based prevalence survey to estimate the prevalence of epilation in
the absence of trichiasis, and factors associated with this behaviour, in the Western Division
of Fiji.
Results
We sampled 695 individuals aged 15 years from a total of 457 households in 23 villages.
125 participants (18%) reported epilating their eyelashes at least once within the past year.
Photographs were obtained of the eyes of 121/125 (97%) individuals who epilated, and sub-
sequent analysis by an experienced trachoma grader found no cases of trachomatous con-
junctival scarring or trichiasis. The age- and sex- adjusted prevalence of epilation in those
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aged 15 years was 8.6% (95% CI 5.7–11.3%). iTaukei ethnicity, female gender, and a
higher frequency of drinking kava root were independently associated with epilation.
Conclusion
Epilation occurs in this population in the absence of trichiasis, with sufficient frequency to
have markedly inflated previous estimates of local TT prevalence. Individuals with epilated
eyelashes should be confirmed as having epilated in-turned eyelashes in an eye with scar-
ring of the conjunctiva before being counted as cases of TT.
Author Summary
Trachoma, caused by infection with ocular strains of Chlamydia trachomatis, represents a
major public health issue, and is targeted for global elimination as a public health problem
by the year 2020. Until recently, data on trachoma in the Pacific Island states have been
sparse, with marked variability in the findings of surveys. The most recent studies in Fiji’s
Western Division were conflicted in their estimates of the prevalence of the advanced,
blinding, stage of the disease known as trachomatous trichiasis or “TT”. TT results from
repeated bouts of infection and resolution, leading to scarring of the eyelid tissue, which
causes in-turning of the eyelashes in some individuals so that they grow to touch the globe
of the eye. In populations without ready access to healthcare services, individuals may try
to self-manage TT by epilating their eyelashes, so that the classical trichiasis sign of contact
between eyelashes and eyeball is not seen in surveys. Therefore, the World Health Organi-
zation (WHO) definition of TT includes “evidence of recent epilation of in-turned eye-
lashes”. In the Western Division of Fiji, we carried out a population-based prevalence
survey to estimate the prevalence of this behaviour, and to examine associated risk factors.
The estimated population prevalence of epilation was 8.6% of those aged 15 years, con-
sistent with previously reported estimates of TT in this population, and, importantly, was
not associated with any other evidence of advanced trachoma. These data suggest that eye-
lash epilation is common here, and could inflate estimates of TT wherever such a custom
is common. In trachoma surveys, trachomatous scarring should be confirmed to be pres-
ent when reporting the presence of TT.
Introduction
Trachoma is the leading infectious cause of blindness globally, responsible for the irreversible
loss of vision in 1.9 million people.[1] It is caused by repeated bouts of conjunctival Chlamydia
trachomatis infection and resolution during childhood, resulting in the gradual accumulation
of trachomatous conjunctival scarring (TS). Scarring may progress to distortion of the eyelid
and in-turning of the eyelashes to the point that they touch the eyeball (trachomatous trichia-
sis, TT). Abrasion of the cornea can lead to opacity and blindness[2].
There is international commitment to the global elimination of trachoma as a public health
problem by 2020, defined as a reduction in the prevalence of TT unknown to the health system
in adults aged 15 years to<0.2%, and a reduction in the prevalence of the active trachoma
sign trachomatous inflammation—follicular in 1–9 year-olds to<5% [3], by means of the
SAFE strategy[4]: Surgery for TT, Antibiotics to clear infection, Facial cleanliness and
Population-Based Prevalence Survey of Eyelash Epilation in Fiji
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Environmental improvement to reduce transmission[5]. Accurate estimates of the prevalence
of TT are crucial for intervention planning and monitoring progress towards elimination.
TT is an irritating, painful condition that causes significant morbidity to affected individu-
als.[6,7] Those afflicted may find relief by epilation, which is a traditional treatment for TT in
some settings. Epilation can lead to reasonable outcomes where surgery is unavailable, delayed
or refused, particularly if caregivers are trained and equipped to do it well[8,9]. To acknowl-
edge that this practice occurs and that if not recognised can obscure the presence of TT, the
definition of TT in the WHO simplified trachoma grading system is “at least one eyelash rubs
on the eyeball, or evidence of recent removal of in-turned eyelashes”[10].
The extent to which eyelash epilation in the absence of trichiasis can affect TT estimates in
trachoma surveys is previously unstudied. Due to the low TT prevalence threshold required to
declare elimination of trachoma, significant sources of false-positive TT diagnoses need to be
identified. A small number of false positive TT cases recorded by survey teams, when extrapo-
lated to population-level estimates, could lead to the unnecessary training of many trichiasis
surgeons. This would be an unnecessary expense and needlessly divert trained healthcare per-
sonnel from their regular duties, in places where healthcare staff in general are often in short
supply.
Fiji is an archipelago of over 300 islands in the South Pacific, divided geographically into
four administrative divisions: Central, Northern, Eastern andWestern, with a combined popu-
lation of approximately 837,300 people.[11] Recent surveys have indicated that trachoma is
endemic in Fiji, although prevalence estimates of TT have varied widely. A trachoma rapid
assessment in 2007 found 59/313 (19%) of adults over the age of 40 years living in suspected
high-risk areas to have evidence of TS, but did not find any cases of TT[12]. A population-
based prevalence survey conducted in 2012 identified almost 150 people with TT, and esti-
mated the population prevalence in the Western Division to be 8.7%, among the highest in the
world[13]. In response to these results, a second population-based prevalence survey, sup-
ported by the Global Trachoma Mapping Project, was carried out in Fiji’s Western Division in
2013 in order to re-estimate the prevalence of signs of trachoma and of conjunctival C. tracho-
matis infection. It found no cases of trichiasis in a study population of 2306 people in 31 com-
munities: an estimated prevalence of trichiasis of 0%[14]. During that study, we heard local
anecdotes that suggested some iTaukei Fijians may practice epilation in the absence of TT
symptoms, as a sociocultural behaviour. These individuals might be incorrectly graded as hav-
ing TT: an individual cannot truly have trichiasis if the epilated eyelashes are not in-turned.
This could have major implications for trichiasis estimates and surgery planning in suspected
trachoma-endemic populations in which such behaviour is common.
We sought to understand the motivations for and significance of eyelash epilation in West-
ern Division by first convening a focus group of individuals who reported regularly practising
this behaviour. Using their responses to design a questionnaire, we conducted a population-
based prevalence survey to estimate the prevalence of epilation, and factors associated with it,
in the Western Division of Fiji.
Methods
Focus group discussion
The initial focus group discussion was conducted in 2013 alongside a population-based tra-
choma prevalence survey[14]. We worked in one iTaukei Fijian village in which adults were
known to epilate, and following consultation with the village chief, identified adults who had
epilated at least every 3 months for at least 1 year, using a snowball sampling approach[15].
Informed written consent was obtained from each participant. A focus group discussion was
Population-Based Prevalence Survey of Eyelash Epilation in Fiji
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convened and open questions were used to draw out each individual’s perceptions of factors
associated with epilating behaviour. Each participant’s eyes were examined for clinical signs of
trachoma by a Global Trachoma Mapping Project-certified grader[16] according to the WHO
simplified trachoma grading scheme[10], with photographs of the upper eyelid in primary
position, and of the conjunctiva taken to allow later independent review.
The focus group moderator used a list of questions (S1 Appendix) to guide discussion
about existing knowledge of trichiasis and epilation, and the causes and natural history of com-
mon local eye complaints. A Fijian eyecare nurse assisted with the discussion to clarify cultural
nuances, and to provide translation if needed. Participants were encouraged to express them-
selves in the language in which they were most comfortable. The discussion was audiotaped
and transcribed as soon as possible after the event, with input from a Fijian translator where
necessary.
Questionnaire development
The transcript was analysed independently by two researchers (CM & RB) using conventional
content analysis, with the coding unit as an idea or phrase within a sentence, and each unit
classified into constituent themes. From the themes derived, we developed a questionnaire for
the population-level survey. Variables assessed included basic demographics, kava drinking
habits, ophthalmic history, details of eyelash epilation, and symptoms or factors which influ-
enced the decision to epilate (S2 Appendix). The questionnaire was designed for use with the
Open-Data-Kit Collect (https://opendatakit.org) survey data collection platform for Android
smartphones.[17,18]
Prevalence survey study design
The epilation prevalence survey was conducted in 2015. A cross-sectional cluster random sam-
pling methodology was employed to select individuals aged 15 years in the Western Division
of Fiji, with villages or settlements used as the primary sampling unit (cluster) and the house-
hold used as the secondary sampling unit. Clusters were selected randomly from a list of all
non-urban communities in the Western Division using a probability proportional to size
methodology. Rural communities in Fiji commonly have one majority ethnicity, and the orga-
nisational structures between ethnic groups are distinct and easily identifiable.
Assuming a design effect of 2, we estimated 768 adults over the age of 15 years would be
needed to have 95% confidence of detecting a community prevalence of eyelash epilation in
adults of 10% with a precision of +/- 3%. Based on the number of available adults per house-
hold in previous surveys and assuming 30 households would be surveyed per day, we estimated
the required sample size would be achieved from 26 clusters.
Sampling and examination
In selected clusters, households were randomly selected from a list created on the day of survey
in collaboration with local headmen, village chiefs, or healthcare workers. Following consent
from the head of household, all those aged 15 years resident in selected households were
invited to participate. Consenting participants were interviewed individually in their house-
holds. Questionnaire responses were recorded electronically in the smartphone application.
Those who reported epilating their eyelashes at least once within the past year were invited for
ocular examination and photographs of the upper eyelid in primary position, and of the con-
junctiva. Consenting participants’ eyes were examined and graded using the WHO simplified
trachoma grading system by field workers trained in trachoma grading.[10] Photographs were
Population-Based Prevalence Survey of Eyelash Epilation in Fiji
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collected according to a standardised protocol[19] using a Nikon D60 SLR camera with spe-
cialised macro lens to allow retrospective grading of the clinical findings.
Ethical clearance and consent
Ethical approval was obtained from the research ethics committees at the London School of
Hygiene & Tropical Medicine (reference numbers 012–354 & 9621) and the Fijian Ministry of
Health and Medical Services. Local health workers were contacted in advance of the survey to
allow community sensitisation. Survey teams engaged in sevu-sevu (a traditional gift of kava
roots) with village leaders where appropriate. Written informed consent was obtained from all
participants, with a thumbprint considered acceptable in those unable to provide a signature.
Information sheets and consent forms were provided in English and Fijian language, and the
local nurse provided translation where needed. Participants were advised that they could with-
draw from the survey at any time without adverse consequence to them. A parent or guardian
provided informed consent and was always present for those aged 15–17 years as well as indi-
viduals with mental or physical disabilities. Any individuals found to have ocular pathologies
were referred to the nearest eyecare centre using a standard referral form. All data were anon-
ymised and stored on a secure cloud-based server.
Data analysis
Photographs were independently graded by two experienced trachoma graders masked to the
clinical assessments. Prevalence estimates were adjusted for age and sex using the 2007 census
of Fiji.[11] Confidence intervals were calculated by bootstrapping adjusted cluster-level esti-
mates. A two-level random-effects logistic regression analysis was performed to create a causal
risk factor model, against the binary outcome of the presence or absence of the behaviour of
eyelash epilation at individual level, accounting for clustering at household- and cluster-level.
Variables were assessed for collinearity by tabulation and evaluation with a Mantel-Haenszel
Chi2 test. Variables statistically significant at the p = 0.10 level (Wald’s test) on univariable
analysis were considered for the multivariable model. Variables in the multivariable model
were assessed by stepwise inclusion, with factors retained in the model if they reached signifi-
cance at the p<0.05 level (Likelihood ratio test). Data were analysed using Stata version 13.1
(StataCorp, College Station, TX, USA).
Results
Focus group discussion
The focus group was carried out in October 2013. Focus group participants were 6 iTaukei
Fijians inhabiting one village in the southern part of the Western Division of Fiji. The group
was composed of 2 male construction labourers and 4 female housewives with a median age of
42 years [range 20–53 years]. The village where the focus group occurred was considered by
residents to be of wholly iTaukei Fijian ethnicity. No participants were found to have any sign
of trachoma on clinical examination.
Transcript analysis
The points discussed during the session fell into 4 themes: motivation for epilation, perceived
predispositions to eye symptoms, the Fijian eyecare culture, and a description of the epilation
process. The themes and categories derived from the data are shown in Fig 1.
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Several themes were identified as perceived motivations for eyelash epilation. In each case,
transcript extracts have been provided to support the extracted theme. The most commonly
cited symptom that could be relieved by epilation was itchiness.
• “When it’s itchy, I’ll start pulling the hair out”.
The group felt that eyelashes targeted for epilation were abnormal, being short and sharp
and able to be removed painlessly.
• “the eyelashes that we pull out, they are different from the normal one.”
• “they are prickly. It’s only seen from pigs, swines, they have straight, short, sharp eyelashes”.
The group described a traditional method of “threading” using fibres from coconut husks,
the technique for which was demonstrated during the discussion.
• “They use a coconut husk like that (demonstrates)”
• “And they don’t use the pluckers (tweezers)”
Occasionally people would take out large numbers of eyelashes at one time:
• “I pulled out about 120 from my eyes, both of them, with the small ones. Only that was the
first time I did that”
Some participants felt that epilation was a habit, but others felt it was more a routine part of
their culture.
• “We check our eyes after two, three months. . ., then when you start with it, then it does
become a habit”
• “it’s a habit, once you start you can’t stop so you try to get it out every time”
Fig 1. Categories and themes derived from the transcript of the focus group of epilating individuals, Western Division, Fiji, 2013.
doi:10.1371/journal.pntd.0005277.g001
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The participants described good access to and engagement with healthcare services through
pharmacists or hospitals when deemed appropriate.
• “we’re educated now, we’re trying to go to the hospitals. Before they did not go to the
hospitals.”
Participants described eyecare home remedies and long-held practices
• “actually that was our old people that has been sent from this generation to that generation
downwards. It has been, from that time till now we do that for pain relief”
• “In some villages we Fijians, we use herbs. If someone has an eye problem or so he gets these
and then we just drop them into the eye and then off they go”.
Participants believed epilation-inducing symptoms could be precipitated by occupational
exposures, such as sunlight and dust.
• “(it can be brought on by) not using safety goggles and working out in the hot sun, and then
out on the roadside”.
Some felt that symptoms were associated with the iTaukei cultural practice of drinking
kava, as well as the long nights associated with its consumption
• “one thing is kava, drinking kava, you have more time drinking of kava and less time
sleeping.”
Prevalence survey
The population-based survey was carried out from July-September 2015. 695 participants aged
 15 years from 457 households in 23 clusters consented to participate. Three clusters could
not be reached due to logistical issues at the time of survey. 16 clusters were considered to be
of iTaukei ethnicity, 3 clusters were considered Indo-Fijian ethnicity, and 4 clusters did not
have a clear majority ethnic group. 512 of 695 (74%) participants were female. 437 (63%) par-
ticipants were ethnic iTaukei and 235 (34%) participants were ethnic Indo-Fijian. The median
age of study participants was 43 years (IQR 30–56; total range 15–88).
125 (18%) of the 695 individuals interviewed reported epilating their eyelashes at least once
within the past year. The overall sex- and age-adjusted prevalence estimate of epilation behav-
iour in those aged 15 years in the Western Division was 8.6% (95% CI 5.7–11.3%).
Of the 125 individuals reporting epilation, 124 (99%) consented to examination and con-
junctival photography. In 4 of 124 (3%) consenting participants, one or both eyelids were
unable to be everted due to discomfort. On examination, no cases of trichiasis were identified,
but one suspected case of TS was identified. On subsequent analysis of conjunctival photo-
graphs by two independent trachoma graders, no cases of trichiasis or definite TS were identi-
fied, with the one clinically suspected TS case thought to have (at best) equivocal evidence of
conjunctival scar (Fig 2). Therefore, either none or only one of those who epilated had any evi-
dence of cicatricial trachoma (TS or TT).
Description of epilation habits
Data on the 125 epilators are shown in Table 1. The most commonly reported reason for epi-
lating was eye itchiness (111/ 125 epilators, 89%). 80 (64%) reported that they removed>10
eyelashes each time they epilated, and 80 (64%) reported that they epilated on average every
1–3 months. Front of eye and everted lid photographs from epilators with varying frequencies
of epilation behaviour are shown in Fig 3.
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Risk factor analysis
Table 2 shows the univariable analysis of each potential risk factor against the outcome of eye-
lash epilation behaviour. Responses relating to a history of watery eye or eye discharge in the
previous week were omitted from analyses because of translation difficulties during the survey.
Multivariable model
Results of the two-level multivariable model are shown in Table 3. In the full model, being a
regular epilator was associated with being iTaukei (rather than any other ethnicity) (OR 6.0
95%CI 2.6–13.9), and female gender (OR 4.1 95%CI 2.0–8.6). In addition, those who epilated
had a higher odds of reporting being a kava drinker (OR 1.7 95%CI 1.1–2.7).
When the reported frequency of kava drinking was considered in the full model, a higher
frequency was independently associated with increased odds of being a regular epilator, with
those reporting drinking kava daily having odds 4.9 times higher than those who reported
drinking kava less than monthly or not at all (OR 4.9, 95%CI 1.6–15.2).
Despite being significant on univariable analysis, age was not associated with regular epila-
tion in the final model. Of note, the effect of age was markedly decreased when the frequency
of kava drinking was included in the model, suggesting that this was in part explained by an
Fig 2. Conjunctival photograph of the individual felt to demonstrate equivocal evidence of conjunctival scar, Western Division, Fiji, 2015.
doi:10.1371/journal.pntd.0005277.g002
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increased frequency of kava drinking in younger participants. Eye itchiness in the preceding
week was strongly associated with being an epilator on univariable analysis (OR 4.5 95%CI
2.8–7.1), but was not included in the final model as this was collinear with kava drinking.
The effect of the frequency of kava drinking on epilation was not confounded by ethnicity,
and there was no evidence of interaction between ethnicity and kava drinking frequency on
epilation (Likelihood Ratio Test, p = 0.44).
Discussion
We have documented the presence of a common behaviour in Fiji that has not previously been
described in the literature. Eyelash epilation in the presence of the distorted eyelid morphology
associated with cicatricial trichiasis is a frequent finding in trachoma-endemic populations
[9,20–22]. By contrast, individuals in both phases of this study carried out regular epilation in
an area where little, if any, trichiasis is found. According to the WHO simplified trachoma
grading system, evidence of recent removal of in-turned lashes should be graded as TT. How-
ever, it is difficult to provide guidance on how a grader should determine whether an already-
epilated lash was misdirected while it was still in situ. Additionally, in the simplified grading
scheme, the conjunctiva does not need to be examined to assign a grade of TT. According to
the current system, then, individuals who epilate in-turned eyelashes would be correctly
graded as having TT even if they have trichiasis for reasons unrelated to trachoma. It is possi-
ble, therefore, that this local practice of eyelash epilation in the absence of TT (as demonstrated
by our 2013 prevalence survey data)[14] had a significant impact on the 2012 estimate of TT
prevalence inWestern Division. Our adjusted prevalence estimate of regular epilation inWest-
ern Division (8.6% of those aged 15 years) is very similar to the 2012 TT prevalence estimate
(8.7%) in the same population2. This may account for the apparent discrepancy between TT
prevalence estimates (8.7% in 2012; 0% in 2013) and the lack of people presenting locally for
Table 1. Characteristics of eyelash epilation among 125 epilators, Western Division, Fiji, 2015.
Description of epilation n(%)a
Number of lashes removed
Most or all 3(2.4)
!10 80(64.0)
2–10 40(32.0)
1 2(1.6)
Frequency of epilation
At least weekly 4(3.2)
At least monthly 16(12.8)
Every 1–3 months 80(64.0)
Less than every 3 months 25(20.0)
Median age at first epilation (years) 29(IQR 20–36)
Reasons for epilating
Itchiness 111(88.8)
Feeling of dust 76(60.8)
Habit 54(3.2)
Abnormal eyelash 37(29.6)
Cosmetic reasons 4(3.2)
Tradition 0(0.0)
a Total number of self-reported eyelash epilators = 125
doi:10.1371/journal.pntd.0005277.t001
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TT surgery. Two individuals with TT reportedly presented to surgical outreach clinics in Fiji
between 2011 and 2013, neither of whom received corrective surgery[23].
The origin of the epilation behaviour in this population is unclear, though our data help to
generate hypotheses and exclude some potential explanations. The most commonly described
symptom motivating epilation was itchiness, whereas trichiasis is more commonly associated
with painful, watery or purulent eyes, or blepharospasm[6]. Neither the natural history nor the
examination findings in our subjects were consistent with other ocular pathologies that can
lead to trichiasis, such as involutional changes linked to senescence, marginal entropion from
chronic inflammation due to blepharitis or meibomian gland disease, or distichiasis, when an
extra row of maldirected eyelashes is present[24]. These are all conditions that may prompt
individuals to epilate, but are considered rare at population level. A psychological cause (such
Fig 3. Front-of-eye and conjunctival photographs of individuals who removed (Bottom) 2–10 eyelashes, (Middle)
!10 eyelashes (with pterygium), or (Top) most or all of the eyelashes; Western Division, Fiji, 2015.
doi:10.1371/journal.pntd.0005277.g003
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as the impulse control disorder trichotillomania, whereby the individual cannot control urges
to pull out their own hair) was inconsistent with the descriptions given by the focus group.
Drinking of kava, and particularly drinking kava often, was a strong independent risk factor
for regular epilation in our population. Kava (Piper methysticum) is a perennial plant that can
be used to prepare a non-alcoholic drink by mixing the ground root and stem bases with water
Table 2. Univariable multi-level random effects logistic regression model for associations of eyelash epilation, Western Division, Fiji, 2015.
Variable Total (%) Number of epilators (%) Odds Ratio 95% Confidence Interval p-valuea
Ethnicity Indo-Fijian 235 (33.8) 7 (5.6) 1 - -
iTaukei 437 (62.9) 117 (93.6) 10.7 4.6–25.1 0.001
Otherb 23 (3.3) 1 (0.8) 1.8 0.2–15.9 0.615
Gender Male 183 (26.3) 14 (11.2) 1 - -
Female 512 (73.7) 111 (88.8) 2.9 1.6–5.3 0.001
Age (years) 15–24 93 (13.4) 22 (17.6) 3.4 1.7–7.1 0.042
25–34 154 (22.2) 33 (26.4) 2.5 1.3–4.8
35–44 118 (17.0) 23 (18.4) 2.0 1.0–4.1
45–54 136 (19.6) 24 (19.2) 2.0 1.0–4.0
55+ 194 (28.0) 23 (18.4) 1 -
Frequency of kava drinking Daily 38(5.5) 8(6.4) 2.1 0.8–5.2 0.0608
At least weekly 137 (19.7) 33(26.4) 1.8 1.0–3.0
More than monthly but less than weekly 82 (11.8) 22 (17.6) 1.8 0.9–3.3
Less than monthly 39 (5.6) 6 (4.8) 0.7 0.3–1.8
Never 399(57.4) 56(44.8) 1
Eye itchiness in the previous week No 406 (58.4) 34 (27.2) 1 - -
Yes 289 (41.6) 91 (72.8) 4.5 2.8–7.1 0.001
Eye redness in the previous week No 492 (70.8) 72 (57.6) 1 - -
Yes 203 (29.2) 53 (42.4) 1.7 1.1–2.7 0.015
Past ophthalmic history None 611(87.9) 120(96.0) 1 0.6737
Blind 2(0.3) 0(0.0) -
Current Cataract 12(1.7) 3(2.4) 1.2 0.3–4.9
Previous cataract surgery 4(0.6) 0(0.0) -
Treated for active trachoma 2(0.3) 1(0.8) 2.4 0.1–38.7
Traumatic ocular injury 4(0.6) 1(0.8) 2.0 0.2–23.5
Total 695 125 - - -
a Wald’s test
b European, Chinese, Rotuman, Other Pacific islanders
doi:10.1371/journal.pntd.0005277.t002
Table 3. Multivariable multi-level random effects logistic regression model for associations of eyelash epilation, Western Division, Fiji, 2015.
Variable Adjusted Odds Ratio 95% Confidence interval p-valuea
Female sex 4.1 1.9–8.0 0.0001
iTaukei ethnicity b 6 3.0–18.6 0.0001
Kava drinking frequency
Daily 4.5 1.6–14.6 0.0096
At least weekly 1.9 1.1–3.5
At least monthly 2.2 1.0–3.6
Less than monthly, or never 1 -
a Likelihood ratio test
b Compared to Indo-Fijian, European, Chinese, Rotuman, Other Pacific islanders
doi:10.1371/journal.pntd.0005277.t003
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[25]. Kava has been used in South Pacific communities for centuries, for medicinal, social and
cultural purposes[26]. The active ingredients are kavalactones, which are associated with eye
itchiness as a side effect. Participants in the focus group felt that consumption directly precipi-
tated eye symptoms; others felt symptoms could be brought on by sleep deprivation associated
with its use. In a randomised controlled trial in Tonga, kava drinkers were reported to have
“red, irritated eyes and increased photosensitivity during periods of heavy drinking”[27].
It seems likely that kava may produce eye symptoms, but the potential mechanism for relief
through epilation is unclear. It is possible that it could be a form of distraction, either psycho-
logically, or physically through the pain commonly associated with epilation. Importantly,
although drinking kava was strongly associated with epilation, 56 (45%) of the 125 epilators
reported never drinking kava. This supports the idea that in Fijian custom a variety of eye
symptoms might be considered to be amenable to epilation, with itchiness from kava drinking
being just one. It is possible that epilation in this context could also represent a cultural prac-
tice reflective of a time when trichiasis was more common and that this persisted even after tri-
chiasis became rare.
As further evidence of a cultural determinant of this behaviour, in the full model, we found
that iTaukei individuals had 6.0 times greater odds of being an epilator than those of any other
ethnicity. The major ethnic groups in Fiji are iTaukei and Indo-Fijian—both with distinct cul-
tures, practices, beliefs and languages. iTaukei are predominantly Christian and speak an
indigenous language, whereas Indo-Fijians are mainly Hindu or Muslim and speak a local var-
iant of Hindi. The overall population of Fiji comprises 56.8% iTaukei and 37.5% Indo-Fijian,
with the remainder being a mixture of European, Chinese, Rotuman and other Pacific Island-
ers.[11]
Although its origins are elusive, significant differences are seen between the epilation
behaviour described here, and the anticipated behaviour if epilation was related to trichiasis.
Both the number of eyelashes removed and the frequency of epilation found in this population
are noticeably different from those normally reported in the context of TT. A study in Ethio-
pia, for example, found that among individuals with trichiasis who self-managed symptoms by
epilating, there was a median of 2 eyelashes touching the eye (interquartile range 1–5),[9]
whereas in our population, the majority of epilators (66%) removed more than 10 eyelashes
each time. In addition, the same Ethiopian study found that 96% epilated at least once per
month, with 51% epilating at least once per week,[9] consistent with the need to relieve symp-
toms from eyelash regrowth, whereas in Fiji we found only 16% of epilators epilated at least
once per month, with only 3% epilating at least once per week.
As is commonly found in household surveys carried out during the day, we have an under-
representation of males in the survey. As only those present at the household at the time of sur-
vey were enumerated (rather than all household inhabitants whether present or not), it is not
possible to determine the true extent to which men were under-represented in the households
sampled. It is possible that, given that both survey field researchers were female, there might
have been higher uptake from female community members. This could have potentially been
addressed with a stronger approach to community sensitisation in advance of the surveys. Our
focus group discussion took place in an iTaukei village because when it was conducted we had
not heard that epilation was also practised by other ethnic groups; it is possible that this influ-
enced the choice of possible risk factors assessed at population level. A further potential weak-
ness of our work is the inherent difficulty in standardising the diagnosis of TS, which was not a
feature of the training and standardisation of graders carried out as part of the Global Tra-
choma Mapping Project[16]. We tried to compensate for this last weakness by taking conjunc-
tival photographs and having the images reviewed by highly experienced trachoma researchers
—though even here, one image (Fig 2) was controversial.
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In this study we have highlighted an epilation behaviour that could significantly bias TT
prevalence estimates. We conclude that epilation in the absence of trichiasis has the potential
to impact programme planning for trachoma elimination in countries where this practice is
common. Further studies in Pacific populations where kava is consumed should be under-
taken to see whether the relationship with kava drinking seen in our study is true in other set-
tings. Given the difficulties inherent in determining whether epilated eyelashes were in-
turned, consideration should be given in future surveys to require the presence of TS in epi-
lated eyelids in order to diagnose TT.
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Forms were prepared in .xls format and converted to .xml ODK readable format at 1 
http://opendatakit.org/xiframe.  2 
 3 
Part Question Answer  Format 
1 Start time   
2 Enter the initials of the person entering this data Initials Free text 
3 Are you satisfied the person is informed of the 
purpose of the study and takes part willingly? 
1 Yes 
0 No 
Select one 
4 Please select the island group you are working on. 1 Santa Cruz 
2 Utupua 
3 Vanikoro 
4 Bellona 
5 Other 
Select one 
5 If other, please enter name Island name Free text 
6 Please select the cluster you are surveying. 1 Malo 
2 Nonia 
3 Matu 
4 No’oka 
5 Gaito 
6 Nembao 
7 Matembo 
8 Tanibili 
9 Lale 
10 Lavaka 
11 Buma 
12 Emua 
13 Bellona 
14 Other 
Select one 
7 If other, please enter name Cluster name Free text 
8 Please enter the household number Household number Numeric 
9 Please enter the participants initials Participant initials Free text 
10 Please enter the participants age in full years Age Numeric 
11 Please enter the sex of the participant  1 Male 
2 Female 
Select one 
12 Please enter the participant ID Numeric SB000-000 
13 Please re-enter the participant ID Numeric SB000-000, must match [12] 
14 Is there evidence of TT in the right eye? 0 No 
1 Yes 
2 Unable to examine 
Select one 
15 Is there evidence of TF in the right eye? 0 No 
1 Yes 
2 Unable to examine 
Select one 
16 Is there evidence of TI in the right eye? 0 No 
1 Yes 
2 Unable to examine 
Select one 
17 Was a swab collected? 0 No 
1 Yes 
Select one 
18 Enter the first frame ID Numeric DSC_0000 
19 Enter the second frame ID Numeric DSC_0000 
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20 Enter the third frame ID Numeric DSC_0000 
21 Is there evidence of TT in the left eye? 0 No 
1 Yes 
2 Unable to examine 
Select one 
22 Is there evidence of TF in the left eye? 0 No 
1 Yes 
2 Unable to examine 
Select one 
23 Is there evidence of TI in the left eye? 0 No 
1 Yes 
2 Unable to examine 
Select one 
24 Was a dried blood spot collected? 0 No 
1 Yes 
Select one 
25 Add any relevant notes Note Free text 
 1 
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Local,Principal,Investigator:,Oliver'Sokana,'Solomon'Island'Ministry'of'Health',
,
Consent,form,(v.14.01.15),
'
'
Participant'name:……………………………………………………………………'
'
'
Participant'age:……………………………………………………….................'
'
'
The'information'sheet'concerning'this'study'has'been'read'to'me,/,my,dependent,[CONSENTER,TO,
DELETE,AS,NECESSARY],'and'I'understand'what'will'be'expected'of'someone'taking'part'in'this'study.'
'
I'understand'that'an'individual'taking'part'in'this'study'may'withdraw'from'it'at'any'time'without'giving'a'
reason'and'that'this'will'not'affect'his/her'normal'care.'My'questions'concerning'this'study'have'been'
answered.'
'
! I'give'consent'for'the'above'to'take'part'in'this'study.'
'
! I'give'consent'for'blood'and'eye'samples'from'the'above'to'be'used'for'the'purposes'of'this'study'
'
! I'give'consent'for'photographs'of'the'above'to'be'used'for'the'purposes'of'this'study,'which'may'
involve'dissemination'to'relevant'external'parties'and'potential'publication'online.'
'
Signature/thumbprint:'
'
'
'
Date:…………………………………
' ' ' ' '
'
'
If'participant'is'under'the'age'of'18,'a'parent'or'guardian'should'sign'this'form:'
'
'
Name:……………………………………………………………………''''''''''''Relation:……………….……………………………………………'
,
#######################################################################################,
,
Witness:'I'have'read'this'form'and'the'information'form'to'the'above'person'and'am'sure'that'he/she'has'
understood'what'is'required'of'someone'enrolling'in'this'study.'
'
'
Signed:…..………………………………………………………………'''''''''''''''Date:…………………………………………………………….''
 
[Affix ID label here] 
[Sign/print here] 
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!
Information!for!Participants!!
!
Solving!the!clinical!Enigma!of!trachoma!in!the!Pacific!Islands:!
Phase!2!!You!are!being!invited!to!take!part!in!a!research!study.!!Before!you!decide!it!is!important!for!you!to!understand!why! the! research! is!being!done!and!what! it!will! involve.! !Please! take! time! to! read! the! following! information!carefully!and!to!talk!to!others!about!the!study,!if!you!wish.!!Ask!us!if!there!is!anything!that!is!not!clear!or!if!you!would!like!more!information.!!Take!time!to!decide!whether!or!not!you!wish!to!take!part.!!
1.! What!is!the!purpose!of!the!study?!! After! a! survey! in! 2013,! we! have! found! large! amounts! of! a! disease! that! looks! like! trachoma,! an! eye!infection!that!could!cause!blindness,!but!very!little!infection!with!a!germ!called!Chlamydia)trachomatis,!which!causes!this!disease!in!other!parts!of!the!world.!!!In! this! survey,! we! would! like! to! use! a! different! method! of! detecting! this! germ,! to! make! sure! the!information! from! our! last! survey! is! correct.!We!would! also! like! to! take! photographs! so! experts! can!examine!whether!there!are!any!visible!signs!of!disease!that!may!lead!to!impaired!vision.!We!may!also!search! for!other!germs! that!may!be! causing! this!disease! in!an!attempt! to!work!out!whether! they!are!harmful!or!not.!!!It! is! important! to! determine!what! is! causing! the! disease! that! looks! like! trachoma! to! help! inform! the!Solomon!Island!Ministry!of!Health!on!the!most!appropriate!way!to!treat!this!disease.!!
2.! Why!have!I!been!chosen?!
) We!are!looking!for!people!of!any!age!above!1!year!who!live!in!specific!villages!in!Temotu,!Rennel!and!Bellona! where! our! previous! survey! took! place.! These! villages! were! selected! because! high! levels! of!trachomaJlike! disease! were! seen! here! during! the! past! survey.! In! these! villages,! we! will! select!households!at!random!and!everybody!in!those!households!will!be!offered!the!opportunity!to!take!part.!!!
3.! Do!I!have!to!take!part?!! It! is! entirely! up! to! you! to! decide! to! join! the! study.!We! will! describe! the! study! and! go! through! this!information!sheet.!If!you!agree!to!take!part,!we!will!then!ask!you!to!sign!a!consent!form.!You!are!free!to!withdraw!at!any!time,!without!giving!a!reason.!This!will!not!affect!the!standard!of!care!you!receive.!!
4.! What!will!happen!to!me!if!I!take!part?!
) If! you! decide! to! take! part,!we!will! ask! you! to! come! to! the! centre! of! the! village! along!with! the! other!members!of!your!household,!where!our! team!will!greet!you!and!answer!any!questions!you!may!have!before!the!start!of!the!procedure.!We!will!then:!! 1. Examine! your! eyes! in! the! normal! position! for! signs! of! trachomaJlike! disease,! and! take!photographs!for!our!records.!! 2. Turn!your!eyelid!over!and!examine! the!underside! for!signs!of! trachomaJlike!disease,!and! take!photographs!for!our!records.!!3. Take!a!swab!from!the!underside!of!your!eyelid.!
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!4. Make!a!pinJprick!in!the!top!of!your!finger,!which!will!bleed!a!little.!The!nurse!will!then!collect!a!few!drops!of!blood!on!filter!paper!! The! photographs,! blood! spots! and! swabs! will! be! transported! to! London,! UK,! where! they! will! by!experienced!doctors!and!scientists!for!evidence!of!infection!with!the!germ!Chlamydia)trachomatis)and!evidence!of!disease.!!
5.! What!do!I!have!to!do?!!If!you!decide!to!take!part,!the!examinations!listed!above!(finger!prick,!eyelid!turning,!photograph,!swab)!will!be!the!only!ones!needed!as!part!of!this!survey.!
)
6.! What!are!the!possible!disadvantages!and!risks!of!taking!part?!
) There! are! very! few! risks! to! taking! part! in! this! survey.! The! finger! pricks! and! swabs! can! be!uncomfortable.!We!have! tried! these!procedures!many! times! in! the! Solomon! Islands,! and!many!other!parts!of!the!world!such!as!Fiji,!Tanzania!and!The!Gambia,!and!no!serious!risks!have!emerged.!!
7.! What!are!the!possible!benefits!of!taking!part?!!The!study!will!not!help!you!immediately,!but!the!information!we!get!might!help!improve!the!treatment!of!people!with!trachoma!in!the!Solomon!Islands!and!around!the!world.!
!
8.! What!happens!when!the!research!study!stops?!
) After! the! research! study! stops,! the! findings! of! the! survey! will! be! published! in! an! easily! accessible!format.!We!may!store!the!blood!and!eye!samples!for!up!to!7!years!in!case!anyone!should!question!our!results.!!!Photographs!may!be! used! for! teaching! and! research!purposes,! and!may!be!published! in! open! access!format!meaning!they!may!become!available!on!the!internet.!However,!if!photographs!are!published,!we!would!ensure!that!the!photographs!would!not!be!easily!linkable!to!you!as!an!individual.!!
9.!!!! Will!my!taking!part!in!the!study!be!kept!confidential?!!!Yes.! All! information! collected! about! you! during! the! course! of! the! research! will! be! kept! strictly!confidential.!!!!If!you! join!the!study,!some!parts!of!your!medical!records!and!the!data!collected! for! the!study!may!be!looked!at!by!authorised!persons! from! the!London!School!of!Hygiene!&!Tropical!Medicine.! !They!may!also! be! looked! at! by! representatives! of! regulatory! authorities! and! by! authorised! people! from! the!Solomon!Islands!Ministry!of!Health!to!check!that!the!study!is!being!carried!out!correctly.!!All!will!have!a!duty!of!confidentiality!to!you!as!a!research!participant!and!nothing!that!could!reveal!your!identity!will!be!disclosed!outside!the!research!site.)! !
10.!!!! What!will!happen!if!I!don’t!want!to!carry!on!with!the!study?!! You!are!free!to!withdraw!from!the!study!at!any!time.!If!you!withdraw!from!the!study,!we!will!destroy!all!identifiable!samples,!but!we!will!need!to!use!the!data!collected!up!to!your!withdrawal.!
!
11.!!! What!will!happen!to!the!results!of!the!research!study?!
) The!results!of!the!study!will!be!published,!and!shared!with!healthcare!bodies!in!the!Solomon!Islands,!the!Western!Pacific!Region!and!the!wider!international!community!for!the!purposes!of!making!treatment!decisions!with!the!Ministry!of!Health.!!
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12.! Who!is!organising!and!funding!the!research?!!!! The!Fred!Hollows!Foundation!are!paying!for!the!study.!The!study!is!being!designed!and!conducted!as!collaboration! between! the! Solomon! Islands!Ministry! of! Health! and! the! London! School! of! Hygiene! &!Tropical!Medicine.!!
13.! Who!has!reviewed!the!study?!!!This!study!was!given!a!favourable!ethical!opinion!by!the!London!School!of!Hygiene!&!Tropical!Medicine!Research!Ethics!Committee!and!the!Solomon!Islands!Health!and!Research!Ethics!Committee.!
! !
14.!!! Contact!Details!
) Should!you!have!any!questions!or!worries!about!the!project,!please!feel!free!to!contact!any!one!of!the!study!investigators:!!Oliver!Sokana,!Solomon!Island!Ministry!of!Health!+677J769J1615!!osokana@moh.gov.sb!!Chrissy!h.!Roberts,!London!School!of!Hygiene!&!Tropical!Medicine!0044J207J927J2913!chrissy.roberts@lshtm.ac.uk!!Kelvin!Jack,!Kukum!Clinic!+677J750J0313!!Eric!Kalae,!Lata!Hospital!+677J745J5055!
!
A!copy!of!this!information!sheet!will!be!offered!to!the!leaders!of!each!village!and!household.!
!
Thank!you!for!taking!the!time!to!read!this!sheet.!!!
Field SOP  Solomon Island Phase II 	
Solomon Island Seroepidemiology Survey: 
Sample Collection Standard Operating Procedure 
 
Overview 
 
This survey aims to collect infection and clinical data from communities in the Solomon Islands 
previously found to be hyper-endemic for trachoma, but also to have a low prevalence of current 
infection with Chlamydia trachomatis. The survey aims to describe the prevalence of serological 
evidence of infection, of infection, and of clinical signs of disease following one round of mass drug 
administration in communities studied. 
 
All consenting residents over the age of 1 year in randomly selected households will be asked to 
provide the following: 
 
• Demographic information, including: 
o Location data (village and household location) 
o Name 
o Sex 
o Age (in years) 
• Simplified WHO trachoma grade 
• Photograph of the eyelid while the eye is in the primary gaze (if graded as TT) 
• Photograph of the upper corneal limbus 
• Photograph of the everted conjunctiva 
• Conjunctival swab x 2 
• Dried blood spot 
 
Adults over the age of 18 years will be asked for written consent before taking part. Written consent 
from a parent or guardian will be required for those under 18 years to take part. 
 
The following staff are expected to be required during the survey: 
 
Staff  
Ophthalmic Nurse (GTMP certified) 1 (OS) Honiara 
Nurse 1 (TBC) Lata 
Village guide  1 (LS) Lata 
Sample manager 1 (RB) London 
Boat driver 1 (TBC) Lata 
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Equipment list 
 
Item Number Source 
Training 
Facilities 1 (suggest provincial guest house) Lata 
Computer 1 London 
Swabs 100 London 
Filter papers 100 London 
Alcohol wipes 100 London 
Gloves 100 Honiara 
SLR camera 1 London 
Sharps bin 1 London 
Survey 
Boat 1 Lata 
40hp OBM 1 Lata 
Fuel 500L Lata 
Tarpaulin 2 Lata 
Crate 1 London 
Portable freezer 1 Honiara 
Dry bag 1 London 
Rain coats 5 London 
Plastic box for equipment 1 Honiara 
Laptop 1 London 
Paper replacement forms 500 London 
Consent forms 1500 (375 pages @ 4 per page) London 
Information sheets  50 (150 pages @ 3 pages per sheet) London 
Labels (swab, filter paper, form) 4500 (3 per participant) London 
Swabs  4000 (2 per participant) London 
Filter papers  2000 (1 per participant plus excess) London 
Lancets 2000 (1 per participant plus excess) London 
Alcohol wipes 2000 (1 per participant plus excess) London 
Sweets 2000 (1 per participant) London 
Desiccant sachets 3000 (1 per DBS plus shipping container) London 
Small Ziplock bags 2000 (1 per DBS plus excess) London 
Large Ziplock bags 20 (1 per cluster plus excess) London 
Drying mechanism 1 Honiara 
Tubes 2000 London 
Cryoboxes 20 London 
Eskie 1 London 
SLR Camera  1 London 
Pens 10 Honiara 
Ink pad  2 Honiara 
Receipt book 1 Honiara 
Spare camera battery 3 London 
Spare laptop battery 3 London 
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Phase I: 3 weeks before survey 
 
Step Task 
1 1.1 Arrange procurement of materials 
 1.2 Arrange local consignee and clearance 
 1.3 Arrange staff and equipment availability 
 1.4 Ship equipment and forms 
2 2.1 Book flights London to Lata for RB 
 2.2 Book flights Honiara to Lata for OS 
 
Phase II:  
Step Task 
1 1.1 Meet laboratory staff to arrange freezer storage in Honiara  
 1.2 Meet with Oliver to discuss logistics 
 1.3 Meet Willie at NRH to arrange shipping and logistics 
 1.4 Arrange procurement of tetracycline, gloves, chlorohexamide, wool, alcohol 
gel for blood spots  
 1.5 Arrange onward transit of materials, including freezer, to Santa Cruz 
 1.6 Arrange flights to Santa Cruz 
 
Phase III: 
Step Task 
1 1.1 Arrange safe transit and storage of equipment 
 1.2 Arrange storage space in laboratory 
 1.3 Meet with staff in Lata at Rotary Guest House 
 1.4 Arrange prior notice for all targeted communities 
 1.5 Arrange transport for as much of trip as possible – purchase fuel  
2 2.1 Training day am – discuss general purpose of study, discuss study sites, 
sample size, study requirements 
 2.2 Training day pm – discuss proposed methodology, get feedback about 
feasibility 
 2.3 Charge phones, charge camera batteries 
 2.4 Begin punching out blood spot cards 
3 3.1 Go to nearest cluster (?Matu) and perform first survey site under training 
conditions 
 3.2 Return samples to freezer 
 3.3 Discuss points for improvement 
 3.4 Keep punching out blood cards 
4 4.1 Proceed to first cluster 
 
Phase IV: 
Step Task 
1 1.1 Arrange meeting time and place for first survey cluster 
 1.2 Travel to first cluster. 
 1.3 Meet with village leaders and explain purpose of survey. Gain consent for 
village enrollment 
 1.4 Arrange central site for temporary clinic 
 1.5 Select clusters at random from full household list 
2 2.1 Village guide to approach first household, explain study and gain consent 
 2.2 Consenting participants to approach central site, bringing signed forms with 
them 
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3 3.1 Demographic data collected from participants. 
 3.2 Place ID labels on form (.1), swab tube (.2 and .3) and blood card (.4) 
 3.3 Record ID 
4 4.1 Grader to apply alcohol gel and then gloves 
 4.2 Take photograph of right upper corneal limbus 
 4.3 Examine for TT  
 4.4 Sample manager to prepare 2 x swab packets 
 4.5 Evert right eyelid  
 4.6 Take photograph 
 4.7 Grade TF, TI and TS 
 4.8 Grader collects first swab 
 4.9 First swab passed to sample manager to place in tube (.2) 
 4.10 Grader collects second swab 
 4.11 Second swab passed to sample manager to place in tube (.3) 
 4.12 Sample manager records right eye phenotype 
5 5.1 Sample manager records DSC photo ID 
6 6.1 Grader checks left eye for TT 
 6.2 Grader everts left eyelid 
 6.3 Grader examines left eyelid for TF, Ti and TS 
 6.4 Sample manager records phenotype 
 6.5 Grader removes and discards gloves 
7 7.1 Sample manager passes blood card to blood spot station 
 7.2 Nurse prepares by washing hands with alcohol gel 
 7.3 Nurse puts on gloves 
 7.4 Nurse wipes finger of participant 
 7.5 Nurse pricks finger 
 7.6 Nurse fills 6 extensions on blood card 
 7.7 Nurse places blood card on drying stand 
 7.8 Nurse provides participant with sweet 
 7.9 Nurse confirms blood card collected 
 
Phase V: 
Step Task 
1 1.1 Swabs immediately transferred to tubes, and stored in cryobox – separate 
boxes for swabs 1 and 2 
 1.2 Cryobox transferred to Esky to keep out of sun 
 1.3 Blood spots stored on pencils in polystyrene box 
 1.4 At the end of each sample collection day, the team should return to base clinic 
 1.5 Swabs to be transferred directly to the fridge [NB. If the fridge will not fit more 
than one set of swabs, swab 1 should take priority] 
 1.6 Blood spots to be further aired in the evening 
 1.7 Blood spots to be transferred to individual ziplock bags and refridgerated 
2 2.1 Team to sleep in clinic or related housing where possible 
 2.2 Following one week of sample collection, all swabs and blood spots to be 
returned to Lata for freezing. [NB. Ice packs should be used in transit where 
possible] 
 2.3 Upon return to Lata, first swabs transferred immediately to portable -80 
freezer. 
 2.4 Upon return to Lata blood spots to be transferred immediately to Lab freezer 
 2.5 Upon return to Lata, second swabs to be transferred to freezer if there is 
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space, to refridgerator if no space at -20, or under bench next to portable -80 if 
not. 
 2.6 Upon amalgamation of samples in Lata, samples to be returned to Honiara for 
storage directly in -20 freezer in NRH. 
 2.7 Samples to be collected from NRH for transit to London. 
 
  Swab SOP v.070916RB 	
Standard Operating Procedure: Conjunctival swabs 1 
 2 
v.070916 – Robert Butcher 3 
 4 
Introduction 5 
This protocol should be used for the collection of conjunctival swabs from people of any age for 6 
diagnosis of conjunctival infection with Chlamydia trachomatis. This protocol is taken from Solomon 7 
et al. (Solomon et al., 2003) and validated for use in ddPCR diagnostics by Roberts et al. (Roberts 8 
et al., 2013).  9 
 10 
Staff and Materials 11 
Nurse (for everting eyelid and specimen collection) 12 
Data manager (for data and swab collection, swab labeling and sample management) 13 
Swabs (1 box = 100 swabs) 14 
Polystyrene tubes (1 bag = 50 tubes) 15 
Labels (1 page = 17 labels) 16 
Cryobox (1 box = 100 places) 17 
Reward (Coconut biscuits, banana, small taiyo etc.) 18 
 19 
Standard Operating Procedure 20 
 21 
1. Ensure participant consents to take part – this should be them (participant 18+ years) or 22 
their guardian (participant <18 years) filling in a paper consent form and signing.  23 
 24 
2. Seat the participant in from of the grader. 25 
 26 
3. Grader wears gloves for examination. 27 
 28 
4. Grader everts and grades right eyelid. 29 
 30 
5. Data Manager records clinical data.  31 
 32 
6. Data manager prepares swab for Grader 33 
 34 
7. Grader takes swab, taking care not to touch the head to avoid contamination, and passes it 35 
three times across the everted conjunctiva. 36 
 37 
8. Data manager prepares swab collection tube by labeling with study ID.  38 
 39 
9. Data manager receives swab from grader and closes tube.  40 
 41 
10. Grader examines and records clinical presentation of left eye.  42 
 43 
11. Data manager places swab in cryobox. 44 
 45 
12. Cryobox should be transferred to refrigerator within 24 hours. Swabs can be stored at +4°C. 46 
After 1 week the swabs should be transferred to a freezer for storage at -20°C.  47 
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Droplet Digital PCR 
 
 
Chlamydia research programme 
 
 
Version History 
 
V.7.01 - 13th July, 2012  Chrissy h. Roberts 
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 Summary 
 
This protocol describes a method for detection and quantitation of Chlamydia trachomatis using the Bio-rad 
QX100 droplet digital PCR platform. The protocol was originally developed by Chrissy h. Roberts (Roberts et al., 
J. Clin. Micro. 2013) and Anna Last (Last et al., J. Clin. Micro. 2014), and subsequently updated based on 
ongoing optimisation. 
 
 
Molecular targets 
 
 
ENDOGENOUS CONTROL: Homo sapiens ribonuclease P/MRP 30kDa subunit (gi|13937783|gb|BC006991.1|) 
 
*Forward (Hs-RPP30-F)   5’ AGA TTT GGA CCT GCG AGC G 3’ 
*Reverse (Hs-RPP30-R)   5’ GAG CGG CTG TCT CCA CAA GT 3’ 
^Probe (Hs-RPP30_HEX_BHQ1)  5’ [HEX] TTC TGA CCT GAA GGC TCT GCG CG [BHQ1] 3’ 
 
 
Amplicon sequence, primer/probe binding sites: 
 
agatttggacctgcgagcgggttctgacctgaaggctctgcgcggacttgtggagacagccgctc 
*******************  ^^^^^^^^^^^^^^^^^^^^^^^ ******************** 
 
 
 
TARGET ONE: Chlamydia trachomatis cryptic plasmid ORF2 (pLGV440, X06707; SV 3; circular; genomic DNA; STD; 
PRO; 7500 BP.) 
 
*Forward (Ct-Plasmid-F)   5’ CAG CTT GTA GTC CTG CTT GAG AGA 3’ 
*Reverse (Ct-Plasmid-R)   5’ CAA GAG TAC ATC GGT CAA CGA AGA 3’ 
^Probe (Ct-plasmid-PROBE-QUENCHER) 5’ [PROBE] CCC CAC CAT TTT TCC GGA GCG A [QUENCHER] 3’ 
 
 
Amplicon sequence, primer/probe binding sites: 
 
cagcttgtagtcctgcttgagagaacgtgcgggcgatttgccttaaccccaccatttttccggagcgagttacgaagacaaaacctctt 
**********************                        ^^^^^^^^^^^^^^^^^^^^^^                 ****     
 
cgttgaccgatgtactcttg 
******************** 
 
 
TARGET TWO: Chlamydia trachomatis OmcB (serovar A). 
 
*Forward (Ct-OMCB-F)    5’ GAC ACC AAA GCG AAA GAC AAC AC 3’ 
*Reverse (Ct-OMCB-R)    5’ ACT CAT GAA CCG GAG CAA CCT 3’ 
^Probe (Ct-OMCB-PROBE-QUENCHER) 5’ [PROBE] CCA CAG CCA AAG AGA CTC CCG TAG ACC G [QUENCHER] 3’ 
 
 
Amplicon sequence, primer/probe binding sites: 
 
gacaccaaagcgaaagacaacacttctcataaaagcaaaaaagcaagaaaaaaccacagcaaagagactcccgtagaccgtaaagaggt 
***********************                              ^^^^^^^^^^^^^^^^^^^^^^^^^^^     **** 
tgctccggttcatgagt 
***************** 
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Materials and reagents 
 
Italics denote currently used suppliers. Approximate amounts required shown in brackets. As of September 2014, the total 
cost excluding DNA extraction was approximately GB£3.50 per well. 
 
Reagent          Catalogue number 
 
Bio-rad 
Bio-rad ddPCR supermix for probes (1.1 mL required per 96-well plate)     186-3027 
Bio-rad ddPCR Droplet Generator Cartridges and Gaskets (1 cartridge and 1 gasket per plate column) 186-4007  
Bio-rad ddPCR Droplet Generator Oil (7 mL per 96-well plate)     186-3005 
Bio-rad ddPCR Droplet Reader Oil (1 L per 6 plates)      186-3004 
 
Fisher Scientific 
Fisher Easy pierce foil seals (one per plate)       11979355 
Eppendorf twin.tec 96-well semi-skirted plate (92 samples plus 4 control wells per plate)   10464393 
Life Technologies MicroAmp clear adhesive film (one per plate)     10595025 
Fisher sterile 2.0 mL tube         11568322 
Fisher molecular biology-grade water        10505854 
Fisher Tris-EDTA (1X)         10021703 
 
Wolf Laboratories 
Sterile filter tips (1000 μL)         BT1250 
Sterile filter tips (200 μL)         BT200 
Sterile filter tips (20 μL)         BT20 
 
Sigma Aldrich 
Primers and Probes (as above)        N/A 
  
SOP 7.03 
 Droplet Digital PCR  
 
 4 
Preparation of primers and probes 
 
Primer and probe sequences taken from Last et al. J. Clin. Microbiol. (2014). 52(1): 324-327. 
 
ALL STOCK SOLUTIONS should be at 100 μM.  
 
Primer/probe volumes for smaller well numbers can be calculated using C1 x V1 = C2 x V2 
 
 
Diagnostic screen (C. trachomatis plasmid, H. sapiens RPP30) 
 
9 μM Human RPP30 and C. trachomatis plasmid primers  
2 μM Human RPP30 and C. trachomatis plasmid probes 
   
NOTE: THIS CAN BE SCALED FOR LARGER VOLUMES 
  
 To prepare 230 μL (enough for one 96-well plate plus 10 μL excess) 
 
     volume 
 100 μM Hs-RPP30-F  20.7 μL  
 100 μM Hs-RPP30-R  20.7 μL 
 100 μM Hs-RPP30-HEX-BHQ1 4.6 μL 
 100 μM Ct-Plasmid-F  20.7 μL 
 100 μM Ct-Plasmid-R  20.7 μL 
 100 μM Ct-Plasmid-FAM-BHQ1 4.6 μL 
 0.1X TE buffer (sterile/nuclease free) 138 μL 
                ______ 
    total 230 μL 
 
 
Quantitative assay (C. trachomatis OmcB, C. trachomatis plasmid) 
 
NOTE: THIS CAN BE SCALED FOR LARGER VOLUMES 
 
3 μM C. trachomatis plasmid and OmcB primers  
3 μM C. trachomatis plasmid and OmcB probes 
   
  
 To prepare 230 μL (enough for one 96-well plate plus 10 μL excess) 
 
     volume 
 100 μM Ct-OMCB-F  6.9 μL  
 100 μM Ct-OMCB-R  6.9 μL 
 100 μM Ct-OMCB-FAM-BHQ1 6.9 μL 
 100 μM Ct-Plasmid-F  6.9 μL 
 100 μM Ct-Plasmid-R  6.9 μL 
 100 μM Ct-Plasmid-HEX-BHQ1 6.9 μL 
 0.1X TE buffer (sterile/nuclease free) 188.6 μL 
                ______ 
    total 230 μL 
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PCR setup 
 
WORK IN A PCR CLEAN & DNA FREE ENVIRONMENT 
 
 
 
Each assay uses EITHER diagnostic OR quantitative primer/probe mixes.  
 
 
CRITICAL STEP: MIX AND INVERT THE SUPERMIX AND PCR MIXES EXTREMELY WELL, THEY ARE VISCOUS AND 
THE TESTS WILL FAIL IF YOU DON’T DO THIS PROPERLY. 
  
 
Composition per reaction 
     1X    
2X ddPCR supermix    11 μL    
Primer/probe supermix (10X each of six oligos) 2.2 μL 
Sample DNA    8.8 μL     
     ________ 
total  22 μL 
 
 
001 | To prepare sufficient ddPCR MASTERMIX to run one 96 well plate (100 reactions) 
 
In a 2 mL microcentrifuge tube, add the following: 
 
 
     100X    
2X ddPCR supermix    1100 µL    
Primer/probe mix (10X each of six oligos) 220 μL 
     ________ 
total  1320 μL 
 
 
 
 
 
 
MOVE TO DNA LOADING/PCR CLEAN AREA 
 
 
002 | To each well of a 96-well semi-skirted Eppendorf twin-tec plate (in retainer), aliquot 13.2 μL ddPCR mastermix. Use 
reverse pipetting to allow rapid distribution of viscous material.  
 
003 | Aliquot 8.8 μL of DNA from samples to each well of the plate. Wells 12E and 12F should be taken up by water 
samples as negative controls. Wells 12G and 12H should be taken up by known C. trachomatis and RPP30 positive 
samples (synthetic) as positive PCR controls. 
 
004 | Seal with microamp cover film (ensure close seal) and vortex gently (1000 rpm) to mix reagents for 30 seconds 
 
005 | Centrifugate at 1000 rcf for 1 minute to pool PCR mix at bottom of plate. 
 
006 | Proceed to droplet generation 
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Droplet generation 
 
TURN ON THE HEAT SEALER 
 
007 | Place a new, clean and Eppendorf twin-tec semi-skirted 96-well plate in a retainer 
 
008 | Carefully remove the microamp film, without disturbing the PCR mixes 
 
009 | Place a new droplet generation cartridge in the droplet cassette, the notch should face left (SEE FIGURE). Close the 
cassette by applying gentle pressure to the short edges. 
 
 
 
 
 
 
 
 
 
 
 
010 | Transfer 70 μL droplet generation oil to each oil well of the cartridge (red on figure, marked “oil” on the cassette”) 
 
011 | Transfer 20 μL of each PCR mixture from row 1 in to each sample well of the cartridge (green on figure, marked 
“sample” on the cassette). Take care to avoid introducing air by putting pipette tips to the lowest point where the wall of 
the vessel meets the base. Hold pipette at around 20 degree angle to wall, actuate slowly and raise tips from the base as 
the wells continue to fill 
 
012 | Attach a rubber gasket to the notched teeth on the cassette. Take care not to move the rubber across the wells as 
this could lead to cross-contamination. Ensure that the four teeth are properly engaged with the gasket as failure to do this 
will prevent a good seal forming. 
 
013 | Transfer the cassette to the droplet generation machine. Holding the cassette gently at the top and bottom, place on 
the magnetised platform. A green light will indicate proper engagement. 
 
014 | Activate droplet generation by pressing the button. 
 
015 | Prepare the next cassette. 
 
016 | When the first droplets are complete, exchange the first cassette for the second in the droplet generator. Reactivate 
the device. 
 
017 | Carefully aspirate 45-50 μL of droplets from the droplet wells. Wait for 10s for droplets to float to the top of the 
pipette tip, then carefully expel excess oil back into the cartridge, taking care not to disturb the droplet layer. Ensure that 
aspiration is performed slowly (around 10 s) as failure to do this will lead to droplet instability. 
 
018 | Carefully expel the remaining oil and droplets (blue on figure) to row 1 of the droplet plate. Ensure that expulsion is 
performed slowly (around 10 s) as failure to do this will lead to droplet instability. 
 
019 | Use a short length of lab tape to temporarily seal the wells of row 1. 
 
020 | Prepare the droplet cassette for row 3, then transfer the droplets from row 2. Continue this process until the plate is 
completed. 
 
021 | Remove all lab tape and replace with an easy-pierce heat seal, ensuring that it is the right way up. 
 
022 | Seal the tray for 3 seconds at 170 degrees (ddPCR protocol). Release, turn the plate through 180 degrees, then 
repeat sealing for another 3 seconds. 
 
023 | Put plate in Applied Biosystems thermal cycler and run the program “DDPCR”. Thermal cycling parameters are: 
 
10 minutes at 95°C (activation), 40 cycles of 15 seconds at 95°C (dissociation) followed by 1 minute at 60°C (annealing 
and extension phases combined to optimise exonuclease activity of DNA polymerase), 10 minutes at 98°C (deactivation), 
hold at 12°C. 
 
024 | When the cycle is complete, droplets can be stored at 4°C for up to 48 hours, or counted immediately. 
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DROPLET READING 
 
If this is the first read of the week, start by performing a prime/flush/prime operation. The prime operation must 
be completed before each run. 
 
025 | Transfer the plate to the special retainer and place this device in the droplet reader. A green light will indicate correct 
engagement with the platform. Close the door by pressing the button. 
 
026 | Open the QuantaSoft software and create a new template.  
 
027 | Select all wells on the plate and double click on the plate diagram to edit the details.  
 
028 | For sample names, all wells should be labelled appropriately. Channel one detects FAM and channel two detects 
VIC or HEX. These should be labelled with the appropriate targets in the PCR mix. 
 
029 | Start the droplet count by pressing the run button 
 
 
ANALYSIS 
 
030 | After the run has finished, check the positive and negative controls to ensure (a) the assay has worked and (b) there 
is no systematic contamination of PCR reagents. Using the positive and negative controls as a guide, manually set a 
threshold for each well. The threshold should be set as close as possible to the negative population, as PCR inhibition 
causes reduced fluorescence amplitude of positive droplets.  
 
031 | After gating, the data table should be exported as a .csv filetype. 
 
032 | Create a new folder for ddPCR data containing a subfolder entitled “out”. Save the exported data in the ddPCR data 
folder. 
 
033 | Data should be processed using free R software and the script in Appendix A which generates concentration 
estimates for both channels, and calls positives and negatives based on a 95% confidence in non-zero load, as described 
by Roberts et al. Following analysis, remove output data files from the “out” folder to avoid overwriting them with 
subsequent analyses. 
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Appendix A 
 
########################################################################################## 
#                                   Open source license                                       # 
########################################################################################## 
# To attribute this work, you must cite the name of the original source, the name of        # 
# the author (Chrissy h. Roberts) and their contact details                                  # 
# (chrissyhroberts@yahoo.co.uk). This work is licensed under the Creative Commons           # 
# Attribution-ShareAlike 3.0 Unported License.                                                # 
# To view a copy of this license, visit http://creativecommons.org/licenses/by-sa/3.0/       # 
# or send a letter to Creative Commons, 444 Castro Street, Suite 900, Mountain View,          # 
# California, 94041, USA.                                                                              # 
########################################################################################## 
 
delete.all <- function() 
  rm(list=ls(pos=.GlobalEnv), pos=.GlobalEnv) 
delete.all() 
ls() 
setwd(dir="C:\\Users/Bertie/Dropbox/Bert/ddPCRv1/") 
cwd <-getwd() 
cwd 
cat(cwd,"/out/",sep="") 
outwd <-paste(cwd,"/out/",sep="") 
path <- cwd 
outpath <- outwd 
 
#READ IN PLATE 
samples=read.delim(file.path(path,"140616_cov_final.csv"),header=T,sep=",",na.strings="NA") 
View(samples) 
samples$famposvicpos<-samples$Ch1.Ch2. 
samples$Ch1.Ch2.<-NULL 
samples$famposvicneg<-samples$Ch1.Ch2..1 
samples$Ch1.Ch2..1<-NULL 
samples$famnegvicpos<-samples$Ch1.Ch2..2 
samples$Ch1.Ch2..2<-NULL 
samples$famnegvicneg<-samples$Ch1.Ch2..3 
samples$Ch1.Ch2..3<-NULL 
samples$Freq<-(samples$famposvicneg+samples$famnegvicpos+samples$famposvicpos+samples$famnegvicneg) 
View(samples) 
#calculate values for poisson calculation. 
#phat is estimator of P, the probability of a micelle being positive. P is unknown but phat can be estimated by phat = 
number of positive droplets / total droplets 
samples$phat_fam<-((samples$famposvicneg+samples$famposvicpos)/samples$Freq) 
samples$phat_vic<-((samples$famnegvicpos+samples$famposvicpos)/samples$Freq) 
 
#standard deviation of p_hat estimator 
samples$sd_phat_fam<- sqrt((samples$phat_fam*(1-samples$phat_fam))/samples$Freq) 
samples$sd_phat_vic<- sqrt((samples$phat_vic*(1-samples$phat_vic))/samples$Freq) 
 
#upper and lower confidence intervals (95%) of p_hat estimates 
samples$phat_low_fam <- samples$phat_fam - (1.96 * samples$sd_phat_fam) 
samples$phat_high_fam <- samples$phat_fam + (1.96 * samples$sd_phat_fam) 
 
samples$phat_low_vic <- samples$phat_vic - (1.96 * samples$sd_phat_vic) 
samples$phat_high_vic <- samples$phat_vic + (1.96 * samples$sd_phat_vic) 
 
#lambda is the true concentration of target molecules per chamber. It is unknown but can be estimated by lambda hat. 
lambda_hat =  -ln (1-p_hat) 
 
samples$lambda_hat_fam<-(-log(1-samples$phat_fam)) 
samples$lambda_hat_vic<-(-log(1-samples$phat_vic)) 
 
#upper and lower confidence intervals for lambda hat : 
samples$lambda_hat_low_fam <- (-log(1-samples$phat_low_fam)) 
samples$lambda_hat_high_fam <- (-log(1-samples$phat_high_fam)) 
 
samples$lambda_hat_low_vic <- (-log(1-samples$phat_low_vic)) 
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samples$lambda_hat_high_vic <- (-log(1-samples$phat_high_vic)) 
 
# lambda_hat = concentration target per micelle 
# lambda_hat_low = lower 95% CI for lambda hat 
# lambda_hat_high = upper 95% CI for lambda hat 
 
# calculate concentration of target molecules per reaction. 
 
samples$fam_copies_per_reaction<-samples$lambda_hat_fam*samples$Freq 
samples$vic_copies_per_reaction<-samples$lambda_hat_vic*samples$Freq 
 
samples$fam_copies_per_reaction_low<-samples$lambda_hat_low_fam*samples$Freq 
samples$fam_copies_per_reaction_high<-samples$lambda_hat_high_fam*samples$Freq 
 
samples$vic_copies_per_reaction_low<-samples$lambda_hat_low_vic*samples$Freq 
samples$vic_copies_per_reaction_high<-samples$lambda_hat_high_vic*samples$Freq 
 
samples$volume<-samples$Freq*0.91e-3 
samples$concentration_fam_average_copies_uL <- samples$fam_copies_per_reaction/samples$volume 
samples$concentration_fam_low_copies_uL <- samples$fam_copies_per_reaction_low/samples$volume 
samples$concentration_fam_high_copies_uL <- samples$fam_copies_per_reaction_high/samples$volume 
 
samples$concentration_vic_average_copies_uL <- samples$vic_copies_per_reaction/samples$volume 
samples$concentration_vic_low_copies_uL <- samples$vic_copies_per_reaction_low/samples$volume 
samples$concentration_vic_high_copies_uL <- samples$vic_copies_per_reaction_high/samples$volume 
rownumbers<-c(1:length(samples$Well)) 
for (i in 
rownumbers){if(is.na(samples$concentration_fam_high_copies_uL[i])){samples$concentration_fam_high_copies_uL[i]<-
samples$concentration_fam_average_copies_uL[i]}else{next}} 
for (i in 
rownumbers){if(is.na(samples$concentration_vic_high_copies_uL[i])){samples$concentration_vic_high_copies_uL[i]<-
samples$concentration_vic_average_copies_uL[i]}else{next}} 
 
for (i in 
rownumbers){if(is.infinite(samples$concentration_fam_average_copies_uL[i])){samples$concentration_fam_average_copi
es_uL[i]<-20000}} 
for (i in 
rownumbers){if(is.infinite(samples$concentration_fam_low_copies_uL[i])){samples$concentration_fam_low_copies_uL[i]<
-20000}} 
for (i in 
rownumbers){if(is.infinite(samples$concentration_fam_high_copies_uL[i])){samples$concentration_fam_high_copies_uL[i]
<-20000}} 
for(i in 
rownumbers){if(is.infinite(samples$concentration_vic_average_copies_uL[i])){samples$concentration_vic_average_copies
_uL[i]<-20000}} 
for(i in 
rownumbers){if(is.infinite(samples$concentration_vic_low_copies_uL[i])){samples$concentration_vic_low_copies_uL[i]<-
20000}} 
for(i in 
rownumbers){if(is.infinite(samples$concentration_vic_high_copies_uL[i])){samples$concentration_vic_high_copies_uL[i]<-
20000}} 
 
#plot graphs of calculated concenentration (copies/uL) values with error bars 
#library(gplots) 
 
pdf(file.path(outpath,"001_concentration_vic.pdf")) 
plot (samples$concentration_vic_average_copies_uL,pch=46,cex=4,log="y",xlab="Sample",ylab="HURNASE 
(copies/uL)",xaxt="n",cex.axis=0.4,xlim=c(0,100),ylim=c(0.1,(max(samples$concentration_vic_high_copies_uL)*1.1))) 
for(i in 
rownumbers){arrows(i,samples$concentration_vic_average_copies_uL[i],i,samples$concentration_vic_high_copies_uL[i],l
ength=0.02,angle=90,code=2,col="red")} 
for(i in 
rownumbers){arrows(i,samples$concentration_vic_average_copies_uL[i],i,samples$concentration_vic_low_copies_uL[i],le
ngth=0.02,angle=90,code=2,col="red")} 
axis(1,rownumbers,labels=samples$Var1,cex.axis=0.4) 
grid() 
dev.off() 
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pdf(file.path(outpath,"001_concentration_fam.pdf")) 
plot (samples$concentration_fam_average_copies_uL,pch=46,cex=4,log="y",xlab="Sample",ylab="C.trachomatis Plasmid 
(copies/uL)",xaxt="n",cex.axis=0.4,xlim=c(0,100),ylim=c(0.1,(max(samples$concentration_fam_high_copies_uL)*1.1))) 
for(i in 
rownumbers){arrows(i,samples$concentration_fam_average_copies_uL[i],i,samples$concentration_fam_high_copies_uL[i
],length=0.02,angle=90,code=2,col="red")} 
for(i in 
rownumbers){arrows(i,samples$concentration_fam_average_copies_uL[i],i,samples$concentration_fam_low_copies_uL[i]
,length=0.02,angle=90,code=2,col="red")} 
axis(1,rownumbers,labels=samples$Var1,cex.axis=0.4) 
grid() 
dev.off() 
View(samples) 
samples$FAILS<-NA 
 
#DEFINE FAILS AND RESULTS 
for (i in rownumbers) {if (samples$concentration_fam_low_copies_uL[i]<0){samples$FAILS[i]<-"WARNING : CI for FAM 
crosses zero"}} 
for (i in rownumbers) {if (samples$famnegvicneg[i]<(0.01*samples$Freq[i])){samples$FAILS[i]<-"WARNING: REACTION 
MAY BE SATURATED WITH TOO MANY TEMPLATES"}} 
for (i in rownumbers) {if (samples$concentration_vic_low_copies_uL[i]<0.0000001){samples$FAILS[i]<-"FAIL: HUMAN 
DNA CONCENTRATION TOO LOW"}} 
 
#define amount of area under the curve that is above zero 
for (i in rownumbers){samples$areaabovezerofam[i]<-1-
pnorm(0,mean=samples$phat_fam[i],sd=samples$sd_phat_fam[i])} 
for (i in rownumbers){samples$areaabovezerovic[i]<-1-pnorm(0,mean=samples$phat_vic[i],sd=samples$sd_phat_vic[i])} 
 
#assign endogenous control status 
samples$endogenouscontrolresult<-NA 
for (i in rownumbers) {if (samples$areaabovezerovic[i]>=0.95){samples$endogenouscontrolresult[i]<-"Endogenous control 
OK"}} 
for (i in rownumbers) {if (samples$areaabovezerovic[i]<0.95){samples$endogenouscontrolresult[i]<-"Endogenous control 
failed"}} 
 
#assign warnings based on FI average values and 95% CI platewide 
samples$targetresult<-NA 
for (i in rownumbers) {if (samples$areaabovezerofam[i]>=0.95){samples$targetresult[i]<-"Sample is positive for the 
target"}} 
for (i in rownumbers) {if (samples$areaabovezerofam[i]<0.95){samples$targetresult[i]<-"Sample is negative for the 
target"}} 
 
#print output 
write.table(samples, file = (file.path(outpath,"000_results_full.txt")),row.names=F,col.names=T,quote=F,sep="\t") 
columns<-c(1,55,56,47,48,49,50,51,52,53,54,2,13,14,15,16,11,12,46) 
write.table(samples[,columns], file = 
(file.path(outpath,"000_results_concise.txt")),row.names=F,col.names=T,quote=F,sep="\t") 
View(samples) 
 
########################################################################################## 
#END OF SCRIPT dropletR_man_thresholds.R 
########################################################################################## 
 
#extract columns required for desired output and print summary table 
#samples_summary<-
subset(samples,select=c("Sample","Ratio","concentration_fam_average_copies_uL","concentration_vic_average_copies_
uL")) 
#write.table(samples_summary,file = (file.path(outpath,"micro.txt")),row.names=F,col.names=T,quote=F,sep="\t") 
ELISA	for	detection	of	antibodies	against	C	trachomatis	antigen	pgp3	
V4.6	–	Summer	2015	beta	testing	
	
Solutions	and	Reagents	
Included:	
Controls:	(human	sera	with	known	ratios	of	pgp3	antibodies)	
• Aliquot	to	30µl	per	tube		
• Store	long	term	at	-80°C.	Working	aliquot	may	be	stored	at	-20°C	
• Thaw	on	ice	or	at	4°C-10°C	(Minimize	freeze-thaw:	no	more	than	5x/aliquot)	
• Dilute	1:50	in	PBST-milk	[2.5μl	+	125μl	PBST-milk	per	plate]	
	
Antigen:	(recombinant	GST	tagged	pgp3	in	PBS,	0.25mg/ml)	
• Aliquot	to	120µl	per	tube		
• Store	long	term	at	-80°C.	Working	aliquot	may	be	stored	at	-20°C	
• Thaw	on	ice	or	at	4°C-10°C	(Minimize	freeze-thaw:	no	more	than	5x/aliquot)	
• Do	not	vortex.	Tap	gently	or	pipette	up	and	down	to	mix.	
• Dilute	1:500	in	Sensitizing	Buffer	[11μl	+	5.5mL	Sensitizing	Buffer	per	plate]	
	
Secondary	Antibody:	(mouse	anti-human	IgG(Fc)-HRP,	Southern	Biotech,	cat	no	9042-05)	
• Store	at	4°C-10°C	
• Dilute	1:10,000	in	PBST	[0.55	μl	+	5.5mL	PBST	per	plate]	
	
Substrate:	TMB	(SureBlue,	1	component,	KPL,	cat	no	52-00-00)	
• Store	at	4°C-10°C	
• Ready	to	use,	must	be	room	temperature	for	assay.	
	
Not	Included:	
Sensitizing	Buffer:	(0.1M	NaHCO3,	pH	9.6)	
• For	coating	the	plate	with	pgp3.	One	liter	can	coat	up	to	200	plates.		
• 8.40	g	NaHCO3	qs	to	1	liter	with	dH2O,	pH	with	NaOH	to	achieve	pH	9.6	
• Vacuum	filter	solution.	Store	at	4°C.	
	
PBST:	(1x	PBS	pH	7.2	(ion	free)	+	0.3%	Tween-20)	
• For	blocking	plate,	washing	plate,	and	diluting	antibody	 	
• 1000	ml	PBS	+	3	ml	Tween-20	
• Stir	gently	for	15	minutes	
	
PBST-milk:	(0.3%	PBS/T	+	5%	nonfat	milk	powder)	
• For	eluting/diluting	blood	spots;	make	fresh	daily	
• 50mL	PBST	+	2.5g	milk	powder	
• Stir	gently	for	15	minutes	
	
Stop	Solution:	1N	H2SO4	
• For	stopping	TMB/HRP	reaction	
• 28mL	96%	(18M)	H2SO4	+	472mL	dH2O	
	 								Caution:	H2SO4	is	extremely	corrosive	–	use	concentrated	form	only	in	fume	hood	 	
Equipment:	
Plate	reader	
Analysis	software	(Excel)	
Plate	shaker	(orbital),	room	temperature		
Multichannel	pipette,	P1000,	P200,	P20,	P2	single	channel	pipettes+	tips	
	
Consumables	
Plates:	(Immulon	2HB,	ThermoScientific	cat#	3455)	
• Assay	plate.	
• Can	run	42	samples/plate	
	
Lids/sealing	film	for	plates	[covering	plates	during	incubation	steps]	
Microcentrifuge	tubes	[sample	dilution]	
Round	bottom	96	well	titer	plates	[for	preload	plate]	
Paper	towels,	bleach	[wash	steps,	waste	disposal]	
Multichannel	reservoirs	[pipetting]	
50mL	and	15mL	conical	tubes	[reagent	dilution]	
	
	 	
Before	Starting	
Plate	Washing:	
Choose	method	that	is	practical	in	lab	in	which	the	assay	will	be	run		
• Pipette:	load	200μl/well	with	a	multichannel.	Do	not	touch	bottom	of	well.	Decant	into	sink	to	remove.	
• Automatic	plate	washer:	200μl/well	
• Squirt	bottle	not	recommended	due	to	higher	CVs.	
	
• Between	washes,	tap	plates	4-8	times	firmly	on	a	pile	of	paper	towels	to	remove	excess	liquid.	
• paper	towels	can	be	reused	for	several	ELISAs	
	
Examine	plates	for	bubbles.	These	can	be	gently	popped	using	air	from	an	empty	squeeze	bottle,	a	fine	gauge	
needle	or	pipette	tip.	It	is	very	important	no	large	bubbles	remain	prior	to	the	next	step.		Be	careful	not	to	scratch	
the	bottom	of	the	plate	when	popping	bubbles.		
Adding	samples	to	well:	
If	using	the	multichannel	is	awkward,	a	regular	p200	pipet	can	be	used	instead.		In	this	case,	a	preload	plate	is	not	
necessary.	A	multichannel	is	necessary	to	add	TMB	and	Stopping	Solution	due	to	the	speed	of	the	reaction.	
Suggested	plate	layout:	
 1	 2	 3	 4	 5	 6	 7	 8	 9	 10	 11	 12	
A	 1000u	 1000u	 U03	 U03	 U11	 U11	 U19	 U19	 U27	 U27	 U35	 U35	
B	 500u	 500u	 U04	 U04	 U12	 U12	 U20	 U20	 U28	 U28	 U36	 U36	
C	 200u	 200u	 U05	 U05	 U13	 U13	 U21	 U21	 U29	 U29	 U37	 U37	
D	 50u	 50u	 U06	 U06	 U14	 U14	 U22	 U22	 U30	 U30	 U38	 U38	
E	 NHS	 NHS	 U07	 U07	 U15	 U15	 U23	 U23	 U31	 U31	 U39	 U39	
F	 BLANK	 BLANK	 U08	 U08	 U16	 U16	 U24	 U24	 U32	 U32	 U40	 U40	
G	 U01	 U01	 U09	 U09	 U17	 U17	 U25	 U25	 U33	 U33	 U41	 U41	
H	 U02	 U02	 U10	 U10	 U18	 U18	 U26	 U26	 U34	 U34	 U42	 U42	
	
All	samples	and	controls	are	run	in	duplicate	(U01-U42)	
Blank	is	PBST-milk	alone	
NHS	=	normal	(negative)	human	serum	 	
Before	study	samples	are	tested:	
1. TMB	optimization:	
1. Evaluate	12	TMB	incubation	times	on	one	plate	with	specified	controls:		
a. TMB	incubation	times:	Ranging	from	4-16	min,	increasing	in	one	minute	increments		
b. Controls:	1000,	200,	NHS	and	blank		
2. Stagger	TMB	addition	to	each	column	so	H2SO4	addition	occurs	simultaneously	(i.e.	add	TMB	to	last	column	
first,	then	move	backwards	across	plate:		Column	12,	then	11,	then	10,	etc.)	
	
Suggested	plate	layout:	
	
	
Data	analysis:		
Optimal	TMB	incubation	should	be	chosen	by	the	following	criteria:		
1. The	200	normalization	standard	should	be	around	1	OD	(0.8-1.2	OD	is	acceptable)	
2. The	range	between	the	1000	control	and	NHS	should	be	>	1.5	OD		
3. The	ratio	between	the	1000	control	and	NHS	should	be	>	10		
4. If	several	consecutive	time	points	meet	this	criteria,	choose	a	time	point	in	the	middle	of	this	range	
	
	
Example:	
	
	
	
	
	
	
	
	
	
	
	
	
4	min 5	min 6	min 7	min 8	min 9	min 10	min 11	min 12	min 13	min 14	min 15	min
BLANK
BLANK
1000
1000
200
200
NHS
NHS
4	min 5	min 6	min 7	min 8	min 9	min 10	min 11	min 12	min 13	min 14	min 15	min
1000 1.399 1.532 1.736 1.843 1.927 2.019 2.096 2.095 2.190 2.211 2.294 2.272
200 0.545 0.690 0.678 0.849 0.982 1.009 1.096 1.138 1.215 1.277 1.332 1.294
NHS 0.089 0.098 0.138 0.145 0.179 0.184 0.194 0.199 0.204 0.217 0.232 0.237
Signal:Noise 15.7 15.7 12.6 12.7 10.7 11.0 10.8 10.5 10.8 10.2 9.9 9.6
Range 1.3 1.4 1.6 1.7 1.7 1.8 1.9 1.9 2.0 2.0 2.1 2.0
	
	
2.		Calculation	of	baseline	values	for	controls	
1. Run	10	plates	on	at	least	5	different	days	to	set	baseline	acceptable	parameters	for	controls.	Do	not	
start	running	clinical	samples	until	baseline	parameters	have	been	established.	
a. Run	plates	with	exact	conditions	that	will	be	used	to	run	samples	
b. Normalize	blanked	OD450	values	to	the	blanked	OD450	of	the	200u	control.	
c. Add	and	subtract	20%	to	the	average	to	calculate	the	upper	and	lower	limit	for	controls	
d. Take	ratio	of	1000u	to	0u	(i.e.	NHS)	to	calculate	signal:	noise	ratio.	Should	be	average	of	10.	
e. Subtract	the	OD	value	of	0u	from	1000u	to	calculate	range.	Should	be	greater	than	1.5.		
Example:	
	 	
1 2 3 4 5 6 7 8 9 10 11 12
14-Apr 15-Apr 16-Apr 16-Apr 17-Apr 22-Apr 23-Apr 23-Apr 24-Apr 24-Apr
1 2 3 4 5 6 7 8 9 10
1000 1.98 1.94 2.13 1.80 1.63 1.85 1.65 1.66 1.78 1.51 1.79 10.5
500 1.56 1.54 1.71 1.49 1.33 1.51 1.15 1.28 1.32 1.09 1.40 13.9
200 1.03 1.09 1.25 1.03 0.92 0.95 0.77 0.83 0.87 0.78 0.95 15.9
50 0.42 0.44 0.58 0.53 0.43 0.35 0.35 0.40 0.35 0.37 0.42 18.7
0 0.17 0.16 0.27 0.23 0.21 0.13 0.15 0.20 0.17 0.14 0.18 23.6
Signal:Noise 12 12 8 8 8 14 11 8 11 11 10
Range 1.8 1.8 1.9 1.6 1.4 1.7 1.5 1.5 1.6 1.4 1.6
14-Apr 15-Apr 16-Apr 16-Apr 17-Apr 22-Apr 23-Apr 23-Apr 24-Apr 24-Apr
1 2 3 4 5 6 7 8 9 10
1000 1.91 1.78 1.70 1.75 1.77 1.95 2.14 2.00 2.05 1.93 1.90 7.6 2.28 1.52
500 1.50 1.41 1.36 1.45 1.45 1.59 1.49 1.55 1.53 1.40 1.47 4.8 1.77 1.18
50 0.40 0.40 0.46 0.52 0.46 0.37 0.45 0.49 0.40 0.47 0.44 10.5 0.53 0.36
0 0.17 0.15 0.21 0.22 0.23 0.14 0.20 0.24 0.19 0.18 0.19 18.5 0.23 0.15
1000
500
200
50
NHS
BLANK
Upper	
Limit
Lower	
Limit
Raw	OD Average Percent	
CV
Average Percent	
CV
200	norm
ELISA	procedure:	one	day	prior	to	testing:	
1. Dilute	pgp3	to	500ng/mL	in	sensitizing	buffer	to	make	antigen	coating	solution	
• 11µl	of	0.25mg/mL	pgp3	+	5.5mL	sensitizing	buffer	[per	plate]	
2. Add	50µl	antigen	coating	solution	per	well	(25ng/well)	and	shake	on	plate	shaker	briefly	to	ensure	that	
wells	are	evenly	coated.	Place	in	sealed	Ziploc	bag	with	folded	wet	paper	towel	overnight	at	4°C-10°C.	
3. Dilute	all	samples	1:50	in	PBST-milk	and	keep	overnight	at	4°C	–	10°C.	
• 1	dried	blood	spot	+	250µl	PBST-milk	
• 2.5µl	sera	+	125µl	PBST-milk	(includes	all	standards	and	controls)	
ELISA	procedure:	day	of	assay	
*make	PBST	fresh	weekly	
*get	TMB	out	of	4°C	at	the	beginning	of	the	day	to	come	to	room	temperature	
*Do	not	reuse	sealing	films,	use	a	new	one	for	each	step	
1. Decant	antigen	and	wash	2x	with	PBST.	Add	100µl	PBST	to	each	well	to	block	plate	for	1	hour	at	4°-10°C	
• Plate	can	be	rocking	or	stationary		
	
2. During	blocking	step:	
• 	Remove	samples	from	refrigerator	and	briefly	vortex	to	ensure	a	homogeneous	solution.	All	
samples	must	be	at	room	temperature	(RT)	before	step	4.	
• If	using	a	multichannel	to	load	plate,	create	preload	plate	by	adding	130µl	each	sample	per	well	to	
a	round	bottom	96	well	plate.	This	will	be	enough	for	1	set	of	duplicates.	
	
3. Decant	blocking	solution.	Tap	firmly	2x	to	remove	excess	liquid.	No	wash	step	is	necessary.	
	
4. Mix	samples	by	pipetting	up	and	down	and	add	50µl	of	each	sample	per	well	by	reverse	pipetting.	Run	
controls	and	samples	in	duplicate.	
	
5. Incubate	plate	at	RT	on	orbital	shaker	for	2	hours.	
	
6. Remove	samples	by	decanting	into	sink	with	10%	bleach--avoid	splash	back.	Wash	4x	with	PBST.	
	
7. Dilute	secondary	antibody	1:10,000	in	PBST.	
• 0.55	µl	anti-human-IgG-HRP	+	5.5mL	PBST	[per	plate]	
	
8. Add	50µl	secondary	antibody	to	each	well	by	reverse	pipetting	and	incubate	at	RT	on	shaker	for	1	hour.	
	
9. Wash	4x	with	PBST.	
	
10. Add	50µl	TMB	to	each	well.	Incubate	at	RT	protected	from	light,	no	shaking	
	
11. Add	50µl	1N	H2SO4	per	well	to	stop	the	reaction	(same	order	as	TMB	was	added).	Shake	briefly	to	mix.	
• It’s	very	important	that	no	bubbles	remain	prior	to	reading	the	plate	
	
12. Read	plate	immediately	at	450nm.	
Analysis	procedure	
1. Per	plate	quality	control	
	
Internal	Controls	
• Dynamic	range	of	≥	5	is	acceptable.	
• CVs	for	control	samples	<15%	is	acceptable	
• Normalized	values	fall	within	acceptable	parameters	
i. Repeat	plate	if	both	3/4	controls	are	outside	range	
Duplicate	values	of	samples	
• %CV	between	OD450	of	duplicates	should	be	<15%.	
i. If	both	duplicates	are	20%	below	the	cutoff,	then	sample	does	not	need	to	be	rerun	
	
2. Weekly,	ongoing/cumulative	quality	control	
• Record	all	OD	and	normalized	values	from	standard	curve	and	controls	in	a	single	graph	or	table.	
Observe	trend	weekly	to	make	sure	no	component	of	the	ELISA	is	going	bad	and	skewing	results.	
												Blanked	OD450	 	 	 	 										Normalized	to	200u	
								 	
	
i. If	deviations	from	average	of	10	plate	baseline	of	>20%	is	seen	on	3	consecutive	plates,	
then	do	the	following	and	run	only	standards	until	controls	fall	within	normal	parameters.	
1. Make	fresh	PBST	and	coating	buffer	
2. Use	a	fresh	antigen	aliquot	
3. Use	a	fresh	aliquot	of	all	controls	
	
ii. If	this	does	not	work	
1. Have	ambient	conditions	changed?	
a. Redo	TMB	optimization	with	a	fresh	bottle	of	TMB	
2. Change	secondary	antibody	–	contact	CDC	for	replacement	
Best	practices	
Avoid	touching	the	bottom	plate.	
Sera	and	Antigen	quality	control	
Both	sera	(used	in	controls)	and	pgp3	antigen	are	susceptible	to	degradation	with	repeated	freeze/thaw.	
Take	the	following	precautions	to	minimize	effects	of	freeze/thaw	
• Thaw	samples	at	4°-10°C	or	on	ice.	Do	not	leave	thawed	samples	at	4°C-10°C	longer	than	
overnight.	
• Do	not	vortex	the	antigen		
• Freeze/thaw	any	single	aliquot	no	more	than	5x	
o Aliquot	sera	in	30μl	batches	[enough	for	~10	plates,	run	2	per	day]	
o Aliquot	pgp3	(0.25mg/mL)	in	120μl	batches	[enough	for	~10	plates,	run	2	per	day]	
• Store	all	aliquots	except	the	ones	actively	in	use	at	-80°C;	active	aliquots	may	be	stored	at	-20°C	
• Keep	aliquots	stored	in	screw	cap	microcentrifuge	tubes.	If	only	snap	cap	tubes	are	available,	
Parafilm	tubes	to	prevent	evaporation	
• Discard	any	aliquots	that	show	evidence	of	being	degraded	and	switch	to	a	fresh	aliquot	
o e.g.	controls	gives	value	outside	typical	range	in	3	consecutive	tests	
Safety	
Components	of	this	assay	are	derived	from	biological	materials,	so	take	the	following	precautions	
• Sera	and	eluted	blood	spots	should	be	handled	under	a	biosafety	cabinet	if	possible,	especially	if	
there	is	a	high	risk	for	generation	of	aerosols	(e.g.	pipetting,	centrifugation).	
• Use	universal	lab	precautions:	glove,	lab	coat,	eye	protection	and	close	toed	shoes—take	special	
caution	when	decanting	samples	in	sink	to	avoid	splash	back	
• Sera	and	liquid	biological	derivatives	should	be	mixed	with	bleach	before	disposal	(final	
concentration	of	bleach	should	be	no	less	than	10%).	
• Work	space	surfaces	should	be	wiped	down	with	70%	ethanol	before	and	after	working	with	
ELISA	reagents.	
• All	solid	waste	should	be	treated	as	biohazardous	for	disposal—segregate	and	autoclave	before	
throwing	away.	
	 	
Experiment	Worksheet	
Study:	COR	NTD	alternate	indicators	pgp3	ELISA	 Date:	_______________	
Samples/Reason	for	test:	_____________________________________________	
	
Plate	Layout:	
 1	 2	 3	 4	 5	 6	 7	 8	 9	 10	 11	 12	
A	 1000u	 1000u	 		 		 		 		 		 		 		 		 		 		
B	 500u	 500u	 		 		 		 		 		 		 		 		 		 		
C	 200u	 200u	 		 		 		 		 		 		 		 		 		 		
D	 50u	 50u	 		 		 		 		 		 		 		 		 		 		
E	 NHS	 NHS	 		 		 		 		 		 		 		 		 		 		
F	 BLANK	 BLANK	 		 		 		 		 		 		 		 		 		 		
G	 		 		 		 		 		 		 		 		 		 		 		 		
H	 		 		 		 		 		 		 		 		 		 		 		 		
	
 1	 2	 3	 4	 5	 6	 7	 8	 9	 10	 11	 12	
A	 1000u	 1000u	 		 		 		 		 		 		 		 		 		 		
B	 500u	 500u	 		 		 		 		 		 		 		 		 		 		
C	 200u	 200u	 		 		 		 		 		 		 		 		 		 		
D	 50u	 50u	 		 		 		 		 		 		 		 		 		 		
E	 NHS	 NHS	 		 		 		 		 		 		 		 		 		 		
F	 BLANK	 BLANK	 		 		 		 		 		 		 		 		 		 		
G	 		 		 		 		 		 		 		 		 		 		 		 		
H	 		 		 		 		 		 		 		 		 		 		 		 		
	
Procedural	Notes:	
Step	 Reagent	 µl/well	 Incubation	 Lot/Date	Made/Notes	
Antigen	 pgp3-GST,	25ng/well	 50µl/well	 o/n	at	4°C	 		
Wash	 PBS	+	0.3%	Tween	 200µl/well	 2x	 		
Blocking	 PBS	+	0.3%	Tween	 100µl/well	 1hr	at	4°C	 		
Sample	 DBS	or	sera,	1:50	 50µl/well	 2hr	at	RT	 		
Wash	 PBS	+	0.3%	Tween	 200µl/well	 4x	 		
Antibody	 anti-IgG-HRP,	1:10,000	 50µl/well	 1hr	at	RT	 		
Wash	 PBS	+	0.3%	Tween	 200µl/well	 4x	 	
Substrate	 TMB,	1C	 50µl/well	 RT,	opt.	time	 		
Stop	Sol'n	 1N	H2SO4	 50µl/well	 read	immed.	 		
	
